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Matrix metalloproteinases (MMPs) are members of an enzyme family and, under normal
physiological conditions, are critical for maintaining tissue allostasis. MMPs can catalyze the
normal turnover of the extracellular matrix (ECM) and its activity is also regulated by a group
of endogenous proteins called tissue inhibitors of metalloproteinases (TIMPs) or other proteins, such as
Neutrophil Gelatinase-Associated Lipocalin (NGAL). An imbalance in the expression or activity of the
aforementioned proteins can also have important consequences in several diseases, such as cancer,
cardiovascular disease, peripheral vascular disease, inflammatory disease, and others. In recent years,
MMPs have been found to have an important role in the field of precision medicine as they may serve
as biomarkers that may predict an individual’s disease predisposition, state, or progression. MMPs are
also thought to be a sensible target for molecular therapy [1–4].
This Special Issue includes ten papers: seven original articles and three review articles dealing
with a broad range of diseases related to MMPs.
The article by Santiago Ruiz et al [5] showed that several polymorphisms and genes associated with
metalloproteinases influence the development of Hypersensitivity Pneumonitis (HP), an inflammatory
disease caused by an exaggerated immune response to the inhalation of certain organic particles.
Remodeling of the ECM in the airways and pulmonary interstice seem to relate to the worsening of
lung function. This study documented that some polymorphisms in the MMP-1 and MMP-2 genes are
associated with the risk of hypersensitivity pneumonitis, and, in particular, the MMP-2 polimorphism
also correlates with lung function.
The study by Cione E et al. [6] evaluated the expression of MMP-2, MMP-9, and NGAL in
the plasma and tissue of patients with aneurysmal disease. In particular, the modulation of these
three biochemical indicators, related to vascular remodeling, was also studied in patients under
statin treatment. The study deepens the pathophysiology of arterial aneurysms in light of ECM
alterations, and suggests that statin treatment may have a role in the prevention of aneurysm growth
and subsequent rupture by modulating the effects of MMP-2, MMP-9, and NGAL on ECM alterations,
endothelial function, and also reducing inflammation and oxidative stress.
The paper by Rautava J et al. [7] deals with Crohn’s disease (CD) a complex inflammatory disease
of the gastrointestinal tract, and the tendency of such patients to develop periodontitis, caries, and oral
mucosal lesions. The study speculates that the dysregulation of the immune system in CD may have
an effect on MMP-8 levels in the oral cavity. In this context, MMP-8 seems to be the key inflammatory
mediator in these conditions; In fact, elevated MMP-8 levels have been detected in CD patients both in
the intestine and in the oral cavity.
The article by Rodríguez-Sánchez E. et al. [8] explores the variations in circulating active MMP-9
levels during Renal Replacement Therapy (RRT), which is a condition that may be complicated by
a chronic state of inflammation and a high mortality risk. The study documented that MMP-9 is an
effective marker of vascular dysfunction in patients undergoing RRT.
The study by Heinzmann D et al. [9] explored the recruitment of leukocytes and platelets to
activated endothelia as well as platelet–leukocyte interactions in the context of thromboinflammatory
Biomolecules 2020, 10, 1138; doi:10.3390/biom10081138 www.mdpi.com/journal/biomolecules1
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mechanisms. In particular, this study highlights that the surface receptor CD147 (basigin, extracellular
matrix–metalloproteinase inducer; EMMPRIN) has a role in the host defense from self-derived, as well
as invading targets, and it is also a major factor modulating the expression of MMPs. In this context,
CD147 seems to have pathophysiological relevance in platelet–leukocyte interactions in thrombosis
related mechanisms.
The paper by Ferrigno A et al. [10] studied the involvement of MMPs in hepatic
ischemia/reperfusion (I/R) injury. This study showed the precise role of MMPs, in particular MMP-2
and MMP-9, that may contribute to the development of organ dysfunction and injury, especially in the
early phase of this condition.
The article by O’Sullivan S. et al. [11] studied the role of MMP-9 in inflammatory bowel disease
(IBD) and investigated the mechanism of action of barbiturate-nitrate hybrid compounds and their
component parts using models of intestinal inflammation in vitro in order to inhibit the upregulation
of MMP-9 gene expression. This study highlights the potential of treating colonic inflammation by
means of downregulating MMP-9 activity, and subsequent inflammatory sprout in IBD.
The study by Provenzano M. et al. [12] aimed to examine the role of MMPs in increasing the risk
of peripheral vascular disease (PVD) by the specific factors related to Chronic Kidney Disease (CKD).
This paper speculates on the possibility of a strict link between PAD and PVD, mediated by MMPs, in
particular MMP-2 and MMP-9, and the latter also sustained by an increase in NGAL circulating levels
that are also known to be directly related to diabetic status and inversely to estimated glomerular
filtration rate (eGFR) levels.
The paper by Laronha H. [13] extensively reviewed the currently reported synthetic inhibitors of
MMPs and also provided an accurate description of their properties. In particular, Hydroxamate-Based
Inhibitors, Non-Hydroxamate-Based Inhibitors, Catalytic Domain (Non-Zinc Binding) Inhibitors,
Allosteric and Exosite Inhibitors, and Antibody-Based Inhibitors are presented and discussed.
The article by Liu Z. et al. [14] reviewed the expression, regulation, novel substrates, and
mechanisms of MMP-7 in several kidney diseases. In particular, MMP-7 was found upregulated
in acute kidney injury (AKI), CKD, and glomerular diseases and was also predominantly localized
in renal tubular epithelia. Furthermore, MMP-7 levels may serve as a noninvasive biomarker for
predicting AKI prognosis and monitoring CKD progression.
This Special Issue describes important findings related to MMPs function, and dysregulation in
several areas, such as vascular, kidney, and respiratory systems and also highlights the most recent
progress on the knowledge and the clinical and pharmacological applications related to the most
relevant areas of healthcare.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Among hypersensitivity pneumonitis (HP) patients have been identified who develop
autoantibodies with and without clinical manifestations of autoimmune disease. Genetic factors
involved in this process and the effect of these autoantibodies on the clinical phenotype are unknown.
Matrix metalloproteinases (MMPs) have an important role in architecture and pulmonary remodeling.
The aim of our study was to identify polymorphisms in the MMP1, MMP2, MMP9 and MMP12
genes associated with susceptibility to HP with the presence of autoantibodies (HPAbs+). Using the
dominant model of genetic association, comparisons were made between three groups. For rs7125062
in MMP1 (CC vs. CT+TT), we found an association when comparing groups of patients with healthy
controls: HPAbs+ vs. HC (p < 0.001, OR = 10.62, CI 95% = 4.34–25.96); HP vs. HC (p < 0.001,
OR = 7.85, 95% CI 95% = 4.54–13.57). This rs11646643 in MMP2 shows a difference in the HPAbs+
group by the dominant genetic model GG vs. GA+AA, (p = 0.001, OR = 8.11, CI 95% = 1.83–35.84). In
the linear regression analysis, rs11646643 was associated with a difference in basal forced vital capacity
(FVC)/12 months (p = 0.013, β = 0.228, 95% CI95% = 1.97–16.72). We identified single-nucleotide
polymorphisms (SNPs) associated with the risk of developing HP, and with the evolution towards
the phenotype with the presence of autoantibodies. Also, to the decrease in plasma MMP-2 levels.
Keywords: hypersensitivity pneumonitis; metalloproteinases; genetic association; autoantibodies;
MMP1; MMP2; SNPs
1. Introduction
Hypersensitivity pneumonitis (HP) is a complex disease caused by an exaggerated immune
response to the inhalation of a wide variety of organic particles [1]. Although it has been established
that the development of the disease depends on the time of exposure and the antigenic load, only a
small proportion of individuals exposed to antigens associated with HP develop the disease, suggesting
additional host and environmental factors may play a role in the pathogenesis [2].
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In chronic stages, HP is characterized by progressive lung remodeling, which is associated
with the loss of functional architecture and an excessive extracellular matrix (ECM) deposition [3].
Therefore, ECM proteins have been previously explored as indicators of disease activity, and as potential
biomarkers of diagnosis and prognosis in patients with chronic obstructive pulmonary disease (COPD)
and idiopathic pulmonary fibrosis (IPF) [4].
Recently, the existence of hypersensitivity pneumonitis with autoimmune characteristics (HPAF)
in a US cohort has been described, determining the prevalence of 15% in the HP patients; in addition,
the autoimmunity profile was recognized as an independent predictor of mortality [5]. It is not clear
if HPAF patients have different genetic susceptibility characteristics to the non-autoimmunity HP
patients. So far there are no genetic studies on the transforming phenotype of HP patients positive
to autoantibodies.
Our aim was to identify single nucleotide polymorphisms (SNPs) associated with genetic
susceptibility in metalloproteinases genes (MMP1, MMP2, MMP9, and MMP12) in HP patients with
and without serum autoantibodies, as well as to the progression or development of the disease.
2. Materials and Methods
2.1. Study Population
An analytical, cross-sectional study was conducted. One hundred and thirty-eight patients with
Hypersensitivity Pneumonitis (HP) from the Instituto Nacional de Enfermedades Respiratorias Ismael
Cosío Villegas (INER), at Mexico City, Mexico were included.
The diagnosis was established according to criteria based upon the presence of HP, either by
high-resolution chest tomography, bronchioloalveolar lavage (BAL) with lymphocytosis ≥ 40% and/or
positive avian antigen. Additionally, in cases without a definitive clinical diagnosis, a lung biopsy
was performed to confirm the diagnosis. Subjects with positive serology were included for at least
one of the following antibodies: Antinuclear antibodies (ANAs) with a specific pattern of connective
tissue disease of any kind (cytoplasmic, nucleolar, centromeric); ANA with pattern homogeneous, fine
or coarse mottle, with titles ≥ 1:320; at least one antibody in the autoimmunity profiles for myositis
or systemic sclerosis; rheumatoid factor ≥ 3 times the lower normal limit; Anti-cyclic citrullinated
peptide (anti-CCP) ≥ 20. Salivary gland biopsy (grade 3–4). All of them without classification criteria
according to the American Society of Rheumatology (ACR/EULAR) for connective tissue disease (CTD).
A healthy subjects reference group with one hundred and eighty-four controls (HC) were included.
This study was approved by the Institutional Committee for Science and Ethics of the Instituto
Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER) (approbation codes: B20-15 and
C60-17).
2.2. DNA Extraction
We obtained an 8-mL peripheral blood sample from each participant through venipuncture.
Blood was collected in tubes with EDTA as an anticoagulant. The DNA extraction was performed
using a BDtract DNA isolation kit (Maxim Biotech, Inc. San Francisco, California, USA) and later
was quantified with a NanoDrop 2000 (Thermo Scientific, DE, USA). The contamination with organic
compounds and proteins was determined by establishing the ratio of 260/240 and 260/280 readings,
respectively. The samples were considered free of contaminants in both cases when the ratio was
between 1.7 and 2.0.
2.3. Selection of Single Nucleotide Variation
The selection process of the evaluated single-nucleotide polymorphisms (SNPs) included a
literature review of previous reports of the genetic association of SNPs in matrix metalloproteinase
(MMP) genes associated to respiratory diseases in Caucasian and Asian populations, using the NCBI
6
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(National Center for Biotechnology Information) database, and including scientific articles published
between 2007 and 2016.
For the four included genes, tag SNP selection was performed with HaploView version 4.2, using
the minor allele frequency (MAF) > 10% and r2 ≥ 0.80 in the Caucasian population as a reference.
A total of 12 SNPs were selected, and data including chromosome location and polymorphism base
change are shown in Table 1.
Table 1. Characteristics of single-nucleotide polymorphisms (SNPs) included.







rs470215 chr11:102790368 A>G G = 0.31373 3’ UTR variant
rs7125062 chr11: 102792772 T> C C = 0.33799 Intron variant
rs2071232 chr11:102794938 T>C C = 0.1993 Intron variant
MMP2
rs243839 chr16:55495499 A>G G = 0.2914 Intron variant
rs243835 chr16:55502710 C>T T = 0.4565 Intron variant
rs243864 chr16:55478410 T>G G = 0.1919 2 Kb Upstream variant
rs11646643 chr16:55484965 A>G G = 0.3101 Intron variant
MMP9
rs3918253 chr20:46010872 C>T T = 0.42674 Intron variant
rs3918278 chr20:46007015 G>A A = 0.0218 2 Kb Upstream variant
MMP12
rs12808148 chr11:102862432 T>C C = 0.1190 500 bp Downstream variant
rs17368659 chr11:102872031 G>T T = 0.1014 Intron variant
rs2276109 chr11:102875061 T>C C = 0.0988 2 Kb Upstream variant
* gnomAD: Allele frequencies are from The Genome Aggregation Database. Cite http://gnomad.broadinstitute.org/
Chr: Chromosome. MAF: Minor allele frequency. UTR: Untranslated region.
2.4. Genotyping
Alleles and genotypes were determined by real-time PCR, 3 μL of DNA were obtained at a
concentration of 15 ng/μL. Under the following conditions: 50 ◦C for 2 min, 95 ◦C for 10 min, followed
by 40 cycles of 95 ◦C for 15 seconds, and a final cycle of 60 ◦C for 1 min. The alleles and genotypes of
the SNPs were determined by real-time PCR (Real-time PCR System 7300, Applied Biosystems, CA,
USA) by allelic discrimination using TaqMan Probes at a concentration of 20× (Applied Biosystems.
Foster City CA. USA). In addition, three controls without template (contamination controls) were
included for each plate.
2.5. Obtaining Plasma Levels of MMP-2 with ELISA
Based upon the results of the genetic association analysis, plasma MMP-2 protein levels were
measured using commercial kits (Elabscience Biotechnology Inc. Houston, TX. USA). Readings were
obtained using the iMark™Microplate Absorbance Reader (Bio-Rad, CA, USA).
2.6. Statistical Analysis
The statistics program SPSS v.21 (SPSS Inc., Chicago, IL, USA) was used to describe the study
population and determine the median, minimum and maximum values for each variable, and compared
using U de Mann-Whitney. Continuous variables were reported as means with standard deviation (SD)
and compared using a Student’s t-test. Categorical variables were reported as counts and percentages,
and compared using Fisher’s exact test.
To determine the SNPs associated with the disease’s risk, the frequencies of the alleles and
genotypes of the study groups were compared, and the odds ratio (OR) was calculated with a 95%
confidence interval (CI), using Epi Info version 7.1.5.2 (CDC, GA, USA).
Statistical significance was considered if the p-value < 0.05. The ancestral allele was used as the
reference for each of the polymorphisms, and was included population data for the frequencies of the
7
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SNPs studied in the HapMap-MEX (Mexican population residing in Los Angeles, California, USA),
from the HapMap project (International HapMap Project).
In addition, a linear regression analysis was conducted to investigate the independent effect of the
associated genotypes on lung function: Diffusing lung capacity factor for carbon monoxide (DLCO),
basal forced vital capacity (FVC) and a difference in basal FVC/12 months.
MMP-2 levels were compared by median values and interquartile ranges for three comparisons:
(1) Genotype, (2) the phenotype with positive and (3) negative to autoantibodies phenotype.
3. Results
We included 138 patients with HP for the present study. Thirty-four of these patients had
autoantibodies present in serum without classification criteria for CTD. Additionally, a reference group
with 184 healthy controls was included. They were paired in gender and age with our corresponding
study group. (157 women and 27 men, 54.4 ± 12.78 years of age).
The baseline demographic data and the clinical characteristics of the entire cohort showed that the
mean age at the time of HP diagnosis was 51 years (± 11 years); with a BMI of 27 (± 5). Comorbidities
included diabetes mellitus (12%) and systemic arterial hypertension (22%). 25% of the patients are
former smokers. In the physical examination, the most frequent clinical signs were fever (39%) and
digital clubbing (31%). Exposure to the avian antigen (88%) was the most common environmental
agent identified.
Comparing the demographic characteristics between HPAbs+ and HP without the presence of
autoantibodies (Table 2) both groups were found paired in age and gender. In the HP group, a higher
proportion of former smokers was observed (29% vs. 14%, p = 0.01), also demonstrating more subjects
with systemic hypertension (25.9% vs. 8.8%, p = 0.002). There were no differences between the groups
with respect to other demographic characteristics and antigen exposure. During the study period, 19%
of the entire cohort died. There were no statistically significant differences between the groups with
respect to the number of deaths (20% vs. 18%, p = 0.9). The number of patients with a decrease of
≥ 10% in the predicted FVC differed between the groups (26.4% in HPAbs+ vs. 5.7% in HP, p = 0.0001).
When comparing the respiratory function tests and the clinical laboratory characteristics between
both groups (Table 3), those patients with the presence of antibodies (HPAbs+) showed a better FVC
predicted and DLCO without being statistically significant.
Table 2. Clinical and demographic characteristics.
Characteristics HPAbs+ (n = 34) HP (n = 104) p-Value
Age, years 52.9 ± 9.3 50.9 ± 11.7 0.3
Sex, female. n (%) 29 (85.2) 89 (85.5) 1.0
BMI, kg/m2 27.3 ± 5.6 27.9 ± 5.2 0.5
Former smokers. n, (%) 5 (14.7) 30 (29.1) 0.01
Symptoms before diagnosis, months. 24 (1–120) 24 (6–192) 0.1
Antigen exposure
Avian, n (%) 30 (88.2) 92 (88.4) 1.0
Unknown, n (%) 4 (11.7) 12 (11.5) 1.0
Diabetes mellitus, n (%) 6 (5.7) 10 (9.6) 0.2
Systemic hypertension, n (%) 3 (8.8) 27 (25.9) 0.002
Fever, n (%) 5 (14.7) 10 (9.6) 0.5
Digital clubbing, n (%) 7 (20.5) 26 (25) 0.4
Deceased, n (%) 6 (20) 17 (18) 0.9
≥10% FVC decline, n (%) 9 (26.4) 6 (5.7) 0.0001
HP: Hypersensitivity pneumonitis; Abs: Autoantibodies; mean ± SD; median (minimum and maximum values).
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Table 3. Assessment of lung function and main laboratory findings in HP patients.
Characteristics HPAbs+ (n = 34) HP (n = 104) p-Value
FVC % predicted 60 (29–97) 51 (20–98) 0.1
DLCO % predicted 60 (20–125) 41 (16–102) 0.06
pO2, mm Hg 50 (34.7–77.7) 47 (22–71.1) 0.1
Oxygen therapy, n (%) 9 (26) 37 (35) 0.09
PSAP, mm Hg 32 (20–77) 40 (20–90) 0.02
Laboratory blood test
Optical density for avian antigen 1.45 (0.22–4.40) 0.89 (0.15–3.37) 0.03
White blood cell count, n x 103 /mm3 8.1 (4.7–13.3) 8.1 (2.8–17.8) 0.6
Lymphocytes % 22.6 (12.5–36.5) 20.2 (3.8–77.9) 0.09
Eosinophils % 3.6 (1–12.3) 2.6 (1–18.8) 0.1
Hemoglobin g/dl 15.8 (13.2–20.9) 16 (11.7–21.2) 0.5
Hematocrit % 48.3 (39.4–63.3) 48.8 (35.8-68.7) 0.9
C-reactive protein mg/dl 1.023 (0.121–7.160) 0.541 (0.013–8.920) 0.006
BAL Lymphocytes % 54.5 ± 14.2 46.2 ± 21.2 0.03
HP: Hypersensitivity pneumonitis; Abs: autoantibodies; BAL: Bronchoalveolar Lavage. Mean ± SD; median
(minimum and maximum values).
However, those patients with HP showed differences in relation to PSAP, with a higher median
compared to the HPAbs+ group (32 mm Hg vs. 40 mmHg p = 0.002) required a greater number of
patients with supplemental oxygen (26% vs. 35%; p = 0.09).
In the laboratory studies, the greater optical density of avian antigen was identified in the HPAbs+
group (1.45 DO vs. 0.89 DO, p = 0.03). C reactive protein was also compared as an acute phase reactant
in both groups, showing higher levels in patients with HPAbs+ (1.023 mg/dl vs. 0.541 mg/dl, p = 0.006).
Regarding bronchoalveolar lavage (BAL), the percentage of lymphocytosis was higher in the HPAbs+
group (54.5% vs. 46.2%, p = 0.03).
The most expressed antibodies in our study group (Table 4) were the ANA type (50%) showing a
higher frequency in their expression with a homogeneous pattern (20%) ≥ 1:320. Followed by others,
such as the rheumatoid factor (14.9%) among the most frequently observed.
Table 4. Autoimmune serologic tests.
Characteristics n (%)
ANA ≥ 1:320 17 (50.0)
Nuclear fine speckled 2 (5.8)
Nuclear coarse speckled 1 (2.9)
Homogeneous nuclear 7 (20.7)
Nucleolar 4 (11.7)
Fibrillar Cytoplasmatic 3 (8.9)
Others 17 (50.0)
RF ≥ 3x upper limit normal 5 (14.9)
Anti-topoisomerase (Scl-70) 2 (5.8)
Anti-Ro (SS-A) 1 (2.9)
Anti-La (SS-B) 2 (5.8)
Anti-dsDNA 4 (11.7)
Anti-CCP ≥ 3x upper limit normal 3 (8.9)
ANA: Anti-nuclear antibody; anti-CCP: Anti-Citrullinated Peptide Antibodies.
3.1. Analysis of Association by Alleles and Genotypes
Alleles associated with risk were identified in the MMP1 and MMP2 genes. The T allele for
rs7125062 was found associated when comparing groups of patients with healthy subjects: HPAbs+ vs.
HC (p < 0.001, OR = 3.69, CI 95% = 2.16–6.29); HP vs. HC (p < 0.001, OR = 2.97, CI 95% = 1.99–4.09).
(Supplementary Table S1). Regarding rs11646643 in MMP2, the allele A in frequency was statistically
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significant when comparing both groups of patients: HPAbs+ vs. HP (p = 0.03, OR = 1.88, CI 95%
1.06–3.33). When compared with healthy subjects, only the HPAbs+ group obtained a statistically
significant difference (p = 0.01, OR = 2.35, CI = 95% 1.36–4.05). The group of HP patients showed
no difference with the reference group of healthy subjects. (Supplementary Table S1) Allele and
genotype frequencies for the three study groups and HapMap-MEX population are included in the
Supplementary Tables S2–S4.
Using the dominant model of genetic association, comparisons were made between the three
groups. For rs7125062 (CC vs. CT + TT) in the MMP1 gene, an association was found when comparing
both groups of patients with healthy subjects, respectively: HPAbs+ vs. HC (p < 0.001, OR = 10.62,
CI 95% = 4.34–25.96) and HP vs. HC (p < 0.001, OR = 7.85, CI 95% = 4.54–13.57). (Table 5).
In addition, grouping all HP patients (HPAbs+ and HP) were compared against HC group,
observing an association, (p < 0.001, OR = 8.42, CI 95% = 5.07–13.98). (Supplementary Table S6).
On the other hand, for rs11646643 in MMP2, HPAbs+ patients presented a lower frequency in
the homozygous GG genotype compared to the HP group (GF = 5.88% vs. 33.65%). The difference
was statistically significant when comparing them based on the dominant genetic model GG vs. GA +
AA, (p = 0.001, OR = 8.11, CI 95% = 1.83–35.84). A similar effect occurs when comparing the group
HPAbs+ vs. HC (p < 0.001, OR = 11.51 CI 95% = 2.67–49.49). (Table 5) Interestingly, the association was
significative comparing all HP patients (independently of the serological phenotype) against healthy
subjects, respectively: HP (all) vs. HC (p = 0.006, OR = 1.96, CI 95% = 1.21–3.16). (Supplementary
Table S6).
For the rest of the SNPs of MMP1 and MMP2, no significant associations were found. There was
no association for the MMP9 and MMP12 genes. Data for genetic association models for SNPs and
genotypes in MMP9 and MMP12 genes are shown in Supplementary Tables S7 and S8.
In the linear regression analysis, only rs11646643 (GA+AA) was associated to a difference in
basal FVC/12months (p = 0.013, β = 0.228, 95% CI, 95% = 1.97–16.72). No other SNPs or variables
were associated.
The genotype and allele frequencies of the 12 evaluated SNPs in Mexicans residing in Los Angeles
(HapMap-Mex) are shown in the Supplementary Tables S2–S4.
Genotype frequencies of the two associated SNPs in the HC group were compared to those in
the HapMap-Mex. The frequency of the rs7125062 CT genotype in the MMP1 gene in the HC group
was reduced when compared with the population data from the HapMap-Mex (2.17% vs. 58.0%),
contrary to observed with the frequency of the CC genotype, which was elevated in the HC group.
(Supplementary Table S2).
For the associated SNP in the MMP2 gene, (rs11646643) the AA genotype frequency in the HC
group was similar from the reported in the HapMap-Mex (32.61% vs. 30.0%). Interestingly, the GG and
GA genotype frequencies have important differences in their distribution. (Supplementary Table S3).
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3.2. MMP-2 Plasma Levels
Plasma levels of the MMP-2 protein of the HPAbs+ and HP groups were measured by ELISA
using commercial kits. There were no significant differences when comparing the levels between
patients’ groups (132.98 vs. 130.06 ng/ml, p = 0.8). However, when these groups were merged and
grouped by the rs11646643 genotype (GG vs. GA+AA), there was a statistically significant difference
(188.84 vs. 123.39 ng/ml, p = 0.009), maintaining this tendency in the same comparisons, but this time
intragroup. (Figure 1)
Figure 1. Median values and interquartile ranges of MMP-2 plasma levels in (a) genotypes of
hypersensitivity pneumonitis (b) phenotype with positive autoantibodies (c) phenotype negative
to autoantibodies.
4. Discussion
In this study we demonstrated that some patients with HP express autoantibodies during clinic
evolution without classification criteria for connective tissue disease.
We observed that the presence of autoantibodies establishes an inflammatory phenotype with
an elevation of acute phase reactants compared to seronegative HP. However, no differences were
observed in respiratory function tests.
There is little knowledge regarding this transforming phenotype with the presence of antibodies
present in the serum, as well as the identification of clinical factors associated with poorer results.
In the cohort of patients with HP, most of the subjects were in a chronic phase. The group of subjects
with HP (without the presence of antibodies) showed a higher degree of pulmonary hypertension with
a decrease in DLCO compared to the seropositive subjects, while in the group with HPAbs+, the levels
of avian antigen and C-reactive protein were higher, remarking inflammation and lymphocytosis in
the BAL.
We can propose from these differences that the HPAbs+ group develops an inflammatory
phenotype, and the presence of autoantibodies could have a detonating role. As in IPF, acute
exacerbations can occur in chronic HP conditions, and exposures to inhaled antigens can trigger
these exacerbations.
However, despite the avoidance of antigens, progressive pulmonary fibrosis and death may occur,
suggesting that additional factors may contribute to the activity of the disease.
In the chronic stages, HP is characterized by a progressive pulmonary remodeling, which is
associated with the loss of functional architecture and the excessive deposition of ECM.
Among the metalloproteinases, it has been shown that MMP-1 and MMP-2 play an important
role in the remodeling of the respiratory tract, and also are implicated in the degradation of fibrillar
collagen, gelatin and collagen type IV, that are the most abundant compounds of the extracellular
matrix and the basal membranes [6,7]. Besides, it is known that MMP-1 increases the proliferative and
migratory capacities of the epithelial alveolar cells and protects the cells of death [8].
Recently some studies prove that MMP-1 and MMP-2 mediate the suppression induced by
interleukin-13 of the expression of the mRNA of elastin in the fibroblasts of the respiratory tract.
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MMP-2 also induces the production of collagen, activating the latent transforming growth factor beta-1,
an important factor that helps fibrogenesis [9].
In this study of genetic association, we show that two SNPs (of the twelve evaluated in the MMP1,
MMP2, MMP9 and MMP12 genes) are associated with genetic susceptibility for HP in Mexican Mestizo
population. In the MMP1 gene, the rs7125062 was associated in the comparations HPAbs+ and HP vs.
HC group; while rs11646643 in the MMP2 gene is associated with the risk of disease and the decline
of the lung function in HP; i.e., we can able to identify genetic differences among HPAbs+ and HP
patients without autoantibodies.
The rs7125062 was associated in comparisons between groups by serological phenotypes against
healthy subjects (HC); In addition, this association was maintained comparing all patients regardless of
the phenotype (positive or negative to autoantibodies) against healthy subjects. Observing a tendency
of association in relation to the respiratory disease, and not necessarily to the serological phenotype.
Regarding rs11646643 of the MMP2 gene, it is possibly associated with the serological phenotype of
the disease. It is possible to perceive due to the increased risk in the respective comparisons: HPAbs+
vs. HP; HPAbs+ vs. HC, (OR = 8.11, OR = 11.51). However, this does not happen to compare the HP
vs. HC group.
The modification of the effect on the risk is observed when comparing all patients with HP
(regardless of the serological phenotype) against healthy subjects (p = 0.006, OR = 1.96), observing the
influence of the seropositive phenotype on this association and therefore the role of this SNP.
Just a little proportion of the exposed individuals to an antigen associated with HP will develop
the disease, suggesting the existence of another genetic factor associated with the risk. Nowadays
there are no studies of the genetic association of rs7125062 and rs11646643 with HP. Therefore, this is
the first report of genetic association that involves polymorphism of a single nucleotide with the risk of
developing and decline of lung function in the Mexican mestizo population.
In the last SNP, it is located at the GATA-1 (CTATCT) site of the promoter region of the MMP2
gene [10], that has two sites of the union for the transcription factors AP-2, p53, Sp1 y Sp3 [11].
These transcription factors regulate the transcription rate of the gene and therefore the expression
of the protease. Also, there is a tag SNP of the polymorphism rs243865 (-1306 C/T) and rs243866
(-1575G/A) [12], that are found in the gene promoter.
On the other hand, the genetic factor could interact with immunological and environmental
factors to influence the individual susceptibility. A similar phenomenon could have been happening
with the genotypical frequencies of the group of subjects with autoantibodies in comparison with HP
seronegative subjects. The genotype GA+AA of rs11646643 in the MMP2 gene shows a difference of
27.77% between these two populations, respectively. Curiously this genotype has been correlated to a
difference between basal FVC/12 months through of linear regression.
This finding supports the participation of the rs11646643 genotype (GA+AA) in MMP2 and its
association in the lung function decline, independently of the development, or not autoantibodies.
Regarding MMP-2, this is involved in the remodeling of the extracellular matrix in the airways and
pulmonary interstice, degrading molecules like collagen type I, III, IV, V, VII y X, gelatin, fibronectin,
laminin and aggrecan [13].
In the comparison between the patient groups (HPAbs+ vs. HP), a higher plasmatic level of
MMP-2 was identified in those with the GG genotype, suggesting that plasmatic levels were modified
in a genotype-dependent mode. In our study, we found that the plasmatic levels of MMP-2 decrease in
the subjects with genotype (GA+AA) of rs11646643 in comparison with the subjects genotype (GG).
MMP-2 has the capacity of cleaving the chemotactic protein of the monocytes 3 (MCP-3) that allows
getting to join to the chemotactic receptors 1, 2 and 3 without activating them. This characteristic
suggests that the MMP2 decrease contributes to the persistent inflammatory response, not allowing
the modification MCP-3 [14].
The variation in the levels of MMPs is affected by the course and progression of the disease;
interestingly, the association seems to be in function of the genotype and not of the clinical phenotype.
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A limitation in our study is that our Mexican mestizo population for ancestry has several genetic
contributions, mainly Amerindians and Caucasians in different proportions.
Our result contributes to scientific knowledge, identifying candidate polymorphisms/genes in
the development and progression of the HP. Nowadays we still require more assays to evaluate
these variants like potential markers of clinical phenotypes for the disease, considering that HP is an
inflammatory disease that in some people can develop chronic fibrosing disease, increasing morbidity
and mortality.
5. Conclusions
Our findings demonstrate a subgroup of patients with hypersensitivity pneumonitis who develop
autoantibodies without meeting the classification criteria for connective tissue disease. The presence of
these antibodies contributes to a significant inflammatory response, possibly detonated by chronic
exposure to a given environmental antigen.
Two polymorphisms in the MMP1 and MMP2 genes are associated with the risk of hypersensitivity
pneumonitis in the Mexican mestizo population.
There are differences in the plasma levels of the MMP-2 protein among HP
patients genotype-depending.
Our study suggests that polymorphisms and genes associated with metalloproteases influence
the development of HP and worsening of lung function.
The identification of autoantibodies in patients with HP can have an impact on the course of the
disease and the subsequent therapeutic management of interstitial lung diseases, since our results
show, there are demographic and functional differences that probably influence prognosis.
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Abstract: Background: Matrix metalloproteinases (MMPs) are involved in vascular wall degradation,
and drugs able to modulate MMP activity can be used to prevent or treat aneurysmal disease. In this
study, we evaluated the effects of statins on MMP-2, MMP-9, and neutrophil gelatinase-associated
lipocalin (NGAL) in both plasma and tissue in patients with aneurysmal disease. Methods:
We performed a prospective, single-blind, multicenter, control group clinical drug trial on 184
patients of both sexes >18 years old with a diagnosis of arterial aneurysmal disease. Enrolled patients
were divided into two groups: Group I under statin treatment and Group II not taking statins.
In addition, 122 patients without aneurysmal disease and under statin treatment were enrolled as a
control group (Group III). The expression of MMPs and NGAL in plasma was evaluated using ELISA,
while their expression in endothelial tissues was evaluated using Western blot. Results: The ELISA
test revealed greater plasma levels (p < 0.01) of MMPs and NGAL in Groups I and II vs. Group III.
Western blot analysis showed higher expression (p < 0.01) of MMPs and NGAL in Group II vs. Group
I, and this increase was significantly higher (p < 0.01) in patients treated with low potency statins
compared to high potency ones. Conclusions: MMPs and NGAL seem to play a major role in the
development of aneurysms, and their modulation by statins suggests that these drugs could be used
to prevent arterial aneurysmal disease.
Keywords: MMPs; NGAL; statins; arterial aneurysms; patients
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1. Introduction
An aneurysm is the dilatation of the aorta induced by vascular wall degradation that can localize
centrally or peripherally, affecting all portions of the aortic tube [1]. Several biochemical mediators
are involved in the vascular wall degradation of the aorta, e.g., neutrophil elastase, serine proteases,
and matrix metalloproteinases (MMPs) [2]. This latter class of enzymes is divided into collagenases
(MMP-1, MMP-8, MMP-13, MMP-18), stromolysins (MMP-3 and MMP-10), matrilysins (MMP-7 and
MMP-26), and gelatinases (MMP-2 and MMP-9), according to their protein degradation capabilities.
In general, MMPs are able to degrade most components of the extracellular matrix (ECM) of the vessel
wall, leading to an imbalance between ECM synthesis and degradation [3]. MMP-2 and MMP-9 are the
most common MMPs involved in endothelial degradation [4–6]. Their activity chiefly depends on
the balance between the formation of complexes containing MMP-9, neutrophil gelatinase-associated
lipocalin (NGAL), and the expression of MMP tissue inhibitors (TIMPs) [7]. An imbalance between
these factors results in uncontrolled changes in the ECM, which may lead to a widening of the
aneurysm vessel with a future aortic aneurysm rupture [3,8–10]. Previously, we reported that plasma
MMP-9 and NGAL levels were significantly elevated in patients with cerebral artery aneurysms [11].
Moreover, we also documented that several drugs/compounds can modulate the activity of MMPs,
improving a patient’s clinical outcomes [12,13]. It has been documented that HMG-CoA reductase
inhibitors, also known as statins, inhibit the synthesis of cholesterol in the liver and can decrease
arterial aneurysm growth rates by stabilizing endothelial function [14–16] and reducing inflammation
and oxidative stress [17,18]. In this pilot clinical trial, we evaluated the effects of statins on MMP-2,
MMP-9, and NGAL plasma levels in patients with aneurysmal disease.
2. Materials and Methods
2.1. Study Design
We performed a prospective, single-blind, multicenter, control group study from October 2017 to
October 2019 in subjects admitted to the Department of Medical and Surgical Science at University
Magna Graecia, Catanzaro and to the Unit of Vascular and Endovascular Surgery at the Regional
Hospital “Pugliese Ciaccio”, Catanzaro.
The study was approved by the Investigational Review Board, in accordance with the Declaration of
Helsinki and the Guideline for Good Clinical Practice. Before the beginning of the study, all participants
provided written informed consent.
2.2. Patients
In this prospective, pilot clinical drug trial, we enrolled patients of both sexes >18 years old
with aneurysmal disease that had been diagnosed clinically and instrumentally. Patients who had
not signed the informed consent form were excluded from the study. The diagnosis of aneurysmal
disease was determined by assessing patient presentation and vascular examination, including an
ankle–brachial index of <0.9 (in peripheral diseases) and duplex ultrasonography.
2.3. Experimental Study
Enrolled patients were divided into two groups: Group I (statin-treated): patients with a central or
peripheral aneurysm under statin treatment; Group II (statin-free): patients with a central or peripheral
aneurysm without a history of statin use. The cardiovascular risk factors that were analyzed included
a history of smoking, diabetes mellitus, hypertension, hyperlipidemia, and coronary artery disease
based on a presenting thallium nuclear stress test or transthoracic echocardiogram. Chronic renal
failure was defined as serum creatinine level >1.5 mg/dL.
At the time of admission, each patient underwent a baseline contrast-enhanced computed
tomography scan for diagnosis of the disease and for evaluation of the aneurysm length, maximum
aneurysm diameter, diameter of the access vessels, and presence or absence of a wall thrombus at the
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level of the central or peripheral aneurysm. Follow-ups were performed at 1 (T1) and 3 (T2) months
after surgery. Finally, patients >18 years old without aneurysmal disease, but treated with statins,
were enrolled as Group III and were defined as a control group.
2.4. Endpoints
Primary endpoint: Statistically significant difference (p < 0.05) in the plasma levels of MMP-2,
MMP-9, and NGAL between patients with central and peripheral aneurysms treated or not treated
with HMG-CoA reductase inhibitors. In addition, the statistically significant difference (p < 0.05) of
plasma levels of MMP-2, MMP-9, and NGAL among patients with aneurysmal disease taking statins
at high and low doses/potencies.
Secondary endpoint: Correlation between the expression of MMP-2, MMP-9, and NGAL in plasma
and tissue levels and the maximum diameter of the aneurysm.
Safety endpoint: Development of muscle pain in patients under statin treatment compared to the
patients free of statins and correlation with plasma levels of MMP-2, MMP-9, and NGAL.
2.5. Enzyme-Linked Immunosorbent Assay (ELISA)
In patients enrolled in Groups I and II, to evaluate the plasma levels of MMP-2, MMP-9, and NGAL,
blood samples collected at the time of admission (T0) and during the follow-ups (T1 and T2) were frozen
at −80 ◦C for ELISA evaluation. In contrast, in patients enrolled in Group III, blood collected during the
routine evaluation for lipid plasma levels (T0) was frozen at −80 ◦C for ELISA evaluation. The ELISA
test was conducted according to our previous study [19–21]. Commercially available sandwich ELISA
kits for the inactive form of MMP-2, MMP-9, and NGAL (Biotrak MMP-2 and MMP-9 Human ELISA
System, Amersham Pharmacia Biotech, Buckinghamshire, UK; NGAL Human ELISA System, Bioporto
Diagnostics, Gentofte, Denmark) were used, following the manufacturers’ instructions. The absorbance
of each well was measured with a microtiter plate reader (Synergy H1, BioTeck, Winooski, VT, USA).
2.6. Protein Extraction and Immunoblot Analysis
Western blot analysis was performed in agreement with our previous studies [22–24] and only
on tissue derived from arterial aneurysms (Groups I and II). About 40 mg of arterial aneurysm
obtained by removing the aneurysm wall during the surgical procedures was immediately washed
in ice-cold physiological saline. In agreement with the instructions of the total protein extraction kit,
the tissues were lysed in 2 mL of tissue protein extraction reagent (25 mmol/L bicine, 150 mmol/L
sodium chloride pH 7.6 (Thermo Scientific, Waltham, MA, USA)) and then were placed in ice for
homogenization by grinding. Tissue homogenates were centrifuged twice for 10 min at 12,000× g and
4 ◦C. Supernatants were collected and proteins were quantified according to the instructions of the
Quant-iT™ Protein Assaykit (Thermo Fisher). They were then lyophilized and resuspended in 100 μL
tissue protein extraction reagent, and an equal amount of protein extracts was then separated using
15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) under constant voltage
(about 150 V) and transferred to nitrocellulose membranes (Amersham Pharmacia, Little Chalfont, UK).
Immunoblotting of protein was performed using anti-MMP-2, anti-MMP-9, and anti-NGAL (abcam
#ab86607, #ab119906, and #ab23477, respectively) monoclonal primary antibodies (1:1000); each one
was separately incubated for 1 h at room temperature in TBST 1x and 5% of milk under shake. Then,
goat antimouse IgG-HRP (abcam #ab205719) secondary antibody (1:5000) was incubated for 2 h at room
temperature in TBST 1x as described [7]. Loading conditions were determined with polyclonal GAPDH
(Sigma-Aldrich) primary antibody (1:1000) after membrane stripping for 1 h at room temperature in
TBST 1x and 5% of milk under shake. Then, goat antirabbit IgG-HRP (Santa Cruz #sc-2004) secondary
antibody (1:10,000) was incubated for 2 h at room temperature in TBST 1x. Bands were visualized by
enhanced chemiluminescence (ECL Plus, Amersham Pharmacia); the intensities of experimental bands
were analyzed and normalized by loading control GAPDH by computer-assisted densitometry using
Photoshop and then expressed as arbitrary units. All experiments were performed in triplicate.
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2.7. Safety Evaluation
The development of adverse drug reactions (ADRs) (e.g., liver toxicity and myalgia) and drug–drug
interactions were evaluated using the Naranjo scale and the drug interactions probability scales,
respectively, in agreement with our previous studies [25–28].
2.8. Statistical Analysis
Patient characteristics data (Table 1) are expressed as absolute values or as mean ± standard
deviation. MMP and NGAL expression data (Figures 1–4) are represented as mean values ± standard
error of the mean (SEM). The Student’s t-test was performed to analyze the difference between each
group and the control. Analysis of variance was used to evaluate the difference between the groups.
The threshold of statistical significance was set at * p < 0.05. SPSS (SPSS Inc., Chicago, IL, USA) software
was used for statistical analyses. We defined and labeled this study as exploratory; therefore, we did
not determine a power calculation.
Table 1. Enrolled patients in Group I (statin-treated), Group II (statin-free), and Group III (without
aneurysm, taking statins, defined control group). Data are expressed as absolute values or as mean ±
standard deviation.
Characteristics Group I (n = 95) Group II (n = 119) Group III (n = 122)
Mean age (years) 71.5 ± 6.3 70.6 ± 6.4 69.3 ± 6.3
Male 65 78 68
Female 30 41 54
Aneurysm diameter 54.2 ± 15.2 49.3 ± 17.9 - - - -
Cigarette smokers 42 63 59
Body mass index
>30 12 10 22
25–29.9 70 94 83
18.5–24.9 13 15 17
<18.5 0 0 0
Glutamic oxaloacetic transaminase 33.3 ± 3.2 28.1 ± 4.9 26.7 ± 4.1
Glutamic pyruvic transaminase 32.5 ± 4.3 31.1 ± 3.6 29.3 ± 5.5
Platelet count 290.630 ± 21.315/μL 312.250 ± 28.530/μL 279.870 ± 53.210/μL
Comorbidity
Blood hypertension 86 112 108
COPD 45 60 36
Hypercholesterolemia 95 - - - - 68
Acute coronary syndrome 55 - - - - 15
Diabetes type II 42 21 35
Diabetes type I 8 10 9
Pharmacological therapy
Antihypertensive 86 112 108
Antiarrhythmic 32 - - - - 2
Bronchodilators 45 60 36
Statins 95 - - - - 68
Hypoglycemic drugs 39 16 35
Insulin 8 10 9
ADRs related to statins
Myalgia 38 39
Gastrointestinal disturbance 12 16
Increase in transaminases 8 10
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Figure 1. Plasma levels of matrix metalloproteinase (MMP)-2, MMP-9, and neutrophil
gelatinase-associated lipocalin (NGAL) in enrolled patients at the time of admission (T = 0). Group I:
aneurysmal patients using statins; Group II: aneurysmal patients, statin-free; Group III: control patients.

























Figure 2. Plasma levels of MMP-2, MMP-9, and NGAL in aneurysmal patients under statin treatment
(Group I) at the time of admission (T0) and 1 (T1) and 3 (T2) months later. T1 vs. T0, * p < 0.01; T2 vs.
























Figure 3. Plasma levels of MMP-2, MMP-9, and NGAL in aneurysmal patients free of statin treatment
(Group II) at the time of admission (T0) and 1 (T1) and 3 (T2) months later. T1 vs. T0, * p < 0.05; T2 vs.
T1, # p < 0.05.
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Figure 4. (A) Representative tissue levels of MMP-2, MMP-9, and NGAL in aneurysmal tissue.
(B) GAPDH is used as loading control. (C) Tissue expression of MMP2, MMP-9, and NGAL in patients
enrolled in Group I and treated with statin high potency (I SHP) (taking rosuvastatin 40 mg/day or
atorvastatin 80 mg/day) or statin low potency (I SLP) (taking rosuvastatin <40 mg/day or atorvastatin
<80 mg/day) and in patients enrolled in Group II (statin-free treatment). The results are expressed as
mean ± standard error of the mean (SEM); * p < 0.01 vs. Group I SHP; # p < 0.01 vs. Group I SLP.
3. Results
3.1. Patients
In this study, we enrolled 184 patients—123 males (mean age 73.2 ± 8.6 years) and 61 females
(mean age 68.7 ± 4.1 years)—with a diagnosis of central or peripheral aneurysmal disease: 15 in the
popliteal artery (APA = 8.1%), 6 in the femoral artery (AFA = 3.3%), 28 in the iliac artery (AIA = 15.2%),
and 135 in the abdominal aorta (AAA = 73.4%). Group I statin-treated: there were 65 patients—45
males (mean age 73.5 ± 8.4 years) and 20 females (mean age 69.4 ± 4.3 years)—taking rosuvastatin
10–40 mg/day or atorvastatin 20–80 mg/day. In this group, we designated further subgroups as statin
high potency (SHP) (taking rosuvastatin 40 mg/day or atorvastatin 80 mg/day) and statin low potency
(SLP) (taking rosuvastatin <40 mg/day or atorvastatin <80 mg/day). Group II statin-free: there were
119 patients—78 males (mean age 72.9 ± 8.8 years) and 41 females (mean age 68.3 ± 4.0 years)—who
had never used statins as pharmacological treatment. Both groups had true aneurysms and had not
received a vascular intervention or any other operative vascular interventions within the 3 years prior
to inclusion in this study.
The control group was classified as Group III. In this group, there were 122 patients—68 males
(median age 71 ± 7.3) and 54 females (median age 67.5 ± 5.2)—under statin treatment; they were
screened with duplex ultrasonography to exclude the presence of asymptomatic central or peripheral
aneurysms. Finally, in 58 patients of Group I (61%) and in 65 patients of Group III (53.3%), adverse drug
reactions related to statin use were present. Despite this, statin treatment was not dismissed.
Patients’ characteristics are shown in Table 1.
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3.2. Elisa Test of MMP-2, MMP-9, and NGAL Plasma Levels
ELISA biochemical determination revealed greater plasma levels (p < 0.01) of MMP-2 and MMP-9
in patients with aneurysms (Groups I and II), compared to control patients (Group III); lower levels of
MMP-2, MMP-9, and NGAL (p < 0.01) were found in patients treated with statins (Group I) compared
with untreated patients (Group II) (Figure 1).
The same trend was evident in Groups I and II (Figures 2 and 3; p < 0.05). The reduction (T2)
remained significantly higher (p < 0.01) compared to patients enrolled in Group III (Figure 4). Finally,
we did not record any difference in the expression of MMP-2 and MMP-9 in patients who developed
myalgia during statin treatment.
3.3. Protein Expression Levels of MMP-2, MMP-9, and NGAL in Aneurysmal Tissues
Western blot analysis showed increased protein expression (p< 0.01) of MMP-2, MMP-9, and NGAL
in tissues of statin-untreated patients (Group II) compared to statin-treated patients (Group I).
This increase was significantly higher (p < 0.01) in patients receiving low potency statins (Group I SLP)
compared to patients treated with high potency statins (Group I SHP) (Figure 4A–C).
4. Discussion
In this study, we evaluated the expression of MMP-2, MMP-9, and NGAL in the plasma and tissue
of patients with aneurysmal diseases. The modulation of these three biochemical indicators of aortic
integrity in patients under statin treatment was also studied. Recently, in a preclinical experimental
model, Krueger et al. [29] documented that vascular damage is associated with the upregulation of
MMPs, which are involved in elastin degradation. An uncreated expression of MMPs causes loss
of elastin and can induce compensatory fibrosis and inflammation with the destruction of all major
matrix components, excessive distension, and vessel wall rupture [30–32]. In this view, recently, we
documented that vascular damage induces an inflammatory response that can evoke a local reaction
with the activation and recall of cytokines and inflammatory mediators [33] involved in aneurysmal
diseases [32,34]. In an interesting pilot study, Yuwen et al. [35], investigating the expression of a plethora
of cytokines in patients with aortic aneurysmal disease compared to healthy patients, described the
role of several cytokines (i.e., CC chemokines, CXC chemokines, proinflammatory cytokines, growth
factors, proteolytic proteins, and cell adhesion cytokines) in the pathogenesis of the aneurysms. In this
study, several cytokines (e.g., IL-1α, IL-1β, IL-2, and IL-17) and growth factors (e.g., insulin-like growth
factor-1, transforming growth factor-α, and tumor necrosis factor-α) were reported to activate NGAL,
a marker of neutrophil activation [36] that is involved in tissue injury [37,38]. In our previous study,
we documented an increase in plasma levels and tissue expression of both MMP-9 and NGAL in
patients with central and peripheral aneurysms [7]. In the present study, we confirmed the involvement
of MMP-2, MMP-9, and NGAL in aneurysmal lesions (Figure 1), and we also demonstrated their
plasma decrease during the follow-ups (Figures 2 and 3). We also detected the protein expression
levels of those biochemical mediators in aneurysmatic tissues, with no differences with respect to
the location of the lesion. MMP-2 is derived from smooth muscle cells and fibroblasts and to a
lesser extent macrophages [39], whereas MMP-9 is predominantly derived from macrophages and
neutrophils [40]. Both are involved in the development of thoracic and aortic aneurysms [41,42].
On the other hand, NGAL levels reflect both inflammation and leukocyte activation in patients with
arterial aneurysms and are correlated with aneurysm growth [43]. Of note, NGAL is released in the
acute phase of inflammation by the secretory machinery of leukocytes and, in the glycosylated form,
covalently binds to MMP-9 to make the MMP-9/NGAL complex. This complex, in turn, triggers an
enhancement of the enzymatic activity of MMP-9 and protects MMP-9 from proteolytic degradation by
TIMP1 and 2 proteins [37,44]. The crucial role of MMP-9 in the imbalance of the aortic wall drives
the need to have pharmacological tools that can decrease its levels in the aneurysmal patient. In this
view, we documented that several drugs/compounds are able to inhibit MMP expression [13,20].
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Likewise, we reported that HMG-CoA reductase inhibitors (simvastatin and rosuvastatin) can block
RAS prenylation, and thus are able to inhibit NF-κB signaling as well as decrease MMP-2 and MMP-9
protein expression in cell culture models [17,18]. In the present study, we reported that treatment
with HMG-CoA reductase inhibitors at a high dose decreases the aneurysmal tissue levels of MMP-2,
MMP-9, and NGAL (Figure 4). In an experimental study, Luan et al. [45] reported that statins inhibit
in a dose-dependent manner the secretion of MMPs and decrease their collagenolytic, caseinolytic,
and gelatinolytic activities. Moreover, other authors have documented that statins reduce the secretion
of a broad spectrum of MMPs from macrophages and vascular endothelial cells, suggesting a beneficial
effect of these drugs on these cells [46,47]. In our study, we documented that high potency statins
compared to low potency ones have chemical characteristics that allow them to independently affect
MMP-2, MMP-9, and NGAL in aneurysmal tissue levels, with no difference with respect to the site of
the aneurysm. On the other hand, in the current study, we documented that 61% of patients in Group I
and its relative subgroups, as well as 53.3% of patients in Group III, developed muscle pain as ADRs
related to statin use. It is worth mentioning that the inhibition of HMG-CoA reductase blocks the
synthesis of mevalonate, a precursor of farnesyl pyrophosphate that, in addition to being a substrate of
cholesterol, is also the substrate for ubiquinone, also known as coenzyme Q synthesis [48]. Therefore,
integrating coenzyme Q with supplements can be a strategy for reducing muscle pain mediated by
statins [49,50]. Our study adds knowledge for clinical practice, but it also has some limitations. First,
we measured the immune reactivity of MMP-2, MMP-9, and NGAL in the plasma of patients suffering
from aneurysmal disease. These biochemical assays do not reflect the enzymatic activity of the protease.
Second, the aneurysmal tissues were obtained from surgery patients in which the aneurysm had
reached a specific size, so we do not know if the early stages of aneurysms have the same alterations
described here. Third, more biochemical and mechanistic studies are required to determine the action
of HMG-CoA reductase inhibitors, since NGAL decreased as well as MMP-9.
5. Conclusions
In conclusion, MMP-2, MMP-9, and NGAL levels seem to play a major role in the development of
aneurysms, and their levels are modulated by statin treatment, suggesting that HMG-CoA reductase
inhibitors have a role in the prevention of these clinical manifestations.
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Abstract: The diagnostic accuracy of point-of-care (PoC) applications may be compromised in
individuals with additional inflammatory conditions. This cross-sectional study examined the
performance of a commercial oral rinse active matrix metalloproteinase-8 (aMMP-8) PoC immunotest
in individuals with (n = 47) and without Crohn’s disease (CD) (n = 41). Oral rinse collected from
the participants was analyzed by the PoC immunotest. Molecular forms and fragments of salivary
MMP-8 were detected by western immunoblotting. The sensitivity of the immunotest for periodontitis
was 60.0% in the CD group and 90.0% in the control group. The respective specificity was 75.0% and
80.0%. In both groups, clinical diagnosis of periodontitis exhibited a significant association with the
immunotest results, however, the odds ratio (OR) was more than ten-fold in controls (OR 54.3, 95%
CI: 3.1–953, p = 0.006) in comparison to CD patients (OR 5.2, 95% CI: 1.3–21.6, p = 0.022). According to
Western immunoblot results, the immunotest MMP-8 positivity was not related to elevated levels of
molecular forms and fragments of MMP-8 in the CD group, as in the control group. The diagnostic
accuracy of the aMMP-8 PoC oral rinse immunotest is reduced in CD patients, which may be related
to lower levels or undetectable complexes.
Keywords: collagenases; Crohn’s disease; dental caries; mouth; periodontitis
1. Introduction
Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract, involving a
complex interplay between genetic risk, environmental exposures, the microbiota, and the immune
system. Individuals suffering from CD seem to be prone to developing periodontitis, caries, and oral
mucosal lesions [1–3]. CD patients have a higher decayed-missed-filled teeth (DMFT) index than
healthy individuals, which could be due to differences in their diet [3]. Indeed, CD patients reportedly
exhibit an increased sugar consumption and have insufficient oral hygiene [4]. The suggested link
between CD and periodontitis may be explained by shared pathways in their pathogenesis related
to altered gut/oral microbiota [5,6] and immune responsiveness [7]. Both CD and periodontitis have
been linked to a disrupted immunological response to the local microbiota. The innate immune
system, particularly neutrophils and their inadequate function, plays a major role in the pathogenesis
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of these diseases [8–10]. Of tissue-degrading matrix metalloproteinases (MMPs), MMP-8 is the key
inflammatory mediator in their inter-relationship; elevated MMP-8 levels have been detected in CD
patients both in the intestine and in the oral cavity [11,12].
Periodontitis is diagnosed based on clinical signs of gingival bleeding, loss of clinical attachment,
deepened periodontal pockets, and the presence of radiographical alveolar bone loss [13,14]. Yet, the use
of these parameters carries limitations, since they do not recognize the onset of inflammation or
identify individuals who are at risk of disease initiation or progression in a given population [15].
Instead, biomarker-based diagnostic methods are less laborious, non-invasive, and do not require
trained dentists, being especially useful in studies with large study populations [16].
In periodontology, point-of-care (PoC) tests aim to detect periodontal diseases by analyzing the
levels of biomarkers in oral fluids (saliva, oral rinse, and/or gingival crevicular fluid) without need of a
laboratory [17,18]. Among the tested biomarkers, salivary and oral rinse levels of MMP-8 are shown to
be effective in distinguishing periodontitis patients from periodontally healthy individuals [19–21].
For instance, PoC tests using active MMP (aMMP)-8 as a diagnostic marker with a threshold of
20 ng/mL can successfully identify periodontitis with 64–95% sensitivity and 60–100% specificity [22–25].
Notably, the test sensitivity improves in line with disease severity [22,24].
To date, no data exist on the performance of the selected oral rinse aMMP-8 PoC immunotest
in individuals with compromised immune responsiveness. In the present case-control study,
we hypothesized that CD, a systemic condition with impaired immune function, leads to decreased
sensitivity and specificity of the PoC immunotest. Our aim was to evaluate the utility of the immunotest
for chair-side diagnostics of periodontal disease in subjects with and without CD. As a main conclusion,
we state that the accuracy of the immunotest was impaired in individuals with CD.
2. Materials and Methods
2.1. Study Design and Enrolment of Participants
This was a case-control study conducted at the Institute of Dentistry, University of Turku, from
January 2017 to May 2018. The CD group, consisting of 47 CD patients between the ages of 22 and
77 years, was recruited from a Crohn and Colitis patient organization (IBD Association of Finland).
Their diagnosis of CD had previously been confirmed by endoscopy and histopathological analysis of
intestinal biopsy specimens. The control group, including 41 age- and gender-matched individuals
without CD or other immune-related diseases, was recruited using advertisements placed at the
Institute of Dentistry, University of Turku. Exclusion criteria for both groups included diabetes mellitus,
smoking, excessive use of alcohol, less than 24 teeth, and the use of antimicrobial medication in the
preceding six months prior to the clinical examination. In addition, individuals with periodontitis as a
manifestation of systemic disease [26] as well as pregnant or lactating women were excluded.
The research protocol was approved by the Ethical Committee of the Hospital District of Southwest
Finland (114/1801/2016), and the study was conducted according to the guidelines of the World Medical
Association Declaration of Helsinki. Each participant was informed of the purpose, potential side
effects and benefits of the study and gave their written consent. A structured questionnaire was
collected from all participants regarding their demographic data (such as age, sex, and residence),
general health, medications, and previous dental care. Additionally, the short Crohn’s disease activity
index (CDAI) was used to assess the disease activity of the CD patients [27].
2.2. Clinical Oral Examination
The full-mouth clinical examination included registrations of oral mucosal status performed by a
specialist in oral pathology (JR) together with cariological and periodontal measurements generated
by a periodontist (MG). Before this study, the intra-examiner (MG) agreement was tested in double
measurements of 10 patients and discovered to be very good.
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The oral mucosal examination included visual inspection of the lips, mucous membranes of the
oral cavity, and oropharynx while pressing the tongue down as well as manual palpation of the neck.
All mucosal findings were described by clinical appearance and the site of the lesion. CD-associated
mucosal lesions (sulcular ulceration, aphthous stomatitis, mucosal cobblestone appearance, lip swelling,
angular cheilitis, mucogingivitis) were registered separately [28,29].
Cariological status was assessed based on visual inspection, fiber-optic transillumination and
tactile examination on the five surfaces of each tooth. Additionally, initial caries lesions together
with other hard tissue defects on tooth surfaces, such as erosion and attrition, were determined.
Caries prevalence in the whole dentition (excluding the third molars) was expressed using the
decayed-missed-filled surface (DMFS) index. The participants were classified as having caries when
they had at least one tooth surface with a carious lesion.
Periodontal status was obtained from six sites per each natural tooth and dental implant using a
WHO probe (LM-Instruments Oy, Parainen, Finland) with a ball-tip end diameter of 0.5 mm. A full-mouth
dichotomous visible plaque index (VPI) score was recorded as percentage. Gingival recession (REC) was
detected as the distance between the cemento-enamel junction and free gingival margin, while probing
pocket depth (PPD) was measured from the free gingival margin to the most apical penetration point of the
probe. Loss of clinical attachment level (CAL) was determined as the sum of REC and PPD. A full-mouth
dichotomous gingival bleeding score was obtained upon bleeding on probing (BOP) and presented as
percentage. In addition, furcation defects and tooth mobility scores were recorded.
Individuals with BOP < 15%, PPD < 4 mm, and no loss of CAL were regarded as periodontally
healthy, whereas gingivitis was diagnosed in the presence of BOP ≥15% without periodontal pockets
and loss of CAL [30]. The diagnostic criteria for periodontitis included PPD ≥ 4 mm and/or loss of
CAL on ≥ 2 non-adjacent teeth together with BOP [31]. The severity of the disease was classified based
on PPD and loss of CAL as follows: initial periodontitis (PPD 4 mm, CAL loss 1–2 mm), moderate
periodontitis (PPD 5–6 mm, CAL loss 3–4 mm), and severe periodontitis (PPD ≥ 7 mm, CAL loss ≥
5 mm). After the clinical examination, the patient was informed both orally and in written form of the
findings. The patients with need for treatment were advised to contact their own dentist.
2.3. Application of an Oral Rinse aMMP-8 PoC Immunotest
The study participants were instructed to avoid tooth brushing, eating, and chewing gum 30 min
prior to the visit. Oral rinse sampling was performed before the clinical oral examination. First, each
participant pre-rinsed the mouth with tap water for 30 s and then spitted out or swallowed the fluid.
After 60 s of waiting, they re-rinsed vigorously the mouth with 5 mL of rinsing fluid‡ for 30 s and then
poured the entire sample into a measuring cup, from which the sample was drawn up into a syringe
and used for the aMMP-8 PoC analysis.
The immunotest (PerioSafe® PRO, Dentognostics GmbH, Jena, Germany) was used according to the
manufacturer’s instructions. A single examiner (UKG) ran all tests, and the result was interpreted by visual
estimation 5 min after testing. The outcome was defined as positive (+) when a double line (i.e., both test
and control line) was visible on the test window or negative (−) when only a single line was observed [22].
2.4. MMP-8 Western Immunoblot
Stimulated saliva samples were collected for 5 min from the patients, separately from the
immunotest. A modified enhanced chemiluminescence (ECL) western blotting kit (GE Healthcare,
Amersham, UK) was used to detect the molecular forms of MMP-8 from the stimulated saliva as
described earlier [32,33]. Salivary flow levels were measured to minimize the variations in sample
collection and sample loading during immunoblottings. Briefly, the saliva samples were mixed with
Laemmli’s buffer without any reducing reagents. The samples were heated for 5 min, followed by
protein separation with 11% sodium dodecyl sulphate (SDS)-polyacrylamide gels. The proteins were
then electro-transferred onto nitrocellulose membranes (Protran, Whatman GmbH, Dassel, Germany).
Milk powder (5%; Valio Ltd., Helsinki, Finland) was used to block non-specific binding in TBST
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buffer (10 mM Tris-HCl, pH 7.5, containing 22 mM NaCl and 0.05% Triton-X) for 1 h. The membranes
were incubated with polyclonal primary antibodies anti-MMP-8 [34] overnight and followed by the
horseradish peroxidase-linked secondary antibody (GE Healthcare, Buckinghamshire, UK) for 1 h.
The target proteins were visualized using the ECL system, and scanned and converted into arbitrary
units (relative levels of mean intensity) using GS-700 Imaging Densitometer Scanner (BioRad, Hercules,
CA, USA) and Bio-Rad Quantity One program. Purified human activated MMP-8 (BioTeZ, Berlin,
Germany) was used as positive control and low range prestained SDS-PAGE Standards (BioRad)
served as a molecular weight marker.
2.5. Statistical Analyses
All statistical analyses were performed using the SPSS statistical program (version 24.0; IBM
Inc., Armonk, NY, USA). The Chi square test was used for comparing demographic and clinical
data (with the exception of age and number of teeth) between the CD and control groups.
Age, salivary flow rate, and number of teeth were compared between the groups with one-way
ANOVA test. Multinomial regression analyses were performed to describe the associations between
periodontal diseases and the immunotest result, after adjusting for furcation and attrition defects.
Statistical significance was defined as p < 0.05.
3. Results
3.1. Crohn’s Disease Status
Of the 47 CD patients, 89.4% received medication for CD and 34.0% had undergone surgical
treatment for CD. According to the short CDAI score, 53.2% of the subjects were in remission (short
CDAI < 150 points), 31.9% had mild disease (short CDAI 150–219 points), 14.9% had moderate disease
(short CDAI 220–450 points), and none had severe disease (CDAI > 450 points).
3.2. Oral Health Status
Characterization of the CD and control groups on the basis of periodontal findings is presented in
Table 1.
Table 1. Characterization of the study groups (patients with Crohn’s disease and their age- and
gender-matched healthy controls) according to periodontal health status and stimulated salivary flow.
PPD = probing pocket depth; BOP = bleeding on probing.
Findings
Crohn’s Disease





Gender (male %) 23.4 29.3 0.629
Age, years (mean, st.dev) 46.4 (13.9) 47.4 (13.2) 0.734
No. of teeth (mean, st.dev) 27 (2.3) 27.6 (2.4) 0.192
VPI % (mean, st.dev) 23.8 (20.8) 22.9 (18.7) 0.828
BOP % (mean, st.dev) 32.7 (23.3) 33.9 (28.6) 0.820
Individuals with PPD 4 mm (n, %) 22 (46.8) 13 (31.7) 0.192
Individuals with PPD 5–6 mm (n, %) 1 (2.1) 8 (19.5) 0.011
Individuals with PPD ≥ 7 mm (n, %) 0 5 (12.2) 0.019
Individuals with REC ≥ 1 mm (n, %) 33 (70.2) 28 (68.3) 1.000
Individuals with REC ≥ 3 mm (n, %) 14 (29.8) 12 (29.3) 0.073
Periodontal diagnosis 0.021
Periodontally healthy (n, %) 12 (25) 15 (36.6)
Gingivitis (n, %) 20 (42.6) 15 (36.6)
Initial periodontitis (n, %) 14 (29.8) 4 (9.8)
Moderate periodontitis (n, %) 1 (2.1) 2 (4.9)
Severe periodontitis (n, %) 0 (0) 5 (12.2)
Stimulated salivary flow, ml/min (mean, st.dev) 1.42 (0.72) 1.59 (0.90) 0.313
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The DMFS index was 35.8 for the CD patients and 23.9 for the controls (p = 0.015). At least
one dentin caries lesion was found in 31.9% of the CD patients and 12.2% of the controls (p = 0.028).
The mean stimulated salivary flow was 1.42 mL/min and 1.59 mL/min, respectively. CD-associated
mucosal lesions were detected in 10.6% of the CD patients. Mucosal lesions not associated with CD
were found in 34.0% of the CD patients and 36.6% of the controls.
3.3. Oral Rinse aMMP-8 PoC Immunotest
The outcomes of the aMMP-8 PoC immunotest were tested against various clinical outcomes and
diagnoses in terms of its sensitivity and specificity as presented in Table 2. Sensitivity and specificity
values of the aMMP-8 PoC immunotest for detecting periodontitis were 60.0% and 75.0% in the CD
patients, 90.9% and 80.0% in the controls, and 73.1% and 77.4% in the whole population, respectively.
Table 2. Sensitivity and specificity of the oral rinse active matrix metalloproteinase-8 oral rinse
point-of-care immunotest in relation to the presence of probing pocket depth (PPD), bleeding on probing
(BOP), furcation defects, attrition, periodontal diseases (gingivitis or periodontitis), and periodontitis.
(- = no individuals with PPD ≥ 7 mm)
Periodontal Findings Sensitivity/Spesificity Crohn’s Disease Group Control Group Whole Population
(N = 47) (N = 41) (N = 88)
PPD 4 mm Sensitivity 54.5 84.6 65.7
Specificity 80 82.1 81.1
PPD 5–6 mm Sensitivity 100 87.5 88.9
Specificity 65.2 72.7 68.4
PPD ≥ 7 mm Sensitivity - 100 100
Specificity - 69.4 66.3
BOP ≥ 15% Sensitivity 37.1 57.7 45.9
Specificity 66.7 93.3 81.5
Furcation defect Sensitivity 40 66.7 54.5
Specificity 64.9 72.4 68.2
Attrition Sensitivity 52.4 38.9 46.2
Specificity 76.9 60.9 69.4
Periodontal diseases Sensitivity 35.3 57.7 45
Specificity 61.5 93.3 78.6
Periodontitis Sensitivity 60 90.9 73.1
Specificity 75 80 77.4
The results of the aMMP-8 PoC immunotest were significantly associated with the diagnosis of
periodontitis in the CD patients (OR: 5.2, 95% CI: 1.26–21.6, p = 0.022), in the controls (OR: 54.3, 95% CI:
3.09–953, p = 0.006), and in the whole population (OR: 8.5, 95% CI: 2.88–25.3, p < 0.001), as shown in
Table 3.
Table 3. Unadjusted and adjusted (furcation defects and attrition) associations of the selected oral rinse
active matrix metalloproteinase 8 point-of-care immunotest with periodontal diseases (gingivitis or
periodontitis) or with periodontitis. Data are given as odds ratio (95% confident intervals), and p-value.
Group Periodontal Diseases Periodontitis
Unadjusted Adjusted Unadjusted Adjusted
Crohn’s disease group (N = 47) 0.9 (0.23–3.26), 0.84 1.3 (0.29–5.58), 0.752 4.5 (1.22–16.6), 0.024 5.2 (1.26–21.6), 0.022
Control group (N = 41) 19.1 (2.17–167), 0.08 20.4 (1.92–216), 0.012 40 (4.25–376), 0.001 54.3 (3.09–953), 0.006
Whole population (N = 88) 3.0 (1.06–8.45), 0.038 4.16 (1.34–12.9), 0.014 9.3 (3.25–26.6), <0.001 8.5 (2.88–25.3), <0.001
3.4. MMP-8 Immunoblot
Figure 1 presents the relative levels of molecular forms, activations, and fragments of
MMP-8 in saliva.
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Figure 1. Western immunoblot analysis of salivary samples studied for molecular forms, degree
of activation and related fragmentation of matrix metalloproteinase (MMP)-8. “PMN” indicates
neutrophil-type collagenase (70–80 kDa) and “Mes” fibroblast-type MMP-8 collagenase (50–65 kDa)
together with their pro and active forms. “Complexes” indicate multiple forms of MMP-8 (>110 kDa)
and “fragments” the fragmented MMP-8 species (20–30 kDa). Lanes 1 and 2 illustrate the Crohn’s
disease group, and lanes 3 and 4 the control group. All laboratory conditions (incl. time of exposure)
and image analyses were standardized. Purified human activated MMP-8## was used as positive
control (lane 5). Mobilities of the molecular weight markers (low range prestained SDS-PADE Standards
(Bio-Rad Laboratories, Inc, Richmond, CA, USA) are indicated on the left.
According to the immunoblot results, in the control group the PoC immunotest positivity is
related to elevated levels of different forms and fragments of MMP-8 in saliva (Table 4). In CD patients,
however, no difference in the levels of salivary forms of MMP-8 was observed between the PoC
immunotest positive and negative individuals.
Table 4. Relative levels of mean intensity (median, min-max) of molecular forms and fragments of
salivary MMP-8 as regards to oral rinse point-of care immunotest positivity (+) and negativity (−). p


























P 0.330 0.877 0.708 0.303 0.061 0.192 0.982
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P 0.022 0.037 0.015 0.121 0.209 0.046 0.015
Whole
Population














P 0.032 0.174 0.140 0.670 0.689 0.020 0.062
4. Discussion
To our knowledge, this is the first study to investigate the sensitivity and specificity of a
chairside diagnostic kit in detection of periodontitis in patients with disrupted immune responsiveness.
Our findings demonstrate that both the sensitivity and specificity of the aMMP-8 oral rinse PoC
immunotest are significantly impaired in CD patients.
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A comprehensive examination of periodontal, cariological, and oral mucosal health is the strength
of the present study. Although there was no significant decrease in salivary flow in the CD group,
the DMFS index was significantly higher in CD patients than in controls. Only 25% of the CD
patients were periodontally healthy compared to 37% of the control group. In addition, CD patients
presented more gingivitis and initial periodontitis than their generally healthy controls. These clinical
findings are in line with several previous studies indicating differences in caries and periodontal
states of CD patients in comparison to systemically healthy individuals [1–3]. On one hand, a higher
DMF index may be attributed to nutritional and behavioral changes, such as an increased intake of
carbohydrates and alterations in bacterial conditions in the oral cavity favoring mutans streptococci and
lactobacilli [4,34,35], although these factors were not examined in the present study. On the other hand,
the association between CD and periodontitis has been attributed to common predisposing factors,
including age, genetic predisposition, and lifestyle factors, but perhaps more importantly to defects
in the mucosal barrier, disrupted immune responses, and the exuberant host-response to bacteria
leading to chronic inflammation [36]. Moreover, CD patients seem to exhibit a higher prevalence and
more generalized and more severe periodontitis than non-CD individuals [2,3,37,38]. Contrarily, in the
present study, severe periodontitis (12%) was diagnosed only in the control group. The small group
size may have an impact on the results, but it was not possible to expand the present study sample size
due to the low prevalence of Crohn’s disease. The cross-sectional study design is another limitation of
the present study, and thus, we cannot infer any temporal association between CD and oral disease.
Moreover, the recruitment of the control group was in part undertaken at a dental clinic, which may
result in a selection bias. However, this does not weaken the associations between the outcomes of the
chairside test and periodontitis diagnosis after adjusting for clinical parameters.
The PoC oral rinse and salivary tests can be used as noninvasive and economic methods for
screening and diagnosing disease. Various inflammatory proteins present in saliva have been tested
as candidate biomarkers for periodontitis [39–43]. For example, salivary MMP-8 can be detected in
different isoforms based on its origin (neutrophilic or mesenchymal type) or molecular forms (active,
pro-, fragmented, complex) [32,33]. Moreover, neutrophils, fibroblasts, and endothelial cells are the
main sources of MMP-8 in the oral cavity [44,45]. Some studies have indicated that dental caries
has an impact on oral MMP-8 levels, and thereby, caries lesions may affect the outcome of oral rinse
aMMP-8 PoC immunotests [22,46]. The causal relationship between caries and salivary MMP-8 has
not been established, but the association between the number of cariotic lesions and MMP-8 levels
suggests a role for the collagenase in the dentin caries process [46]. In our study, the sensitivity and
specificity of the kit for caries detection in the whole population were low, 55.0% and 67.6%, respectively.
One explanation for this could be the activity of the cariotic process. In comparison to chronic or stable
caries lesions, active lesions seem to correlate more with MMP activity [47]. In addition, open caries
lesions may more likely cause leakage of MMPs into the saliva in comparison to non-cavitated small
caries lesions [47].
Recent research has shown promising results regarding the use of aMMP-8 as a diagnostic
biomarker in PoC oral rinse tests for periodontitis [22–25,43,48]. The oral rinse aMMP-8 PoC
immunotest, also used in the present study, applies lateral flow chromatography and detects the
active form of MMP-8 with targeted antibodies [43,48]. A positive result of the test is based on a
cutoff of 20 ng/mL for aMMP-8, and it can identify periodontitis with 64–95% sensitivity and 60–100%
specificity [22–25]. In comparison to salivary MMP-8 analyses, the oral rinse aMMP-8 PoC immunotest
has demonstrated a higher accuracy when differentiating periodontal health from the disease [43,48].
However, little information is still available regarding the limitations of this test.
There are common and discordant elements in the pathogenesis of CD and periodontitis.
Indeed, both disorders lead to a substantial defect in the mucosal barrier and exuberant host response
to bacteria, resulting in inflammation and tissue destruction. It is reasonable to speculate that the
dysregulation of the immune system in CD may have an effect on MMP-8 levels in the oral cavity.
It has been shown in a mouse model simulating inflammatory bowel disease that inflammation in the
35
Biomolecules 2020, 10, 395
colon changes the microbiota not only in the colon but also in the oral cavity [9]. In the current study,
the sensitivity and specificity estimates of the aMMP-8 PoC immunotest for detecting periodontitis
were found to be poorer in CD patients (60.0% and 75.0%) than in systemically healthy controls
(90.9% and 80.0%). The reasons for this are most likely multifactorial. Firstly, it can be argued
that the prescribed immunomodulatory or anti-inflammatory medications affect the test accuracy.
However, these medications act as suppressors of inflammatory response, which means that both
clinical and sub-clinical indices of periodontitis (i.e., bleeding on probing as well as MMP-8 expression
and activation, respectively) can be restrained. Thus, the use of medications does not fully explain the
low sensitivity and specificity values of aMMP-8 PoC test in periodontitis patients with Crohn’s disease.
Secondly, impaired neutrophil MMP-8 function might be another explanation for the low sensitivity
of the test in CD patients. Our western immunoblot experiment of salivary MMP-8 indicated that
the aMMP-8 PoC oral rinse immunotest positivity in the CD group does not reflect the changes in
the levels of molecular forms and fragments of MMP-8, varying from that observed in the control
group. The difference may be explained, at least in part, by genetics. Indeed, a mutation in the
nucleotide-binding oligomerization domain 2/caspase recruitment domain 15 (NOD2/CARD15) gene,
which impairs the ability to recognize bacterial components and thus triggers an inadequate immune
response, has been reported in patients with CD [49]. Interestingly, when patients suffering from
rheumatoid arthritis - another example of a disease with dysregulated immune system - were compared
to systemically healthy periodontitis patients, they exhibited increased aMMP-8 levels in gingival
crevicular fluid [50]. Additionally, in presence of vascular leakage components in saliva samples,
alpha 2-macroglobulin may form complexes with proteases, which in turn may partly explain the
high-molecular weight complexes [51]. Formation of these complexes, however, may not totally explain
the current results, since all samples were free of blood contamination. Finally, all these observations
indicate that patients with a systemic disease manifested with impaired immune responsiveness
need to be evaluated in a disease-specific manner before any diagnostic test can be reliably utilized.
The reasons why (1) MMP-8 is not a functioning biomarker in CD patients or (2) aMMP-8 PoC
immunotest seem to produce less accurate results in CD patients remain unsolved. Therefore, further
studies are still required.
5. Conclusions
In conclusion, the performance of the oral rinse aMMP-8 PoC immunotest for recognizing
periodontitis seem to be less reliable in CD patients than in systemically healthy individuals.
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Abstract: Renal replacement therapy (RRT) is complicated by a chronic state of inflammation and a
high mortality risk. However, different RRT modalities can have a selective impact on markers of
inflammation and oxidative stress. We evaluated the levels of active matrix metalloproteinase
(MMP)-9 in patients undergoing two types of dialysis (high-flux dialysis (HFD) and on-line
hemodiafiltration (OL-HDF)) and in kidney transplantation (KT) recipients. Active MMP-9 was
measured by zymography and ELISA before (pre-) and after (post-) one dialysis session, and at
baseline and follow-up (7 and 14 days, and 1, 3, 6, and 12 months) after KT. Active MMP-9 decreased
post-dialysis only in HFD patients, while the levels in OL-HDF patients were already lower before
dialysis. Active MMP-9 increased at 7 and 14 days post-KT and was restored to baseline levels three
months post-KT, coinciding with an improvement in renal function and plasma creatinine. Active
MMP-9 correlated with pulse pressure as an indicator of arterial stiffness both in dialysis patients
and KT recipients. In conclusion, active MMP-9 is better controlled in OL-HDF than in HFD and is
restored to baseline levels along with stabilization of renal parameters after KT. Active MMP-9 might
act as a biomarker of arterial stiffness in RRT.
Keywords: matrix metalloproteinase-9; dialysis; on-line hemodiafiltration; high-flux dialysis; renal
replacement therapy; kidney transplantation
1. Introduction
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure and/or function for
a period of at least three months, with implications for health [1]. CKD is an irreversible disorder and
often progresses to end-stage renal disease (ESRD), which is life-threatening and requires some form of
renal replacement therapy (RRT) such as dialysis or kidney transplantation (KT). Since KT is limited
by organ availability, dialysis is the most common form of RRT to remove uremic toxins in ESRD.
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There are two types of dialysis treatments that can be applied to the ESRD patient: peritoneal dialysis
and hemodialysis. Hemodialysis can be further classified depending on the membrane modality
(convective vs. diffusive). For example, high-flux dialysis (HFD) is based on the use of high diffusion
and low convection, whereas on-line hemodiafiltration (OL-HDF) is based on lower diffusion and
higher convection, enabling the removal of middle- and larger-molecular weight substances. However,
whatever the dialysis strategy used, it is only a temporary solution until the patient can undergo KT.
Patients with CKD, especially ESRD, are regarded as being at high risk of fatal and non-fatal
cardiovascular events because cardiovascular and renal disease often have similar origins and risk
factors [2]. Cardiovascular risk is particularly high for patients undergoing dialysis [3] because of
CKD-associated complications such as atherosclerosis and systemic inflammation [4]. Indeed, this
enhanced risk of atherosclerotic cardiovascular events begins from the earliest stages of CKD. Moreover,
dialysis-specific risk factors such as mineral bone disorders and excess fluid load induce vascular
calcification and hypertension, which in turn induce arterial stiffness [5], a process characterized by a
thickening of the arterial wall and a loss of elastin fiber integrity leading to a decrease in elasticity [6].
Arterial stiffness is a predictor of cardiovascular disease in dialysis and KT recipients [7,8], and is
associated with graft dysfunction and rejection [9]. Interestingly, vascular thickening tends to diminish
after KT [10] and, in fact, KT improves the longevity and quality of life of patients as compared with
long-term dialysis treatment [11], although cardiovascular risk remains higher than in the general
population [12].
The anomalous turnover of extracellular matrix components favors deleterious vascular
remodeling, which is a major mechanism underlying arterial stiffness. Matrix metalloproteinases
(MMPs) play a central role in the regulation of both physiological and pathological connective tissue
turnover. In particular, the inducible MMP-9, degrades laminin, elastin, and type IV collagen [13], which
are the main components of the glomerular basement membrane of the kidney. In fact, the exaggerated
activation of MMP-9 has been associated with an abnormal glomerular basement membrane structure
and consequent albuminuria escape in treated hypertension [14]. MMP-9 activation is triggered under
stress conditions including inflammation and oxidative stress [13] and is consequently upregulated in
inflammation-dependent conditions such as hypertension and associated with cardiovascular risk in
patients undergoing hemodialysis [15].
Although the use of MMP-9 as a marker of cardiovascular risk has been widely described, there
is a paucity of studies examining how RRT affects its activity [16]. MMP-9 can be assessed as total
MMP-9 or active MMP-9 levels measured by the MMP-9/tissue inhibitor of MMP (TIMP)-1 ratio,
zymography, or solid-phase immunoassays. Total MMP-9 abundance is, however, not a direct measure
of its activity, as both active and inactive MMP-9 are considered. Likewise, the indirect measure of
active MMP-9 using the MMP-9/TIMP-1 ratio might be inadequate because it considers that TIMP-1,
the endogenous inhibitor of MMP-9, interacts completely with MMP-9 in a 1:1 stoichiometry [17]. It is
known that reactive oxygen and nitrogen species can interact with both TIMP-1 and MMP-9, blocking
endogenous MMP-9 inhibition and activating MMP-9 constitutively [13] and, therefore, assessment of
the MMP-9/TIMP-1 ratio as an indicator of MMP-9 activation is not recommended [18], especially in
conditions of oxidative stress such as CKD or ESRD.
Given the heterogeneity in MMP-9 measurements and the gap in our knowledge on MMP-9 activity
in RRT, the aim of this study was to assess the effect of different types of RRT (HFD, OL-HDF, and KT) on
active MMP-9 measured in a direct manner by zymography and enzyme-linked immunosorbent assay
(ELISA), as well as by the direct protein interaction between MMP-9 and TIMP-1 using AlphaLISA®
technology (PerkinElmer, Waltham, MA, USA).
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2. Materials and Methods
2.1. Study Population
The study included two independent cohorts of patients receiving RRT: 32 dialysis-dependent
patients recruited for a cross-sectional analysis between November 2016 and March 2017 [19], and
46 KT recipients recruited for a longitudinal study between November 2014 and June 2016 [20,21].
The exclusion criterion for KT recipients was development of acute rejection in the first year post-KT.
Both cohorts of patients were recruited at the Nephrology Unit of the Hospital Universitario 12 de
Octubre (Madrid, Spain). Dialysis-dependent patients underwent clinical examination before dialysis,
and KT patients underwent clinical examination before transplant. Pulse pressure (PP) was determined
as the difference between systolic blood pressure (SBP) and diastolic (DBP) blood pressure [9]. Blood
samples were drawn before (pre-) and after (post-) one dialysis session, or in the case of KT at baseline
and 7 days, 14 days, 1 month, 3 months, 6 months, and 12 months post-KT. Blood samples were
collected in heparin tubes and immediately centrifuged at 2000 rpm for 10 min. Plasma samples were
stored at −80 ◦C until use.
All patients signed informed consent. The study was approved by the local ethics committee in
compliance with the guidelines of the Declaration of Helsinki.
2.2. Assessment of Active MMP-9
Active MMP-9 was assessed by zymography and ELISA. Zymography was performed under
non-reducing conditions using 10% SDS/PAGE containing 0.1% gelatin. Following electrophoresis, gels
were incubated in 500 mM Tris, 6 mM CaCl2, and stained with Coomassie Brilliant Blue R-250 (Bio-Rad,
Hercules, CA, USA). Digitalized gel images were analyzed with ImageJ software (NIH, Bethesda,
MD, USA). Quantification of active MMP-9 was performed with a commercially available ELISA kit
(QuickZyme BioSciences, Leiden, The Netherlands). Given the consistency between zymography
and ELISA, follow-up of KT patients was exclusively assessed by ELISA at 7 days, 3 months, and 12
months post-KT. In the case of dialysis-dependent patients, active MMP-9 post-dialysis was corrected







where Cc is the corrected concentration post-dialysis, Cpost is the concentration post-dialysis, BWpre is
the body weight pre-dialysis, and BWpost is the body weight post-dialysis [22].
2.3. Assessment of Total MMP-9, Total TIMP-1, and MMP-9/TIMP-1 Interaction
Quantification of total MMP-9 and TIMP-1 was performed in KT patients at baseline, 7 days,
3 months, and 12 months post-KT using commercial ELISA Quantikine kits (R&D Systems, Minneapolis,
MN, USA). MMP-9/TIMP-1 was calculated by dividing the levels of total MMP-9 by the levels of TIMP-1.
AlphaLISA® technology was used to detect the interaction between MMP-9 and TIMP-1 following
a published protocol [18]. Briefly, AlphaLISA® acceptor beads (PerkinElmer, Waltham, MA, USA)
were conjugated with an anti-MMP-9 antibody (ThermoFisher Scientific, Waltham, MA, USA) and
then incubated with plasma samples from KT recipients and a biotinylated anti-TIMP-1 antibody
(ThermoFisher Scientific). Streptavidin-coated donor beads were then added to bind the biotinylated
anti-TIMP-1 antibody and detect the MMP-9/TIMP-1 interactions. Plates were read on an EnSpire
Multimode Microplate Reader (PerkinElmer) using an excitation wavelength of 680 nm and an emission
wavelength of 615 nm.
43
Biomolecules 2020, 10, 505
2.4. Statistical Analysis
Normality of data was determined with the Kolmogorov–Smirnov test. HFD and OL-HDF groups
were compared using unpaired Student’s t-test or the Mann–Whitney U test. Categorical variables were
compared with Fisher’s exact test. Pre- and post-dialysis groups were compared using the Wilcoxon
signed-rank test, and KT follow-up groups were compared using the Friedman test. Spearman’s
rank-order correlation was used to analyze correlations. Results are expressed as mean ± SEM unless
otherwise stated, and p-values < 0.05 were considered significant. Analyses were performed using




Baseline characteristics of all hemodialysis patients stratified according to the type of dialysis
applied (HDF or OL-HDF) are shown in Table 1. No differences were found in the mean age between
the two groups. Likewise, there were no differences between the HFD and OL-HDF groups for
hypertension, SBP, PP, diabetes mellitus, or N-terminal pro-brain natriuretic peptides. Dialysis-related
parameters were also the same between the groups except for the duration of dialysis. Patients in
the OL-HDF group were significantly longer on dialysis (31.4 vs. 98.4 months for HFD and OL-HDF,
respectively). There were no differences between the groups for the cause of CKD or the medication
used. The proportion of men was significantly higher in the OL-HFD group (65%) than in the HFD
group (11%). Baseline characteristics of the KT recipients are shown in Table 2.
Table 1. Baseline characteristics of dialysis patients.
All Patients (n = 32) HFD Patients (n = 9) OL-HDF Patients (n = 23) p-Value
Age (years) 60.0 ± 16,4 64.7 ± 22.0 58.2 ± 13.8 0.322
Male sex (n, %) 16 (50) 1 (11) 15 (65) 0.016
Hypertension (n, %) 25 (78) 7 (78) 18 (78) 0.999
SBP (mmHg) 128.4 ± 23.0 126.2 ± 23.2 129.3 ± 23.4 0.739
PP (mmHg) 55.5 ± 17.5 58.4 ± 14.6 54.3 ± 18.7 0.556
Diabetes mellitus (n, %) 7 (22) 2 (22) 5 (22) 0.999
NT-proBNP (pg/mL) 2565 ± 1735 2753 ± 1245 2509 ± 1881 0.769
Dialysis-related parameters
Serum creatinine (mg/dL) 7.61 ± 2.22 7.16 ± 2.22 7.78 ± 2.25 0.486
Serum albumin (g/dL) 4.05 ± 0.43 3.91 ± 0.24 4.10 ± 0.48 0.259
Potassium (mEq/L) 5.15 ± 0.90 5.06 ± 0.78 5.19 ± 0.95 0.725
Bicarbonate (mEq/L) 21.3 ± 2.9 21.2 ± 3.8 21.3 ± 2.6 0.974
Dialysis vintage (months) 79.5 ± 74.3 31.4 ± 24.5 98.4 ± 79.1 0.020
Kt/V 1.63 ± 0.24 1.68 ± 0.25 1.61 ± 0.24 0.463
eGFR (ml/min/1.73 m2) 6.92 ± 3.00 6.48 ± 2.92 7.09 ± 3.08 0.614
Residual diuresis (n, %) 15 (52) 5 (56) 10 (43) 0.699
Interdialytic urine volume (mL) 375 (163–875) 250 (100–500) 500 (175–1000) 0.518
Cause of CKD 0.547
Glomerulonephritis (n, %) 7 (22) 2 (22) 5 (22)
Diabetic nephropathy (n, %) 5 (16) 1 (11) 4 (17)
Polycystic kidney disease (n, %) 4 (12) 0 (0) 4 (17)
Hypertensive nephropathy (n, %) 2 (6) 0 (0) 2 (9)
Other or undetermined (n, %) 14 (44) 6 (67) 8 (35)
Medication
ACEi/ARB (n, %) 8 (25) 2 (22) 6 (26) 0.999
Diuretics (n, %) 3 (9) 0 (0) 3 (13) 0.541
β-blockers (n, %) 13 (41) 5 (56) 8 (35) 0.427
Cinacalcet (n, %) 3 (9) 0 (0) 3 (13) 0.541
Paricalcitol (n, %) 12 (38) 5 (56) 7 (30) 0.253
SBP: systolic blood pressure; PP: pulse pressure; NT-proBNP: N-terminal (NT)-pro B-type natriuretic peptide; Kt/V:
where K is the dialyzer urea clearance, t is the total treatment time, and V is the total volume within the body that
urea is distributed; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; ACEi: angiotensin
converting enzyme inhibitor; ARB: angiotensin receptor blocker.
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Table 2. Baseline characteristics of kidney transplant recipients.
All Patients
(n = 46)
Age of the recipient (years) 54.6 ± 15.8
Male sex (n, %) 27 (59)
Previous kidney transplant (n, %) 4 (9)
Pretransplant dialysis (n, %) 41 (89)
Dialysis vintage (months) 21.0 ± 19.0
SBP (mmHg) 134.5 ± 14.8
PP (mmHg) 49.9 ± 12.9
Serum creatinine (mg/dL) 6.27 ± 2.56
Serum albumin (g/dL) 4.23 ± 0.52
eGFR (mL/min/1.73 m2) 9.82 ± 4.28
Donor
Male sex (n, %) 25 (54)
Age (years) 52.6 ± 14.6
Living donor (n, %) 5 (11)
Number of HLA-mismatches 5 (4–5)
Cause of CKD
IgA nephropathy 9 (20)
Glomerulonephritis 2 (4)
Diabetic nephropathy 7 (15)
Polycystic kidney disease 8 (17)
Hypertensive nephropathy 3 (7)
Other or undetermined 17 (37)




Mycophenolate mofetil/mycophenolic acid 42 (91)
Cyclosporine A 0 (0)
SBP: systolic blood pressure; PP: pulse pressure; eGFR: estimated glomerular filtration rate; CKD: chronic kidney
disease; HLA: human leukocyte antigen.
3.2. Dialysis Reduces Active MMP-9 Levels
We first compared the plasma levels of active MMP-9 in all dialysis patients pre- and post-dialysis.
Active MMP-9 estimated by zymography (Figure 1A) or quantified by ELISA (Figure 1B) was lower
post-dialysis than pre-dialysis, and this was significant for the ELISA analysis. Baseline plasma levels
of active MMP-9 were significantly lower in the OL-HDF group than in the HFD group, both by
zymography (Figure 1C) and ELISA (Figure 1D), and active MMP-9 levels were reduced by dialysis
only in the HFD group while OL-HDF patients’ active MMP-9 levels remained at the same level
after the dialysis process. Active MMP-9 negatively correlated with the interdialytic urine volume
(Figure 1E), in the sense that less urine volume was associated with higher MMP-9 activity.
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Figure 1. Matrix metalloproteinase (MMP)-9 activity in pre- and post-dialysis according to the type of
dialysis applied. (A) Representative zymography gel showing plasma gelatinase MMP-9 activity (upper
panel) and quantification (bottom panel). (B) Quantification of active MMP-9 by ELISA in plasma of
dialysis patients before (pre-dialysis) and after (post-dialysis) one session of dialysis. (C) Representative
zymography gel showing plasma gelatinase MMP-9 activity (upper panel) and quantification (bottom
panel). (D) Quantification of active MMP-9 formed by ELISA in plasma of dialysis patients stratified as
those on high-flux dialysis (HFD) (pre- and post-dialysis) and on-line hemodiafiltration (OL-HDF) (pre-
and post-dialysis). (E) Negative correlation between interdialytic urine volume and pre-dialysis active
MMP-9 in dialysis patients with residual urine volume. Correlation was performed using Spearman’s
test and a linear regression of the data is displayed. * p < 0.05 vs. pre-dialysis; # p < 0.05 and ## p < 0.01
vs. HFD pre-dialysis.
3.3. Kidney Transplantation Increases Total and Active MMP-9 and Total TIMP-1 Levels, but Not
MMP-9:TIMP-1 Protein Interactions
Representative gel zymography of active MMP-9 in KT recipients before KT and at follow-up is
shown in Figure 2A. Active MMP-9, measured by gel zymography (Figure 2B) or quantified by ELISA
(Figure 2C), increased significantly 7 days after KT. Active MMP-9 levels remained high 14 days after
KT (Figure 2A,B), but thereafter decreased significantly at one month after KT, reaching levels not
significantly different to baseline at 3 and 12 months after KT (Figure 2A–C). Active MMP-9 levels
were related to renal function, decreasing as estimated glomerular filtration rate (eGFR) increased and
plasma creatinine decreased (Figure 2D).
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Figure 2. MMP-9 activity profile before and after kidney transplantation. (A) Representative
zymography gel showing plasma gelatinase MMP-9 activity. (B) Quantification of active MMP-9 by
zymography in plasma of kidney transplantation (KT) patients at baseline (before KT) and after 7
and 14 days, and 1, 3, 6, and 12 months. (C) Quantification of active MMP-9 by ELISA in plasma of
KT patients at baseline and after 7 days, 3 months, and 12 months. (D) Evolution of eGFR, plasma
creatinine, and active MMP-9 at baseline and 7 days, 3 months, and 12 months after KT. *** p < 0.001 vs.
baseline and ### p < 0.001 vs. 7 days after KT.
To evaluate whether the changes in active MMP-9 abundance were due to changes in its expression
or, alternatively, to its endogenous inhibition by TIMP-1, we measured total MMP-9 and TIMP-1 levels
in KT recipients. Total MMP-9 levels increased significantly at 7 days after KT relative to baseline
levels, but significantly decreased at 3 and 12 months after KT (Figure 3A). A similar pattern was
observed for TIMP-1 levels, with a significant increase at 7 days after KT and a return to baseline levels
at 3 months (Figure 3B). However, TIMP-1 levels continued to decrease at 12 months after KT and
were significantly lower than baseline levels at this time (Figure 3B). To indirectly estimate MMP-9
activity and following the line of the majority of clinical studies, we calculated the MMP-9/TIMP-1
ratio, which revealed a significant increase in the MMP-9/TIMP-1 ratio over baseline levels at 7 days
after KT (Figure 3C). The ratio decreased to baseline levels 3 months after KT but increased 12 months
after KT, reaching an intermediate level (Figure 3C). To confirm the interaction between both molecules,
we used the AlphaLISA protocol to measure MMP-9:TIMP-1 protein interactions [18]. No changes in
MMP-9:TIMP-1 interactions were found until 12 months after KT, when the interaction was significantly
higher than at baseline (Figure 3D).
47
Biomolecules 2020, 10, 505
Figure 3. Total protein MMP-9 and tissue inhibitor of MMP (TIMP)-1 levels, MMP-9/TIMP-1 ratio,
and MMP-9:TIMP-1 interactions before and after KT. (A) Total MMP-9 protein levels (B) and total
TIMP-1 protein levels quantified by ELISA at baseline and at 7 days, 3 months, and 12 months after
KT. (C) MMP-9/TIMP-1 ratio estimation. (D) AlphaLISA® MMP-9:TIMP-1 interaction immunoassay
expressed as binding relative luminescence units (RLUs). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. baseline;
# p < 0.05, ## p < 0.01 and ### p < 0.001 vs. 7 days after KT; and ϕ p < 0.05, ϕϕ p < 0.01, ϕϕϕ p < 0.001
vs. 3 months after KT.
3.4. Active MMP-9 Positively Correlates with Arterial Stiffness in RRT Patients, but Not with Systolic
Blood Pressure
We examined for correlations between active MMP-9 levels, SBP, and the arterial stiffness PP
parameters in patients undergoing RRT. No correlation was found between active MMP-9 and SBP in
the dialysis or KT cohorts (Figure 4A,B). However, we found a positive significant correlation between
active MMP-9 levels and PP in both dialysis and KT cohorts (Figure 4A,B).
Figure 4. Correlation between MMP-9 activity and systolic blood pressure (SBP) and pulse pressure (PP)
at pre-dialysis and before KT. (A) No association of MMP-9 activity with SBP (in green) and a positive
significant correlation with PP (in blue) in dialysis patients in pre-dialysis. (B) No association of MMP-9
activity with SBP (in green) and a positive significant correlation with PP (in blue) in KT recipients
before KT (baseline). Correlation was performed using Spearman’s test and a linear regression of the
data is displayed.
4. Discussion
Our study shows that: (i) patients undergoing OL-HDF have lower levels of active MMP-9
compared with those undergoing HFD; (ii) active MMP-9 increases early post-KT at 7 and 14 days and
48
Biomolecules 2020, 10, 505
stabilizes in parallel with renal markers at 3 months after KT; and (iii) active MMP-9 is associated with
arterial stiffness measured by PP in RRT (pre-dialysis and before KT).
Renal dysfunction is characterized by a uremic state that aggravates as renal function declines,
reaching its maximum in ESRD. This state is intimately associated with all-cause mortality and
especially with cardiovascular morbidity and mortality. Undoubtedly, RRT improves the lifespan
and the quality of life of patients with ESRD. Among RRT patients, KT significantly improves the
quality of life compared with dialysis, but the access to renal transplants is limited and not all ESRD
patients can undergo a surgical procedure. Although dialysis is the cornerstone of RRT, it is also
associated with a state of chronic inflammation and oxidative stress [23]. Dialysis per se triggers an
increase in oxidative stress and inflammation because of incompatibilities with the dialysis membrane,
which activates circulating leukocytes, and also because low-molecular weight antioxidant systems are
filtered and therefore eliminated during the procedure. In addition, the type of dialysis used directly
influences the oxidative status of the patients. Indeed, recent studies demonstrate that patients under
OL-HDF have less inflammation, endothelial damage, and oxidative stress [19,24,25], which could be
associated with the improved prognosis in this group [26,27]. The reduction in middle-molecules is
associated with the preservation of residual renal function [28], which decreases the mortality risk in
dialysis [29] and is improved in OL-HDF [30]. The systemic activation of MMP-9 is a marker of a lasting
inflammatory state that is inherent to renal disease, as has been demonstrated even with adequate
pharmacological treatment in patients with CKD [14,31]. In the case of ESRD, and especially dialysis,
there are conflicting results on the levels of MMP-9 in the pre- and post-dialysis states [32,33]. This
could be due to the different types of dialysis membranes [34,35], or to the type of dialysis itself [19,25].
We demonstrate herein that active MMP-9 is cleared during dialysis when the type of dialysis is not
considered, but a decrease in active MMP-9 is only seen in HFD. Other authors have described a
decrease in total MMP-9 during OL-HDF, but not during other hemodialysis [36]. Nevertheless, total
MMP-9 does not necessarily correlate with active MMP-9, and the measurement of active MMP-9 is a
more direct assessment of its pathophysiological activity [14]. The fact that only HFD effectively clears
active MMP-9 might suggest that HFD is more efficient than OL-HDF; however, pre-dialysis active
MMP-9 was significantly lower in the OL-HDF group than in HFD patients, indicating that the levels
of active MMP-9 are better controlled in patients under OL-HDF. Moreover, residual renal function is
associated with lower inflammation in OL-HDF [37,38]. Supporting this, we also observed that active
MMP-9 is lower in patients with greater interdialytic urine volume, which is superior to eGFR as an
estimate of residual renal function in dialysis [28].
KT is the only curative treatment for ESRD and long-term survival is significantly greater after KT
than after dialysis. Despite its benefits, however, KT is not without risks, such as the inevitable ischemia
and reperfusion (I/R) injury, which triggers several processes such as immune system activation,
endothelial dysfunction, and cell death. Likewise, I/R induces morphological changes in the kidney
that lead to fibrosis, as shown by the elevation of fibrosis-related biomarkers in the kidney of patients
with chronic allograft nephropathy [39]. By contrast, a well-known benefit of KT is the normalization
of inflammatory and oxidative stress markers [40]. For example, the C-terminal agrin fragment, a
biomarker for kidney function and a breakdown product of agrin, the major proteoglycan of the
glomerular basement membrane, strongly correlates with creatinine and eGFR and is stabilized at
1–3 months after KT [41]. In the same line, interleukin 6, a well-known precursor of MMP-9 activation,
shows a burst of activity one week after KT before stabilizing [42]. In the present study, we demonstrate
that systemic active MMP-9 levels increase one week after KT, but rapidly and significantly decrease
from the second week after surgery. We speculate that the increase in active MMP-9 evident one week
after KT likely originates from neutrophils in response to leukocyte activation inherent to I/R processes.
This is supported by experimental studies demonstrating that MMP-9 promotes mononuclear cell
infiltration in a rat model of early allograft nephropathy [43].
The peak in active MMP-9 observed early post-KT (after 7 and 14 days) might be due to an
increase in total MMP-9 or an enhancement in the enzyme activation by the inflammatory environment.
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MMP-9 is synthesized as a zymogen with a covered zinc-containing active site. Other MMPs and
MMP-9 itself cleave the peptide chain that covers the active site in physiological conditions. However,
reactive oxygen and nitrogen species can pathologically expose the active site by binding to the zinc
ion. Reactive oxygen and nitrogen species can also bind to TIMP-1 and hamper the physiological
inhibition of MMP-9. Indeed, MMP-9:TIMP-1 interactions are reduced under conditions of increased
oxidative stress and can therefore mask the results obtained from the surrogate marker of MMP-9
activity, the MMP-9/TIMP-1 ratio [18]. Given the increase in oxidative stress associated with I/R, we
aimed to investigate whether the peak in active MMP-9 was due to the pathological activation of
MMP-9 or to an increase in MMP-9 protein levels. Our results indicate that the peak in active MMP-9
was in fact due to an increase in total MMP-9 expression, and the results of the MMP-9/TIMP-1 ratio
indicate the same. However, the reduction in TIMP-1 levels at 12 months post-KT leads to an increase
in the MMP-9/TIMP-1 ratio, erroneously suggesting increased MMP-9 activity. Indeed, active MMP-9
is unaltered 12 months post-KT because the MMP-9:TIMP-1 interaction is increased, supporting the
importance of measuring active MMP-9 rather than the MMP-9/TIMP-1 ratio. The suggested increase
in active MMP-9 by the MMP-9/TIMP-1 ratio indicates an increase in mortality risk [44]. However,
total and real active MMP-9 do not vary, and TIMP-1, which is also associated with mortality [45],
is reduced. Therefore, the patients might actually have a reduced risk of mortality as the KT becomes
more stable.
Finally, arterial stiffness increases SBP by wave reflection and decreases DBP, which increases
PP, a marker of large artery stiffness [46]. Arterial stiffness is attenuated after KT as compared with
hemodialysis [9,47–50], and is subject to donor age, living kidney donation, and mean blood pressure [5].
Our study shows for the first time, to our knowledge, that active MMP-9 correlates with PP in patients
treated with RRT. We found that, independently of the type of dialysis, PP is lower as the levels of
active MMP-9 decline. A decrease in active MMP-9 suggests that arterial stiffness might be reduced in
patients undergoing OL-HDF. However, we failed to find differences in PP between groups of patients
on the different types of dialysis, in accord with results from other groups describing that arterial
stiffness is not different between hemodialysis and HDF [5]. We also found that baseline active MMP-9
correlates with PP before KT, supporting the idea that a reduction in active MMP-9 levels in ESRD
patients is needed to ameliorate arterial stiffness.
The main limitation of the present study was the small population of dialysis patients. More
studies are needed in order to confirm our results, but this pilot study is the first step in assessing the
insights of arterial stiffness in different types of dialysis.
5. Conclusions
Active MMP-9 is lower in OL-HDF than in HFD and shows a peak in KT recipients after I/R in
the early post-KT stages (7 and 14 days). However, the peak in active MMP-9 is resolved in parallel
with the restoration of renal function, indicating that MMP-9 activity is likely a surrogate of I/R injury.
In both contexts—dialysis and KT—active MMP-9 is associated with PP in pre-dialysis and just before
KT, indicating that MMP-9 is a marker of vascular dysfunction in patients undergoing RRT.
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Abstract: Surface receptor-mediated adhesion is a fundamental step in the recruitment of leukocytes
and platelets, as well as platelet–leukocyte interactions. The surface receptor CD147 is crucially
involved in host defense against self-derived and invading targets, as well as in thrombosis. In the
current study, we describe the previously unknown interaction of CD147 with integrin αMβ2 (Mac-1)
in this context. Using binding assays, we were able to show a stable interaction of CD147 with Mac-1
in vitro. Leukocytes from Mac-1−/− and CD147+/− mice showed a markedly reduced static adhesion to
CD147- and Mac-1-coated surfaces, respectively, compared to wild-type mice. Similarly, we observed
reduced rolling and adhesion of monocytes under flow conditions when cells were pre-treated with
antibodies against Mac-1 or CD147. Additionally, as assessed by antibody inhibition experiments,
CD147 mediated the dynamic adhesion of platelets to Mac-1-coated surfaces. The interaction of
CD147 with Mac-1 is a previously undescribed mechanism facilitating the adhesion of leukocytes
and platelets.
Keywords: Mac-1; CD147; leukocytes; platelets; adhesion; integrin αMβ2
1. Introduction
The recruitment of leukocytes and platelets to activated endothelium as well as platelet-leukocyte
interactions are of fundamental significance for innate and adaptive immunity, as well as thrombosis [1].
The surface receptor CD147 (basigin, extracellular matrix-metalloproteinase inducer; EMMPRIN)
has been shown to be important in the host defense from self-derived as well as invading targets
and is a major factor regulating the expression of matrix metalloproteinases (MMPs). CD147 is
a pathophysiologically important multi-ligand receptor of the immunoglobulin superfamily. It is
expressed in various tissues and cell types, including leukocytes, endothelial cells, and platelets. A
range of different proteins, including cyclophilins, monocarboxylate transporters (MCTs) 1-4, CD43,
CD44, CD98, NOD2, galectin-3, γ-catenin, apolipoprotein-D, members of the S100 protein family, and
integrins, such as α3β1 and α6β1, have been reported to interact with CD147 [2–6].
In the context of thromboinflammation, CD147 acts as a pro-inflammatory and pro-thrombotic
receptor, eliciting leukocyte chemotaxis and adhesion, as well as platelet activation and subsequent
thrombus formation through the binding of various interaction partners [4,7–12]. Notably, its
interaction with cyclophilin A (CyPA) contributes significantly to various inflammatory diseases.
In the context of cardiovascular diseases, CyPA induces leukocyte chemotaxis and adhesion, and
myocardial MMP expression, facilitating subsequent myocardial remodeling. Inhibition of extracellular
Biomolecules 2020, 10, 541; doi:10.3390/biom10040541 www.mdpi.com/journal/biomolecules55
Biomolecules 2020, 10, 541
CyPA significantly decreases platelet activation and thrombus formation as well as the formation of
monocyte–platelet aggregates [4,7,8,13,14]. Furthermore, our group identified glycoprotein VI (GPVI)
to be an adhesion-mediating partner for CD147 on the platelet surface, which is the first time it has been
demonstrated that CD147 plays a direct role in cell adhesive events, apart from mediating adhesion
via intracellular signaling, leading to the expression of adhesion molecules [11].
Mac-1 (integrinαMβ2, complement receptor 3, CD11b/CD18) is a well-characterized heterodimeric
integrin, mostly found on polymorphonuclear leukocytes [15]. As a member of the β2-integrin family,
it is known to be involved in the leukocyte adhesion cascade. After the initial contact of the leukocyte
with endothelial cells lining the vessel wall, a complex signaling cascade is initiated, leading to a
selectin-dependent rolling motion of the leukocyte [16]. To establish a firm contact on the luminal side
of the endothelium necessary for extravasation, chemokine-induced inside-out activation of integrins
on the surface is necessary [17]. Especially on neutrophils, Mac-1 plays an important role in adhesion to
the endothelium upon activation [18–20]. In this context, Mac-1-dependent adhesive interactions enable
the cells to crawl on the surface of endothelial cells prior to extravasation [16,21]. Numerous cell surface
receptors have been identified to interact with Mac-1 in its high-affinity state, including ICAM1-4,
JAM-C, Thy-1, RAGE, DC-SIGN, and CD40L [15,22,23]. A plethora of soluble ligands for Mac-1 have
been identified, amongst which are fibrin, fibrinogen, plasminogen, factor Xa, heparin, polysaccharides,
ssDNA, and dsRNA [15,24]. Mac-1 can also interact with matrix proteins, including vitronectin,
collagen, Cyr61, and fibronectin [15]. Mac-1 is also involved in complement-mediated immune
responses by recognizing complement C3-opsonized pathogens as well as immune complexes [25].
In this study, we describe for the first time the interaction of integrin Mac-1 with CD147. We provide
evidence that CD147 is a novel and relevant binding partner for Mac-1 on leukocytes and platelets.
2. Materials and Methods
2.1. Mac-1-CD147 Binding ELISA
Binding between Mac-1 and CD147 was evaluated using a modified enzyme-linked
immunosorbent assay (ELISA). In a 96-well plate, wells were coated with recombinant Mac-1 (R&D
Systems, Minneapolis, MN, USA) or bovine serum albumin (BSA) as the control. Recombinant
CD147 was added in increasing concentrations (0–20 μg/mL) for 1 h. After removing CD147 and
gentle washing, the wells were incubated with an anti-CD147 antibody (mouse-anti CD147, Abcam,
Cambridge, UK) followed by a biotinylated secondary antibody (polyclonal rabbit anti mouse, Dako,
Glostrup, Denmark) and a streptavidin/HRP complex (Life technologies, Carlsbad, CA, USA). The
binding was detected using 3,3′,5,5′-tetramethylbenzidine (Serva, Heidelberg, Germany). The reaction
was stopped using 1 M H2SO4. The absorption was measured using an ELISA plate reader at 450 nm
with a reference value of 570 nm. Measurements from 6 independent experiments were analyzed.
2.2. Murine Leukocyte Isolation and Static Adhesion
Murine leukocytes were isolated from bone marrow. CD11b−/− mice were from Jackson
Laboratories, and CD147+/− mice were a kind gift from Professor R. A. Nowak (Urbana, IL, USA).
The femur and tibia were removed from sacrificed CD11b+/+ and CD11b−/− (hereafter designated
Mac-1+/+ and Mac-1−/−, respectively, n = 5), as well as from CD147+/− and CD147+/+ (n = 12,
respectively) mice (with a C57Bl/6 background). Throughout this, all efforts were made to minimize
animal suffering. The bone marrow was washed out of the bones using RPMI 1640 medium (Life
technologies, Carlsbad, CA, USA) supplemented with 10% FCS (Life technologies, Carlsbad, CA,
USA), 1% Pen/Strep (Sigma-Aldrich, St. Louis, MO, USA), 1% HEPES (Sigma-Aldrich, St. Louis, MO,
USA), and β-mercaptoethanol. The harvested cells were strained through a 70-μm strainer and were
centrifuged (300× g for 5 min) and resuspended in ammonium chloride to lyse erythrocytes. For the
leukocyte culture, cells were washed and resuspended in RPMI 1640 medium supplemented with
0.0001% GMCSF.
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For the static adhesion assay, a 96-well plate was coated overnight with Mac-1 (10 μg/mL), CD147
(20 μg/mL), or BSA (1%). Hereafter, the coated wells were blocked with 4% BSA for 1 h. Then, 2 × 104
isolated leukocytes from Mac-1+/+, Mac-1−/−, CD147+/+, or CD147+/− mice were added into each well.
After allowing the cells to adhere to the coating for one hour, the plate was washed twice with medium
to remove non-adherent cells. The number of adherent cells was analyzed using photo documentation.
2.3. Isolation of Human Monocytes
Human monocytes were isolated as described before [26]. Briefly, mononuclear cells were isolated
form venous blood drawn from the antecubital vein of healthy volunteers. The blood was collected
in citrate-phosphate-dextrose-adenine (CPDA) buffer and was centrifuged over a Ficoll gradient at
920× g for 20 min. Leukocytes were cultured overnight in RPMI 1640 (Life technologies, Carlsbad,
CA, USA) supplemented with 10% FCS (Life technologies, Carlsbad, CA, USA) and 1% Pen/Strep
(Sigma-Aldrich, St. Louis, MO, USA) in plastic dishes. Non-adherent cells were removed by gentle
washing. The adherent cells were detached using trypsin (Life technologies, Carlsbad, CA, USA) and
were resuspended in RPMI 1640 supplemented with 10% FCS and 1% Pen/Strep for further use.
2.4. Isolation of Human Platelets
Human platelets were isolated as described before [27]. In brief, venous blood was drawn from
the antecubital vein of healthy volunteers in adenosine citrate dextrose (ACD) buffer. The blood
was centrifuged at 210× g for 20 min. Hereafter, the platelet-rich plasma (PRP) was collected and
Tyrodes-HEPES buffer (HEPES 2.5 mM; NaCl, 150 mM; KCl, 1 mM; NaHCO3, 2.5 mM; glucose, 6 mM;
BSA, 1 mg/mL; pH 7.4) was added and centrifuged at 836× g for 10 min. The pellet was resuspended
in Tyrodes-HEPES buffer supplemented with 1 mM CaCl2 and 1 mM MgCl2 for further use.
2.5. Cell Adhesion under Flow Conditions
Using a flow chamber assay, human monocytes (2 × 105/mL, stimulated with 1 μg/mL LPS
(Sigma-Aldrich, St. Louis, MO, USA) for 2 h (n ≥ 7) or platelets (1 × 108/mL, n = 7) were pre-incubated
with anti-Mac-1 (clone #2LPM19c, monoclonal mouse-anti-Mac-1 Santa Cruz, Dallas, TX, USA),
anti-CD147 antibody (clone #UM-8D6, monoclonal mouse-anti-CD147, Ancell, Bayport, MN, USA), or
IgG control (all 20 μg/mL) for 2 h (monocytes) or 30 min (platelets). The cells were then perfused over
Mac-1-, CD147-, or BSA-coated coverslips with arterial shear rates (2000 s−1). All experiments were
recorded in real time and were analyzed for adherent and rolling monocytes/platelets, respectively.
2.6. Ethics Statement
All experiments were conducted in accordance with the German animal protection law and
according to the Declaration of Helsinki. All protocols were conducted according to current animal
protection laws and were approved by Regierungspräsidium Tübingen and the local ethics committee
(Anzeige nach §8a TierSchG).
2.7. Statistical Analysis
Data are shown as mean ± SEM. Differences between groups with cardinal values were evaluated
using Student’s t-test for two groups or ANOVA with subsequent post hoc analyses. Differences
were considered statistically significant if p < 0.05. Analysis was performed using Prism 8 (GraphPad
Software, La Jolla, CA, USA).
3. Results
3.1. Mac-1 Interaction with CD147
We used a binding ELISA to assess whether Mac-1 and CD147 can interact in a stable manner. As a
negative control, coating with bovine serum albumin showed no significant interaction. When Mac-1
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was used for coating the respective capture signal of CD147 was significantly enhanced, demonstrating
a direct and stable interaction between the two molecules (Figure 1).















MAC-1 coating, CD147 detection
BSA coating, CD147 detection
* * *
Figure 1. Mac-1 and CD147 interaction. Mac-1/CD147 interaction was assessed using an ELISA
with recombinant Mac-1 or BSA (control) coating. Recombinant CD147 was added in ascending
concentrations for 1 h. Evaluation was facilitated using a biotinylated secondary anti-CD147
antibody with a streptavidin/HRP complex. Changes in absorption of 3,3′,5,5′-tetramethylbenzidine
were measured at 450 nm. Measurements from 6 independent experiments were analyzed,
* indicates p < 0.05.
3.2. Mac-1/CD147 Interaction under Static Conditions
Based on the initial interaction study, we hypothesized that the interaction of these molecules
could play a role in leukocyte adhesive events, as both have been described in this context separately.
To this end, we performed a static adhesion assay with leukocytes from Mac-1-deficient and -sufficient
mice. Mac-1−/− leukocytes showed a markedly reduced adhesion to immobilized CD147 compared to
wild-type mice, indicating a relevant binding strength. With heterozygous leukocytes from CD147+/−
mice, the effect was expected to be less pronounced. CD147+/− cells showed a higher adhesion under
basal conditions with a slight non-significant increase of adhesion to the Mac-1-coated surface (Figure 2).
Figure 2. Mac-1/CD147 interaction in static leukocyte adhesion. A static adhesion assay with leukocytes
form wild-type, Mac−/− (n = 5) (A), and CD147+/− (n = 12) (B) mice was used. Leukocytes were
allowed to adhere to CD147- or BSA-coated surfaces (A) or to Mac-1- or BSA-coated surfaces (B) for 1 h.
* indicates p < 0.05, n.s. indicates p > 0.05 compared to BSA control, respectively.
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3.3. Mac-1/CD147 Interaction under Dynamic Conditions
After establishing a possibly relevant interaction strength for pathophysiological mechanisms,
we studied LPS-stimulated human monocytes, as prototypical members of innate immunity under
dynamic flow conditions. LPS-stimulated leukocytes were perfused over coated surfaces to evaluate
the relative ability of the Mac-1/CD147 interaction to induce adhesion. Using a flow chamber assay, we
observed a stable number of rolling and adherent cells on CD147- as well as on Mac-1-coated surfaces,
compared to BSA under arterial shear rates (n = 9). In both cases, the effect could be reduced by the
addition of either anti-CD147 or anti-Mac-1 antibody to the setup. The number of adherent monocytes
over CD147 failed to reach statistical significance when treated with anti-Mac-1 (p = 0.06) (Figure 3).
Figure 3. Mac-1/CD147 interaction facilitates leukocyte adhesion under dynamic flow conditions.
To evaluate the relevance of the Mac-1/CD147 interaction for adhesion under arterial shear conditions,
a flow chamber assay was used. LPS-stimulated human monocytes were perfused over BSA- or
CD147-coated surfaces (A rolling cells, B adherent cells), or over BSA- or Mac-1-coated surfaces
(C rolling cells, D adherent cells). Inhibitory antibodies against CD147 or Mac-1, as well as IgG control
were added to determine the relevance of the respective protein for adhesion to its proposed counterpart.
Results of ≥7 independent experiments are shown, * indicates p < 0.05 compared to uninhibited control.
3.4. Mac-1/CD147 Interaction in Platelets
To establish whether this mechanism is specific to leukocytes, we decided to perform a similar
dynamic adhesion assay using isolated human platelets. When isolated platelets were perfused over
immobilized Mac-1, adhesion was greatly induced compared to perfusion over BSA, which was used
as a control. When anti-Mac-1 or anti-CD147 antibody was added, adhesion to Mac-1 was significantly
reduced, almost reaching control levels (n = 7). The addition of IgG antibody had no modifying effect
(Figure 4).
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Figure 4. Mac-1/CD147 interaction facilitates platelet adhesion under dynamic flow conditions.
The adhesion of platelets was studied in a similar flow chamber assay with arterial shear conditions.
Isolated human platelets were perfused over Mac-1- or BSA-coated surfaces. Inhibiting antibodies
against CD147 or Mac-1, as well as IgG control were added to determine the relevance of the protein
for adhesion. Video analysis was performed to assess rolling (A) and adherent cells (B). Results of
7 independent experiment are shown, * indicates p < 0.05 compared to uninhibited control.
4. Discussion
The recruitment of leukocytes is a vital mechanism for innate and adaptive immunological
response. Especially, integrins have been found to play a central role for the adhesion of activated
leukocytes to the endothelium [28].
CD147 is a promiscuous surface receptor expressed on a variety of cell types. Ligand binding
to CD147 has been shown to elicit many pro-inflammatory and pro-fibrotic aspects, such as
induction of matrix-metalloproteinases, induction of leukocyte chemotaxis, platelet activation, and
adhesion [4,7,8,29].
Thus far, especially, homodimeric signaling of CD147 and the interaction with extracellular
cyclophilin A has been characterized in the inflammatory and pro-fibrotic context [30,31]. In this study,
we proposed Mac-1 as a previously unknown binding partner for CD147 on leukocytes and platelets.
Initial interaction studies showed a stable binding of the two molecules, making detection via an
ELISA-based interaction assay feasible. As both molecules have been found to be involved in leukocyte
recruitment, we used static and dynamic adhesion assays to establish whether the stability of the
interaction could be of pathophysiological significance. We found that inhibition of either binding
partner strongly reduced the ability of leukocytes and especially monocytes to adhere to CD147- or
Mac-1-coated surfaces under static and dynamic conditions.
With this in mind, we were interested in identifying the mechanism by using leukocytes from
Mac-1 knock-out mice and CD147 heterozygous mice. Both genotypes showed little adhesion to
the immobilized binding partner, whereas leukocytes from wild-type mice showed strong adhesion.
Interestingly, this interaction also seems to be of importance for the adhesion of platelets. While
platelets play a role in inflammation by releasing pro-inflammatory and pro-fibrotic chemokines, in
clinical practice, their pro-thrombotic properties are especially of great interest, as the initial contact of
the platelets with the activated endothelium and associated factors triggers a wide range of responses,
including degranulation, activation by the presentation of adhesion molecules, and shape changes.
Under flow conditions, platelet adhesion to Mac-1 was abolished by the addition of anti-Mac-1 or
anti-CD147 antibodies. This finding suggests that the binding between Mac-1 and CD147 may mediate
platelet–leukocyte interactions as well.
CD147 has been identified to play a prominent role in the induction of pro-inflammatory and
pro-thrombotic effects in various disease models and across species. Our group has previously
described platelet glycoprotein VI (GPVI) as a novel receptor for CD147, mediating platelet rolling and
monocyte–platelet aggregates [11]. Furthermore, the interaction of CD147 with cyclophilin A (CyPA)
has been intensively investigated in the context of thromboinflammation. CyPA can be released from
the cytoplasm by various pro-inflammatory stimuli. The binding of CyPA to CD147 on the surface
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of platelets induces rapid degranulation and activation, leading to shape changes and the release
of pro-inflammatory chemokines [4]. Furthermore, the CD147–CyPA interaction induces leukocyte
chemotaxis and activation, expression of matrix-metalloproteinases, promotes atherosclerotic plaque
formation, and plays critical roles in several inflammatory and cardiovascular diseases [14,31–33].
CD147 has also been associated with other integrins, including α3β1 and α6β1 [2]. S100A9, belonging
to the S100 family of proteins, has been identified to induce leukocyte migration, thrombosis, and
cytokine release via CD147 [5,34]. Mac-1, predominantly expressed on myeloid cells, has also been
extensively implicated in various thromboinflammatory mechanisms, including leukocyte migration,
phagocytosis, and the facilitation of monocyte–platelet aggregates [15,35].
The presented data therefore links two molecules, both deeply embedded in thromboinflammatory
mechanisms, complimenting the existing literature. However, the pathophysiological importance
in vivo remains to be elucidated. This study was primarily designed to establish a plausible link
between CD147 and Mac-1 in the context of thromboinflammation using in vitro experiments. Further
investigations are necessary to characterize the underlying signaling mechanisms and to subsequently
evaluate its pathophysiological relevance.
5. Conclusions
In this study, we described for the first time the interaction of integrin Mac-1 with CD147.
We furthermore provide evidence that CD147 is a novel and relevant binding partner for Mac-1 on
leukocytes and platelets.
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Abstract: In this study, we demonstrated the involvement of matrix metalloproteinases (MMPs)
in hepatic ischemia/reperfusion (I/R) injury. Our aim is to evaluate the impact of reperfusion on
I/R-related changes in RECK, an MMP modulator, and mitogen-activated protein kinase (MAPKs)
pathways (ERK, p38, and JNK). Male Wistar rats were either subjected to 60 min partial-hepatic
ischemia or sham-operated. After a 60 min or 120 min reperfusion, liver samples were collected for
analysis of MMP-2 and MMP-9 by zymography and RECK, TIMP-1, and TIMP-2 content, MAPKs
activation (ERK1/2, JNK1/2, and p38), as well as iNOS and eNOS by Western blot. Serum enzymes
AST, ALT, and alkaline-phosphatase were quantified. A transitory decrease in hepatic RECK and
TIMPs was associated with a transitory increase in both MMP-2 and MMP-9 activity and a robust
activation of ERK1/2, JNK1/2, and p38 were detected at 60 min reperfusion. Hepatic expression of
iNOS was maximally upregulated at 120 min reperfusion. An increase in eNOS was detected at
120 min reperfusion. I/R evoked significant hepatic injury in a time-dependent manner. These findings
provide new insights into the underlying molecular mechanisms of reperfusion in inducing hepatic
injury: a transitory decrease in RECK and TIMPs and increases in both MAPK and MMP activity
suggest their role as triggering factors of the organ dysfunction.
Keywords: RECK; matrix metalloproteinase; MAPKs; ischemia/reperfusion; eNOS; iNOS
1. Introduction
Hepatic ischemia/reperfusion (I/R) injury may occur in a variety of clinical situations, including
transplantation, liver resection, trauma, and vascular surgery. The reperfusion after ischemia may
trigger I/R injury exacerbating cellular damage. The effects of reperfusion include excessive production
of reactive oxygen species, oxidative stress, mitochondrial dysfunction, and systemic inflammatory
response. Neutrophils play a critical role during the initial phase of I/R (0–6 h) triggering activation of
pro-inflammatory intracellular cascades. One of the best characterized pathways within the context of
organ I/R injury is the mitogen-activated protein kinase (MAPKs) family [1]. Among MAPKs, p38,
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JNK1/2, and ERK 1/2, activated by a variety of cellular stressors including I/R, could potentially serve
as potential targets in hepatic I/R injury [2,3].
Hepatic I/R injury is also connected with matrix metalloproteinases (MMPs) gene expression,
activation, and release concomitant with alterations of tissue integrity [4]. The MMPs are a family of
24 proteases using zinc-dependent catalysis to breakdown extracellular matrix (ECM) components,
allowing cell movement and tissue reorganization. Furthermore, MMP-2 and MMP-9 play a crucial
role as they are the main components of Disse’s space composed of loose extracellular matrix (ECM) [5].
We previously demonstrated that dysregulated expression and activation of MMPs are involved
in hepatic injury and that changes in MMP activities already occur during the early phases of
reperfusion [6]. Among different MMPs, MMP-9 is emerging as an important mediator of leukocyte
traffic in hepatic I/R [7]. MMP-9 plays a crucial role in leukocyte recruitment and activation leading
to liver I/R damage [8]. MMP-9(-/-) mice and mice treated with an anti-MMP-9 antibody showed
significantly reduced I/R damage, altered neutrophil migration, and depressed myeloperoxidase
(MPO) activation [8]. Of note, the regulation of MMP activity appears as a multifaceted process;
in particular, the relationship between the production of nitric oxide (NO) by inducible NO synthase
(iNOS) and MMP-9 induction has obtained much attention over the last few years [9]. Selective
iNOS inhibition down-regulates MMP-9 activity and disrupts leukocyte migration in hepatic I/R
injury [10]. Most recent studies demonstrate that the activity of MMP-2 or MMP-9 is reduced
by interaction with the reversion-inducing-cysteine-rich protein with kazal motifs (RECK) [11,12].
Recently, a study discovered RECK isoforms with opposing effects on cell migration: the short
isoform appears to compete with MMP-9 for binding to the long RECK isoform [13]. RECK was
identified as a transformation-suppressor gene which, regulating the expression of several MMPs,
is involved in the inhibition of the tumor invasion and metastasis process [14]. RECK contains
a glycosylphosphatidylinositol domain and a number of cysteine residues. It presents differences in
the amino acid sequence when compared with the tissue inhibitors of metalloproteinases (TIMPs),
which makes RECK an innovative membrane-targeted MMP regulator [14]. Besides, our understanding
of the time course of activation of signaling cascades exerting a key role in liver injury following
reperfusion remains incomplete and warrants further investigation.
Thus, the aim of the present study is to evaluate the impact of reperfusion on RECK and MAPK
signaling pathways under hepatic I/R conditions. Their correlations with markers of organ dysfunction,
such as MMP activity, iNOS, and eNOS were further investigated to better describe pathogenic
mechanism(s) suitable for pharmacological modulation.
2. Materials and Methods
2.1. Materials
All reagents were of the highest grade of purity available and were obtained from Sigma-Aldrich
(Milan, Italy).
2.2. Animals and Experimental Design
Male Wistar rats (Harlan-Nossan, Italy) were used in this study. The animals were allowed free
access to water and food in all the experiments. The use and care of animals in this experimental study
was approved by the Italian Ministry of Health and by the University of Pavia Commission for Animal
Care (Document number 179/2017-PR). The effects of I/R were studied in vivo in a partial normothermic
hepatic I/R model (n = 18). The rats were anesthetized with sodium pentobarbital (40 mg/kg i.p.),
the abdomen was opened via a midline incision. Ischemia to the left and the median lobe was induced
for 60 min with microvascular clips by clamping the branch of portal vein and the branch of the hepatic
artery after the bifurcation to the right lobe, with the abdomen temporarily closed with a suture [6].
After 60 min of ischemia, the abdomen was reopened, the clips were removed, the abdomen was closed
again, and the liver was allowed to reperfuse for 60 or 120 min. By using partial, rather than total,
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hepatic ischemia, portal vein congestion and subsequent bacterial translocation into the portal venous
blood was avoided. Sham animals were subjected to the same procedure without clamping the vessels
(n = 12). To prevent postsurgical dehydration and hypotension, 1 mL of saline was injected into the
inferior vena cava. All the animals were maintained on a warm support to prevent heat loss with
rectal temperature at 37 ± 0.1◦C. Animals were sacrificed under general anesthesia by exsanguination.
Blood was drawn from the vena cava and allowed to clot at room temperature. After 15 min serum
was centrifuged at 3000× g for 10 min at 4◦C. At the end of ischemia or after 60 min or 120 min
reperfusion, hepatic biopsies were quickly removed from the median lobe and immediately frozen in
liquid nitrogen, as were serum samples.
2.3. Biochemical Assays
Liver injury was assessed by serum levels of alanine transaminase (ALT), aspartate transaminase
(AST), and alkaline phosphatase (ALP). Total and direct bilirubin were quantified using standard
commercial kits (Merck, Italy).
2.4. Gelatin Zymography
Protein extraction from snap-frozen samples and gelatin zymography were performed as described
previously [15]. To detect MMP lytic activity samples were homogenized in an ice-cold extraction buffer
and protein content was normalized by a final concentration of 400μg/mL in the sample loading buffer
(0.25 M Tris-HCl, 4% sucrose w/v, 10% SDS w/v, and 0.1% bromphenol blue w/v, pH 6.8). After dilution,
the samples were loaded onto electrophoretic gels (SDS-PAGE), containing gelatin, under nonreducing
conditions. Following the electrophoretic run, the gels were washed twice and were incubated at 37 ◦C.
To reveal zones of lysis, gels were stained with Coomassie Blue. The zymograms were analyzed by
a densitometer (GS 900 Densitometer BIORAD, Hercules, CA, USA), and proteinases activity was
expressed as optical density (OD), reported to 1 mg/mL protein content.
2.5. Western Blot Assay
Liver tissue samples were homogenized in an ice-cold Lysis Buffer supplemented with Protease
Inhibitor Cocktail and centrifuged at 15,000 g for 10 min. The collected supernatant was stored at
−80 ◦C. Samples of liver extracts containing the same amount of proteins were separated in SDS-PAGE
on 7.5% acrylamide gels and transferred to PVDF membrane. Unspecific sites were blocked for 2 h with
5% Bovine Serum Albumin (BSA) in TBS Tween (20 mMTris/HCl, 500 mM NaCl, pH 7.5, 0.1% Tween 20)
at 4 ◦C. The membranes were incubated with primary antibodies overnight at 4 ◦C, under gentle
agitation. Primary antibodies against mouse monoclonal alpha tubulin (DM1A), mouse monoclonal
anti-RECK, mouse monoclonal anti-eNOS, mouse monoclonal anti-Phospho-JNK (Thr183/Tyr185),
mouse monoclonal anti-Phospho-p38 (Thr180/Tyr182), rabbit monoclonal anti-Phospho-ERK1/2
(Thr202/Tyr204), rabbit monoclonal anti-ERK1/2, rabbit polyclonal antibody anti-iNOS, rabbit polyclonal
anti-JNK, and rabbit polyclonal anti-p38 were used at 1:1000 dilution. Rabbit polyclonal anti TIMP-1 and
TIMP-2 were used at 1:200. Membranes were washed in TBS Tween (Na2HPO4 8 mM, NaH2PO4-H2O
2 mM, NaCl 140 mM, pH 7.4, 0.1% Tween 20) and incubated with peroxidase-conjugated secondary
anti-Rabbit or anti-Mouse antibodies at a 1:2000 dilution. The membranes were then stripped and
incubated with tubulin monoclonal antibody (1:5000) and subsequently with anti-mouse (1:10,000)
to assess uniformity of gel loading. Anti-iNOS was purchased from Cayman Chemical (Ann Arbor,
Michigan, USA). RECK and eNOS were bought from Santa Cruz Biotechnology. Mouse monoclonal
antibody against TIMP-1 and TIMP-2 were purchased from Thermo Fisher Scientific (USA For
the detection of MAPKs, the antibodies were obtained from Cell Signaling Technology [LS1]
(Leiden, the Netherlands). Immunostaining was revealed with BIO-RAD Chemidoc XRS+ visualized
using the ECL Clarity BIO-RAD (Milan, Italy). Bands intensity quantification was performed by
BIO-RAD Image Lab Software™ 6.0.1., and autoradiograms showing statistically significant differences
in terms of gel-loading homogeneity were excluded from the following biomarkers analyses.
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2.6. Liver Histology
Liver biopsies were rapidly removed, fixed in 2% p-formaldehyde in 0.1 M phosphate buffer at
pH 7.4 for 24 h and processed routinely until they were embedded in Paraplast wax. Sections were cut
at 7 μm and stained with Hematoxylin and Eosin (H&E) for histological examination [16]
2.7. Statistical Analysis
Results are expressed as means value ± standard error (SE) for all data. The value of p < 0.05
was considered the criterion for statistical significance. To assess normality of variance changes,
the Kolmogorov–Shapiro normality test was used. Data were analyzed by ANOVA with Tukey’s
multiple comparison test as post-hoc test or Kruskall–Wallis and Dunn’s test, as appropriate. Statistical
Analysis was performed using MedCalc Statistical Software version 18.11.3 (MedCalc Software bvba,
Ostend, Belgium; https://www.medcalc.org; 2019).
3. Results
3.1. Transient Expression of Reck, Mmps, and Timps in a Rat Model of Hepatic I/R Injury
To study the expression of RECK under hepatic I/R, we used a rat model of partial I/R injury.
After 60 min reperfusion, a time-dependent increase in serum levels of AST, ALT, ALP, and total and
direct bilirubin was observed (Table 1).
Table 1. Serum levels of AST, ALT, ALP (U/L), and total and direct bilirubin (mg/dL).
Sham 60/60 I/R 60/60 Sham 60/120 I/R 60/120
AST 243 ± 57 3444 ± 1062 198 ± 43 10,387 ± 1158 *
ALT 66 ± 19 3830 ± 961 61 ± 28 9320 ± 1040 *
ALP 431 ± 50 605 ± 51 417 ± 55 769 ± 29 *
Total Bilirubin 0.13 ± 0.024 0.25 ± 0.070 0.12 ± 0.011 0.35 ± 0.043
Direct Bilirubin 0.045 ± 0.019 0.17 ± 0.032 0.04 ± 0.024 0.18 ± 0.013
Aspartate transaminase, AST; alanine transaminase, ALT; alkaline phosphatase, ALP; * p < 0.05.
This trend was supported by histological analysis (Figure 1). Livers from sham-operated animals
showed well-preserved hepatic architecture while I/R caused marked injury to the parenchyma with
sinusoid dilatation, extensive areas of cytoplasmic vacuolation, and wide areas of necrotic cells detached
from the parenchyma, especially after 120 min reperfusion.
Figure 1. Liver histology at the end of reperfusion. Paraplast-embedded sections were cut at 7 μm and
stained with H&E. Panel (A) and (C): 60/60 and 60/120 min sham-operated rats, respectively. Panel (B)
and (D): rats submitted to ischemia followed by 60 or 120 min reperfusion, respectively.
The results of RECK protein analysis showed a significant decrease in RECK only at 60 min
reperfusion when compared with 60 min ischemia or 120 min reperfusion or sham-operated groups;
a complete recovery of RECK levels was found at 120 min reperfusion (Figure 2, Panel A). In addition,
no changes in RECK content at the end of ischemia occurred when compared with sham-operated
group. The opposite trend occurred for both MMP-2 and MMP-9 activities that increased after 60 min
reperfusion when compared with sham-operated rats followed by a significant decrease in both hepatic
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MMP activities detectable at 120 min reperfusion comparable with those found in sham-operated
rats (Figure 2, Panel B). The analysis of TIMP-1 showed a decrease after 60 min reperfusion but was
re-expressed at 120 min reperfusion relative to the 60 min time point. No differences in expression
between TIMP-2 were detected between 60 min versus 120 min reperfusion (Figure 2, Panel C).
Figure 2. Hepatic MMP-2 and MMP-9 activity, RECK, TIMP-1, and TIMP-2 at the end of ischemia and
after 60 min or 120 min of reperfusion. Panel (A): RECK, * p = 0.02; Panel (B): MMP-2, * p = 0.006;
MMP-9: * p = 0.007; Panel (C): TIMP-1 * p = 0.04; TIMP-2, * p = 0.03. The results are reported as the
mean ± SE of 6 different experiments. RECK, reversion-inducing cysteine-rich protein with Kazal
motifs; TIMPs, tissue inhibitor of metalloproteinases.
3.2. Transient Expression of Mapks under Hepatic I/R
Animals that had undergone 60 min ischemia followed by 60 min reperfusion displayed higher
phosphorylation of MAPKs (ERK1/2, JNK1/2 and p38) expression than ischemia or sham-operated
animals (Figure 3 A–C), suggesting an early enhancement of the activation of these pathways by I/R
injury. On the contrary, the longer I/R challenge resulted in lower expression levels of the MAPK
phosphorylated forms, with values similar to those recorded in sham-operated animals, thus indicating
a time-dependent quenching of I/R-injury. No significant changes in expression of total MAPK isoforms
were recorded in ischemia group as well in sham-operated rats.
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Figure 3. Hepatic MAPK pathways (ERK1/2, JNK1/2 and p38) at the end of ischemia and after 60
min or 120 min reperfusion. Panel (A): ERK1, * p = 0.025; ERK2, * p = 0.025; Panel (B): JNK1, * p =
0.028; JNK2, * p = 0.043; Panel (C): P-38, * p = 0.014. The results are reported as the mean ± SE of 6
different experiments.
3.3. Changes in Enos and Inos Expression Under Hepatic I/R
At 120 min reperfusion, a significant increase in eNOS expression was found and it was about
3-fold compared with sham-operated or 60 min reperfused animals (Figure 4, Panel A). Changes
in iNOS expression emerged comparing sham and I/R treated groups both after 60 min or 120 min
reperfusion: a time-dependent increase in iNOS content was found (Figure 4, Panel B).
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Figure 4. Hepatic eNOS and iNOS at the end of reperfusion. Panel (A): eNOS, * p = 0.002; Panel (B):
iNOS, * p = 0.004. The results are reported as the mean ± SE of 6 different experiments.
4. Discussion
The present data provide new insights into the underlying molecular mechanisms that occur
during reperfusion in hepatic I/R injury: a transitory decrease in RECK and TIMPs, concomitant
with an increases in both MAPK and MMP activity, suggests their role as triggering factors of the
organ dysfunction.
As previously documented, the kinetics of the reperfusion injury may also affect the entity of
the expression and activation of MAPK signaling pathways involved in the I/R-induced damage [17].
A crucial intracellular step that can counteract the deleterious effects of I/R injury is the selective
activation of MAPK. A time-course experiment of MAPK expression after liver I/R showed an increase
in phosphorylation of each MAPK (ERK1/2, JNK1/2, and p38), detectable after 60 min reperfusion and
the activation decreased after 3 h reperfusion, especially for JNK [18]. Here we confirmed the early
and transient MAPK activation, coming back to values similar to those recorded in basal condition
after 120 min reperfusion.
In keeping with the data on MAPK activation, when we measured MMP-2 and MMP-9 activity as
well as the expression of their respective TIMP physiological inhibitors in the liver homogenates, we
found a parallel between the early and transient activation of MMP-2 and MMP-9 and that observed
for MAPKs, suggestive of simultaneous contribution to I/R-induced protein expression changes.
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Here, for the first time, we demonstrated that both MMP-2 and MMP-9 over activation at 60
min was associated with RECK down-regulation, whereas the up-regulation of RECK expression was
recorded at 120 min when no significant MMP activation was detectable. It has been reported that RECK
overexpression decreases the amount of active MMP-2 and MMP-9 in conditioned medium and inhibits
metastatic activity in vitro [19] and in vivo [12]. The evaluation of genotypes among hepatocellular
carcinoma (HCC) patients suggested a possible involvement of RECK gene rs11788747 polymorphism
in increasing the susceptibility of individuals to HCC [20]. In addition, RECK expression was found to
be reduced in kidney epithelial cells subjected to hypoxia [21]. Here, for the first time, we demonstrated
that modulation of RECK expression following liver I/R injury was paralleled by changes in MMP-2
and MMP-9 activation, thus suggesting a potential cross-talk mechanism linking these two signaling
cascades. Our results were supported by findings reported in a recent study using a rat model of
cerebral ischemia [22]. Besides, we did not measure activation of signaling cascades (neither at the
very beginning of reperfusion, nor in non-ischemic liver lobes; thus, we cannot offer a comprehensive
understanding here of all the kinetics factors potentially affecting their expression and activation.
MMPs and TIMPs play also an important function in the preservation of liver homeostasis [23]. In
particular, the major endogenous regulator of MMP-9, TIMP-1, exerts a protective role in the control
of the survival of liver cells during I/R injury [24]. Curzio et al. reported that TIMP-1 was induced
following liver I/R with an earlier induction so we can hypothesize that the failure to recover TIMP-2
at 120 min is due to slower induction times [25]. In addition, TIMP-1 has been reported to play the
major protective role: the inability of TIMP-1−/− mice to express TIMP-1 resulted in enhanced liver
damage and in lethal hepatic I/R injury [24]. Our data support these results: an opposite trend was
found comparing MMP-9 activation versus TIMP-1 content.
RECK downregulation under hypoxic conditions has been demonstrated to be mediated by
involvement of ERK1/2, JNK, and p38 MAPK signaling pathways [26]. The same authors demonstrated
that inhibition of the MAPK signaling pathways restores RECK expression and its ability to affect MMP
activity. In particular, activation of the p38 pathway and p38-associated inflammatory processes play a
crucial role in post-ischemic damage [27]. Although several studies have demonstrated a detrimental
role of JNK activation in I/R injury [28], the results about a protection by JNK inhibition are still
controversial [27,29]. There are also studies indicating the potential involvement of ERK 1/2 in hepatic
I/R injury [30]; to date, the potential role of ERK1/2 as a therapeutic target for liver I/R injury has not
been clarified yet, because the molecules used are also able to modulate other pathways different from
ERK1/2 [28]. However, liver protection against I/R injury was recently obtained via suppressing the
MAPK signaling [1]. Although we demonstrated a time-dependent effect of reperfusion injury on the
cross-talk mechanisms linking RECK expression to MAPK activity, we cannot rule out the potential
impact of the kinetics of the ischemia injury on the activation/expression of the tested signaling cascades.
In fact, as shown by Cursio and colleagues [18], a longer kinetics of ischemia (120 min of normothermic
liver ischemia) resulted in sustained p38 MAPK activation until 3 h reperfusion, whereas, in keeping
with our findings, ERK1/2 degree of activation already decreased after 1 h reperfusion.
We also showed no significant differences in RECK and MAPK content between ischemic
livers without reperfusion and either the sham-operated and 120 min reperfusion groups, thus
confirming that activation of the signaling cascades is mainly related to the reperfusion injury in our
experimental conditions.
Once the MAPK pathway is activated, MAPKs phosphorylate downstream protein kinases and
transcription factors, resulting in upregulation of both iNOS and eNOS. Under normal conditions, only
eNOS is present in the liver, and low levels of NO regulate the hepatic perfusion [31]. Alternatively,
the excess production of NO, generated primarily by iNOS, has been implicated as a mediator of
cellular injury at sites of inflammation, including liver I/R injury [32]. Under these circumstances,
NO reacts with molecular oxygen or superoxide and generates reactive nitrogen species, which may
interfere with many biological functional and structural processes of liver injury evoked by hepatic I/R,
including ECM degradation [10]. Here, we confirmed that the early MAPK activation resulted following
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overexpression of iNOS and eNOS, leading to excessive NO production, which contributes to the liver
damage [33] and also remote organs [34]. Besides, specific iNOS inhibition has been demonstrated
to down-regulate MMP-9 activity and disrupts leukocyte migration in hepatic I/R injury [10]. These
findings further support the mechanistic loop linking MAPKs to MMPs here described. However,
only the use of drugs that specifically inhibit these signaling cascades may allow to identify a causal
relationship between these two pathways and their modulation by RECK. Unfortunately, the lack of
knowledge of the in vivo pharmacological profile of highly selective pharmacological inhibitors limits
further investigation.
5. Conclusions
In conclusion, we demonstrated that the kinetics of reperfusion selectively affect the activation
of signaling pathways involved in hepatic I/R injury. Both MAPKs and MMPs showed an early and
transient activation, which contribute to the development of organ dysfunction and injury. Our data
show that reperfusion-induced modulation of RECK expression is paralleled by opposite changes
in MAPK activation and MMP activity. These findings may contribute to better understanding
intracellular pathways cross-regulation sensitive to liver I/R injury and, thus, to providing the rationale
for much needed novel agents to fill the current therapeutic gaps. However, further studies are needed
to better clarify the reciprocal interaction of these pathways for a wider understanding of the intricate
network of cellular and functional interactions leading to I/R-related liver injury.
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Abstract: Matrix metalloproteinase-9 is upregulated in inflammatory bowel disease. Barbiturate nitrate
hybrid compounds have been designed to inhibit MMP secretion and enzyme activity. In this study,
we investigated the mechanism of action of barbiturate-nitrate hybrid compounds and their component
parts using models of intestinal inflammation in vitro. Cytokine-stimulated Caco-2 cells were used
in all in vitro experiments. The NO donors SNAP and DETA-NONOate were used to study the
effect of NO on MMP-9 mRNA. Mechanistic elucidation was carried out using the soluble guanylate
cyclase (sGC) inhibitor, ODQ, and the cGMP analogue, 8-Bromo-cGMP. Further experiments were
carried out to elucidate the role of NF-κB. NO donors exerted an inhibitory effect on MMP-9 mRNA in
cytokine-stimulated cells. While the non-nitrate barbiturates had a limited effect on MMP-9 expression,
the hybrid compounds inhibited MMP-9 expression through its NO-mimetic properties. No effect could
be observed on mRNA for MMP-1 or MMP-2. The sGC inhibitior, ODQ, abolished the nitrate-barbiturate
inhibition of MMP-9 gene expression, an effect which was reversed by 8-Br-cGMP. This study shows
that the barbiturate scaffold is suitable for hybrid design as an MMP-9 inhibitor in cytokine-stimulated
Caco-2 cells. The inhibition of MMP-9 levels was largely mediated through a reduction in its mRNA by
a sGC/cGMP pathway mediated mechanism.
Keywords: inflammatory bowel disease; inflammation; NO; MMP-9; cGMP; Caco-2
1. Introduction
The matrix metalloproteinases are a group of endopeptidases capable of digesting the extracellular
matrix (ECM), basement membrane as well as having an immunomodulatory role related to
activation of other proteases and inflammatory mediators [1–3]. Inflammatory bowel disease (IBD),
which encompasses ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic, relapsing condition
involving inflammation of the gut leading to abdominal pain, diarrhoea, rectal bleeding and fever.
MMP-9 is known to be up-regulated in IBD [4–7] and is associated with disruption of the epithelial
barrier and activation of pro-inflammatory mediators [8–11]. Inhibition of this enzyme may therefore
aid in reducing the severity of the disease. The development of clinically useful synthetic inhibitors
has, to date, been disappointing, mainly due to dose-limiting side-effects but it is also true that
the efficacy evident in animal models has not translated [12,13]. This has led to a revaluation of
the precise role of specific MMPs in a given pathological setting and to investigate new strategies
for modulating dysregulated MMP activity in disease tissue. Certain appropriately substituted
barbiturates have been shown to possess MMP inhibitory characteristics [14,15] while being without
sedative actions [16]. The barbiturates have, in general, better pharmacokinetic properties than other
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MMP inhibitory compounds such as, for example, the hydroxamates. Our group reported a series of
barbiturate-nitrate hybrid compounds that are potent inhibitors of MMP-2 and MMP-9 at the enzyme
level [17]. Incorporation of a nitrate group as a nitric oxide (NO) donor or mimetic functionality
was intended to confer on the compounds an ability to modulate the enzyme levels of inducible
MMP in order to complement the purely enzyme inhibitory actions of the barbiturate zinc binding
group. Interactions between NO and MMP-9, which have been recently reviewed, are complex
and difficult to predict [18]. In our previous work we showed that the hybrid compounds were
able to reduce MMP-9 activity in cell supernatants as measured by gelatin zymography, a property
that was not shared by barbiturate inhibitors not bearing a nitrate group. Furthermore, the hybrid
compounds were significantly more efficacious than the non-nitrate counterparts in a model of MMP-9
dependent cancer cell invasion [17]. Consistent with this, we subsequently found that one of the
hybrid compounds was more effective in an animal model of IBD than the MMP inhibitor from which
it was derived or its incorporated nitrate component [19]. The objective of the present study was
to determine the mechanism by which the hybrid compounds influence MMP levels, to investigate
the role of NO in this and to assess the selectivity for MMP-9 over other MMP enzymes. We found
that the inhibition of MMP-9 mRNA was largely mediated through a reduction in its mRNA by a
sGC/cGMP-mediated pathway.
2. Material and Methods
All chemicals and biological materials were supplied by Sigma Aldrich® (Dublin, Ireland) unless
otherwise stated.
In this study, we used a group of barbiturate-nitrate hybrid compounds and their component
parts that were previously synthesized in our lab [17].
2.1. Cell Culture
Caco-2 cells were supplied by the European Collection of Cell Cultures (ECACC, Salisbury,
UK). Cells were cultured in minimum essential media (MEM) containing 20% fetal bovine serum
(FBS), 1% sodium pyruvate, sodium bicarbonate 2.2 g/L, gentamicin 5 mg/L, streptomycin 10 mg/L,
penicillin G 6 mg/L. Cells were maintained in a 37 ◦C, 5% CO2 humidified incubator until approximately
75% confluent. All the following in vitro experiments were carried out in FBS-free media. Cells were
incubated with 3 series of test compounds at 10μM for 30 min. The dose of 10μM was chosen in accordance
with our previous study were toxicological studies were carried out [17]. Cytokines TNF-α and IL-1β
10 ng/mL were then added and the cells were incubated for 24 h. For NO-donor experiments, solutions of
SNAP or DETA-NONOate were prepared daily when needed and incubated (in the concentration range
10 to 500 μM). For co-incubation experiments with ODQ, this was added with the nitrate-barbiturate
hybrids to give a concentration in the serum-free media of 10 μM as with the compounds. In experiments
where 8-Br-cGMP was used, this was added with the ODQ and compounds to give a final concentration
of 10 μM in the serum-free media.
2.2. Gelatin Zymography
The conditioned media from cell experiments was removed, centrifuged at 13,000 rpm for 5 min
to remove dead cells or floating debris and the resulting cell-free supernatants were stored at −80 ◦C
until assayed for MMP-2 and MMP-9 using gelatin zymography. Briefly, samples were normalized
with respect to protein content using a Bradford assay. The enzymatic activities of MMP-2 and MMP-9
were assayed by gelatin zymography in serum-free media. The samples were electrophoresed on an
SDS−PAGE containing 2% gelatin. The gels were washed with 2.5% Triton X three times for 20 min
cycles. The gels were then washed twice and finally incubated with zymography buffer (0.15 M NaCl,
5 mM CaCl2, 0.05%NaN3, and 50 mM Tris-HCl buffer, pH 7.5) at 37 ◦C for 48 h. After incubation,
the gels were stained with 0.025% Coomassie Brilliant Blue G250 in 25% MeOH, 10% acetic acid,
and H2O and destained with acetic acid 8%, methanol 4%, and H2O. The gelatinolytic activity was
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detected as a band of gelatin digestion and was quantified by densitometry using gel documentation
system r (Bio-Rad, Dublin, Ireland, Universalhood II and Quantity One 4.6 software) and expressed as
a percentage of the positive control.
2.3. Quantitative PCR
Quantitative PCR (qPCR) was used to study the effect of the different compounds on expression
of MMP-1, MMP-2 and MMP-9 and NF-κB in cytokine-stimulated cells. Briefly, the RNA was isolated
using RNAqueous-4PCR® kit from Ambion (Applied Biosystems, Waltham, MA, USA) according
to the manufacturer’s protocol. The concentration and purity of the RNA yielded was measured
using the NanoDrop ND-1000. RNA samples were converted to single-stranded cDNA using a High
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Waltham, MA, USA). As target probes,
TaqMan MGB human MMP-9 (Hs 00234579_m1), NOS (Hs 01075521_m1), NFKB1 (Hs 00949904_m1),
RelA (Hs 01042014_m1) and IKBKG (Hs 01006763_m1) were used. Endogenous 18s rRNA was used as
a control to normalize gene expression data, and an RQ value (2−ΔΔCt, where Ct is the threshold cycle)
was calculated for each sample. RQ values are presented as fold change in gene expression relative to
the stimulated group, which was normalized to 1.
2.4. Nitrate and Nitrite Quantification–Modified Griess Assay
A spectrophotometric method was used to measure the nitrate and nitrite in conditioned media.
Nitrate and nitrite standards were serially diluted to a range 1.6–200 μM in ddH2O and 200 μL of each
concentration was added to 12-well plates in duplicate. Nitrate was reduced to nitrite with the addition
of 200 μL saturated vanadium (III) solution (400 mg VCl3 in 50 mL 1M HCl) and then staining of the
nitrite was carried out with rapid addition of 100 μL sulfanilamide (2% w/v in 5% v/v HCl) and 100 μL
N-1-(naphthyl) ethylenediamine (NEDD) (0.1% w/v in ddH2O). The plate was incubated with rocking
for 45 min and absorbance was read at λ 540nm. Measurement of nitrite standards were carried out as
above with ddH2O added instead of VCL3 solution and ddH2O was used as a blank for both sets of
standards. Conditioned media samples were normalised for protein concentration, and 200 μL loaded
onto 12-well plates in duplicate for both methods described above used to measure the nitrite and
nitrate levels. Addition of VCl3 to the conditioned media samples will give a measure of total NO2−
and NO3− given NOx−.
2.5. NF-κB (p65) Binding Activity
The binding activity of the p65 subunit was measured using an NF-κB (p65) Enzyme Linked
Immunosorbent Assay (ELISA) kit (Cayman Chemicals, Dublin, Ireland). Nuclear extraction was first
carried out from cultured and treated cells after 24 h using the nuclear extraction kit (Cayman Chemicals,
Dublin, Ireland) according to the manufacturer’s protocol. The biding of p65 in these nuclear
extracts was then determined using the NF-κB (p65) transcription factor assay according to the
manufacturer’s instructions.
2.6. Statistical Analysis
Analysis of results was carried out using Graph Pad Prism® 5 for Windows (San Diego, CA, USA,
Graph Pad software). All results shown represent n ≥ 3 and were analyzed using a one way ANOVA
and Dunnett’s or Tukey post-test where appropriate. Graphs are presented as the mean ± the standard
error of the mean (SEM) and statistical significance was judged as a p value of <0.05.
3. Results
3.1. Barbiturate-Nitrate Hybrids Reduce MMP-9 Expression in Cytokine-Stimulated Caco-2 Cells
We have previously demonstrated that the barbiturate-nitrate hybrids (series 1, Figure 1) can
reduce supernatant MMP-9 activity as measured by gelatin zymography to a greater extent than the
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barbiturate-alcohols (series 2, Figure 1) [17]. Here we examine the effect of the hybrid compounds at
the gene level and use the barbiturate-alcohols and nitrate side-chains (series 3, Figure 1) to measure
the relative contributions of the component parts of the series of compounds.
Figure 1. Structures of compounds used. Column one shows the nitrate side-chains. Columns two and
three show the barbiturate scaffold and the nitrate and alcohol side-chains, respectively.
The nitrate-barbiturates (10 μM) caused a statistically significant reduction in MMP-9 mRNA
in cytokine-stimulated Caco-2 cells after 24 h compared to the untreated, stimulated cells (Figure 2).
Compounds 1c and 1a caused the greatest mean inhibition. The alcohol-barbiturates also inhibited the
transcription of MMP-9 at 10 μM but to a lesser extent. The nitrate side-chains did reduce MMP-9
expression when tested at 10 μM (Figure 2), but this inhibition did not reach statistical significance
except for compound 3f. The compounds in parallel experiments did not affect mRNA levels of MMP-1
or MMP-2, showing selectivity for inhibition of MMP-9.
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Figure 2. Barbiturate-nitrate hybrids (series 1) reduce MMP-9 mRNA to a greater extent than the
barbiturate alcohols (series 2) or the nitrate side-chains (series 3). Caco-2 cells were incubated with
series of the barbiturate-nitrate hybrids, barbiturate-alcohols or nitrate side-chains at 10 μM for 30 min
prior to addition of TNF-α and IL-1β (10 ng/mL). ### p < 0.001 vs. unstimulated Caco-2 cells (negative
control); * p < 0.05 vs. cytokine-stimulated Caco-2 cells (positive control); ** p < 0.01 vs. positive control;
*** p < 0.001 vs. positive control.
3.2. Nitric Oxide Donors Reduce MMP-9 mRNA Levels in Cytokine-Stimulated Caco-2 Cells
In order to establish whether the effects that the nitrate-barbiturates had on MMP-9 mRNA in
cytokine-stimulated Caco-2 cells were NO-mediated, we tested the effects of two NO-donors at a range
of concentrations for 24 h. In this study we used the S-nitrosothiol, S-Nitroso-N-acetylpenicillamine
(SNAP), which has been previously shown to have a half-life in aqueous media of approximately 4 h;
the NO formation is high, where 100 μM yields about 1.4 μM NO/minute at 37 ◦C, and it is linear over
a wide concentration range. In addition, we measured the effects of the diazeniumdiolate compound
DETA-NONOate, which decomposes spontaneously and has been demonstrated to have a half-life of
20 h at pH 7.4 and 37 ◦C [20].
We found that DETA-NONOate reduced MMP-9 expression with the highest concentration tested
(Figure 3A). Figure 3B shows the release of NO species. As expected from a NONOate NO-donor,
there was a linear relationship between the concentration used and the NO released with correlation
analysis results for NOx− (p < 0.0001, R2 = 0.9975), NO2− (p < 0.0001, R2 = 0.9996) and NO3− (p < 0.0001,
R2 = 0.9828) being statistically significant. There was little to no difference in NO yielded from the
lower concentrations of DETA-NONOate used, which may reflect the limited sensitivity of the Griess
assay. At a concentration of 500 μM, DETA-NONOate yielded statistically significantly more of all
NOx− species than the positive control. The highest concentrations of nitrate and nitrite were produced
from the highest concentration of DETA-NONOate, which also produced a significant inhibition of
MMP-9 at the gene level.
We also found that the addition of SNAP caused a significant inhibition of MMP-9 at the gene
level at all concentrations tested (Figure 4A). Figure 4B shows the release of NO species. Incubations
with SNAP showed a linear correlation between the concentration used and the resultant nitrate and
nitrite concentrations that were present in the conditioned media after 24 h. The results of correlation
analysis of SNAP concentration and NOx− (p < 0.0001, r2 = 0.9964), NO2 (p < 0.0001, r2 = 0.9696) and
NO3− (p = 0.0002, r2 = 0.9525) are unsurprising considering that SNAP is expected to spontaneously
yield NO, which will be decomposed to nitrite and nitrate. At 500 μM SNAP, the difference in nitrite
concentrations reached statistical significance for all groups. Similar results were observed for nitrate
and NOx− concentrations, where 500 μM SNAP resulted in statistically significant differences with all
other groups, and 200 μM was also statistically different from the controls and 10 μM SNAP. There is
no obvious correlation between these results and the effect on MMP-9 gene expression.
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Figure 3. (A) DETA NONOate significantly reduced MMP-9 mRNA at high concentrations in
cytokine-stimulated Caco-2 cells (## p < 0.01 vs. unstimulated Caco-2 cells (negative control); * p < 0.05 vs.
cytokine-stimulated Caco-2 cells (positive control). (B) Measurements of nitrate and nitrite concentrations
as breakdown products of NO by the Griess assay on the conditioned media of Caco-2 cells after 24 h of
co-incubation with DETA-NONOate and pro-inflammatory cytokines TNF-α and IL-1β. Top left pane
shows the nitrite concentration, top right panel shows the nitrate concentration, bottom left pane shows
the combined reduced NO groups and bottom right shows the linear correlations of DETA-NONOate
concentrations versus the concentration of measured NOx− species (*** p < 0.001 vs. negative control).
Figure 4. (A) SNAP significantly reduced MMP-9 mRNA at different concentrations tested in
cytokine-stimulated Caco-2 cells: ## p < 0.01 vs. unstimulated Caco-2 cells (negative control);
** p < 0.01 vs. cytokine-stimulated Caco-2 cells (positive control). (B) Measurements of nitrate and
nitrite concentrations as breakdown products of NO by the Griess assay on the conditioned media of
Caco-2 cells after 24 h of co-incubation with SNAP and proinflammatory cytokines TNF-α and IL-1β.
Top left pane shows the nitrite concentration, top right pane shows the nitrate concentration, bottom
left pane shows the combined reduced NO groups and bottom right shows the linear correlations of
SNAP concentrations versus the concentration of measured NOx− species. (** p < 0.01 vs. negative
control; *** p < 0.001 vs. negative control).
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3.3. Barbiturate-Nitrate-Hybrids Inhibit MMP-9 Gene Expression in an NF-κB-Independent Manner
In this study, we examined the effect of the barbiturate-nitrate hybrids on gene expression of
various components of the NF-κB pathway and the nuclear binding of the p65 subunit to test the
hypothesis that the compounds could mimic the effect of NO on NF-κB.
A trend towards inhibition was observed for the nitrate-barbiturates that did not reach statistical
significance (Figure 5A). Therefore, we decided to examine the effect of the compounds on the
transcription of some of the elements of the NF-κB pathway.
The expression of RelA/p65, NF-κB1/p105 and IκBKG/NEMO, which forms part of the IKK
complex, were assessed by qPCR (Figure 5B–D). However, the compounds showed a limited effect
on RelA/p65, NF-κB1/p105 and IκBKG/NEMO with 1a, 1b and 1c causing the greatest reduction in
expression of these elements.
Figure 5. The barbiturate-nitrate hybrids show little effect on the NF-κB pathway. The nuclear translocation
and binding of the NF-κB subunit p65 was measured using ELISA (A) and the gene expression of RelA/p65,
NF-κB1/p105 and a component of the IKK complex, IκBG/NEMO were measured using qPCR (B–D).
# p < 0.05 vs. unstimulated Caco-2 cells (negative control).
3.4. Inhibition of MMP-9 by the Barbiturate-Nitrate Hybrids Is Partly Mediated Through a sGC/cGMP
Pathway
Following the limited effect of the compounds in altering NF-κB nuclear binding or expression of
components of the pathway, we focused on the role of the cGMP pathway in mediating the inhibition
of MMP-9 by the nitrate-barbiturates. This was first achieved using the pharmacological inhibitor
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one (ODQ), which is a highly selective and irreversible heme
site inhibitor of sGC and is competitive with NO [21,22]. As shown in Figure 6A, co-incubation of the
nitrate-barbiturates with ODQ abolished any reduction in MMP-9 gene expression, an effect which
was reversed by adding the cGMP analogue 8-Br-cGMP to the cells (Figure 6B). These effects correlated
with MMP-9 protein activity as shown in Figure 6C,D.
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Figure 6. Barbiturate-nitrate hybrids inhibit MMP-9 via a soluble guanylate-cyclase-dependent pathway.
(A) there was a significant up-regulation of the MMP-9 gene when inducing Caco-2 cells with the
pro-inflammatory cytokines. When cells were activated in the presence of ODQ (0.05 μM), this resulted
in a reversion of MMP-9 mRNA levels in barbiturate-nitrate hybrid-treated cells. (B) Exogenously
added 8-bromo-cGMP restored the effect of ODQ (0.5 μM). These results correlated with the pro-MMP-9
protein activity as shown by zymography (C,D) ## p < 0.01 vs. unstimulated Caco-2 cells (negative
control); ### p < 0.001 vs. negative control; * p < 0.05 vs. cytokine-stimulated Caco-2 cells (positive
control); ** p < 0.01 vs. positive control; *** p < 0.001 vs. positive control.
4. Discussion
Understanding that MMP-9 remains an attractive target for inhibition in a variety of inflammatory
conditions, our group designed a series of barbiturate-based hybrids that are intrinsically active as
MMP inhibitors at the enzyme level but have additional effects on MMP activity through a nitrate
moiety [17]. The present findings indicate that the hybrid compounds, which inhibit at the enzyme
level, also reduce MMP-9 at the gene level in response to inflammatory stimuli. These effects are
mediated by NO mimicry in cGMP activation and they are selective for MMP-9 inhibition over MMP-1
and MMP-2.
MMPIs have failed in clinical trials due to disappointing clinical efficacy results compared to
animal trials and dose-limiting side-effects of MSS; but we can now reflect on how little was known
of the complex protease network or the net effect of inhibition of certain enzymes in a given setting.
The trials added MMPIs as co-therapies for patients with invasive or metastatic cancer, which may
not have been appropriate considering that metastasis was already established and also, the genetic
diversity of the disease [13]. It is now known that the MMPs may play a protective role in tumour
progression [23,24] including MMP-8 and indeed much broader roles in inflammation than previously
appreciated, many of which are protective [25,26]. Setting will be crucial to the success of MMPIs, and so
as we understand more about the interactions of the MMP network and the roles of individual MMPs in
a given disease setting, we may be better able to appropriately target them for inhibition. While broad
spectrum inhibition may be appropriate in certain acute inflammatory settings, selectivity may be
important in reducing side-effects in chronic inflammatory conditions. With the difficulties in finding
selective and clinically useful active-site inhibitors, alternative strategies such as blocking upstream
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pathways of activation [27,28] or indeed targeting the transcriptional upregulation of the enzyme
is of utmost importance. Xanthine-derivatives, NSAIDs and 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitors have all been studied as inhibitors of MMP-9 expression [9].
Doxycycline, the only clinically approved drug acting through MMP inhibition [29], is a weak enzyme
level inhibitor [30] which exerts its effects mainly at the transcriptional level [31–33].
In previous studies, we established that the hybrid compounds affect MMP-9 secretion [17], but it
was unclear if this was at the storage, secretory or transcriptional level. In this study, we found
a profound reduction of MMP-9 mRNA with the hybrid compounds on cytokine-stimulated cells.
These effects were not observed on MMP-1 and MMP-2 mRNA. We also found a smaller but significant
reduction in MMP-9 transcription with the alcohol-barbiturates. The inhibitory effect of the non-nitrates
on MMP transcription is probably due to a general anti-inflammatory effect associated with MMP-9
inhibition at enzyme level. The MMPs catalyse the activation of a broad range of substrates [2,34],
which can promote the transcriptional up-regulation of pro-inflammatory mediators, including MMPs
themselves. MMPs have become common read-outs for inflammation in cell and animal models of
IBD. For example, in a rat model of UC, the broad spectrum hydroxamate MMP inhibitor, ilomastat,
was shown to inhibit MMP-1 expression in the colon [35]. The nitrate side-chains tested alone also
reduced MMP-9 levels with a similar order of magnitude to the alcohol-barbiturates. The striking
effect of the hybrid compounds on MMP-9 expression may be attributed to an indirect inhibitory action
at the enzyme level and an additional NO-mediated effect at the mRNA level.
Next, we tested the effects of NO-donors on MMP-9 in our model of intestinal epithelial
inflammation in order to ascribe some of the MMP-9 inhibitory action of the compounds to the nitrate
moiety. In our experiments, SNAP and DETA-NONOate were chosen as NO-donors to represent
varying NO release profiles. There was a linear relationship between the concentration of the compound
used and the concentration of nitrate and nitrite, breakdown products of NO, that were in the media
after 24 h. Cytokine-stimulated cells that were incubated with SNAP showed a large inhibition of
MMP-9 gene expression. DETA-NONOate was used in the same range of concentrations as SNAP
but did not result in the same effect on MMP-9. It is interesting to note that while there was a direct
correlation between the concentration of donor used and the NOx− species measured, this did not
correlate with the effect on MMP-9 despite both NO-donors having some inhibitory effect. The half-life
of NO in a biological setting is in the range of seconds and so the measurement of its breakdown
products after 24 h may not necessarily be relevant. SNAP is expected to breakdown spontaneously
and has a shorter half-life than DETA-NONOate and will likely produce a higher concentration of
NO that may be sustained for a shorter period of time and it may be this property that resulted in the
inhibition of MMP-9 mRNA.
Knowing that the nitrate-barbiturates can inhibit MMP-9 transcription, that NF-κB is involved
in the upregulation of MMP-9 and that NF-κB is sensitive to NO, we decided to assess the effect of
the compounds on the NF-κB pathway. NF-κB exists in the cytoplasm as an inactive dimer bound
to its inhibitor IκB. Activation of the IKK complex liberates the dimer to migrate to the nucleus and
interact with κB binding sites in the promoter regions of certain genes. The MMP-9 gene contains at
least two of these binding sites in its promoter region [36] and NF-κB has been shown to be essential
for MMP-9 upregulation [37–39]. NF-κB can induce the expression of iNOS when activated and NO
is a known regulator of NF-κB, likely functioning in a concentration-dependent negative feedback
loop [40,41]. We have previously reviewed the evidence for the NO’s modulation of NF-κB in the
context of MMP-9 [18]. Therefore, we decided to assess the effect of the compounds on the NF-κB
pathway. An ELISA of the p65 subunit was used to measure the nuclear binding of the NF-κB complex.
There was a trend of inhibition for all the compounds with a maximum mean reduction of 32%, but the
observed reductions were not statistically significant. To further investigate the effect on p65 nuclear
binding, we measured the effect of the compounds on the expression of some of the components of
the NF-κB pathway. RelA and NF-κB1 are common components of the NF-κB complex, a protein
dimer that will bind to its response element on certain genes. Although the primary mechanism of
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regulation is its liberation from IκB, it is still under transcriptional control and these two components
are both upregulated by pro-inflammatory cytokines in Caco-2 cells. IκBKG is part of the IKK complex,
which can phosphorylate IκB, leaving the NF-κB complex free to migrate to the nucleus. The difference
between the sham and stimulated controls was small, which reflects the fact that transcriptional control
is not the primary mechanism of regulation of IκBKG. The compounds exerted a limited effect on
RelA/p65, NF-κB1/p105 and IκBKG/NEMO.
We next turned our attention to cGMP as a candidate for the NO-mediated effect. The cGMP
pathway is one of the most well-defined ways that NO exerts many of its effects such as vasodilation
and inhibition of platelet aggregation. NO can react with the heme centre of sGC, increasing the rate of
catalytic conversion of GTP to cGMP [42]. sGC can mediate the transcriptional upregulation of COX-2,
TNF, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor receptor-1 (VEGFR1),
mitogen-activated protein kinase phosphatase-1 (MKP-1) and MMP-9. The exact mechanism by which
cGMP exerts its transcription regulatory functions has not been fully explained but it can alter the
function of cGMP-regulated ion channels, cGMP-regulated phosphodiesterases and cGMP-dependent
protein kinases (PKG) [43]. Several lines of evidence suggest PKG as the mediator of sGC action on
MMP-9 gene transcription [44–47]. Co-incubation of the hybrid compounds with the sGC inhibitor ODQ,
abolished their MMP-9 inhibitory effects and no differences were observed between the compound
treated cells and the positive control at the level of gene transcription or enzyme activity. We could
therefore deduce that the nitrate-barbiturates inhibited MMP-9 transcription in a sGC-dependent
manner. To confirm this result and further elucidate the pathway, the cGMP analogue, 8-Br-cGMP,
was added with the compounds along with ODQ, and it was found that the inhibitory properties
of the compounds were restored to what they were with the compounds alone. We can therefore
conclude that nitrate-barbiturates exert their inhibitory action on MMP-9 transcription through a
sGC-cGMP pathway.
In summary, both control NO donors were able to exert some inhibitory effect on MMP-9
transcription in cytokine-stimulated Caco-2 cells, but this effect was independent of the NOx−
concentration after 24 h. The barbiturate-nitrate hybrids, which are established enzyme level inhibitors,
also inhibit MMP-9 at the gene level, an effect that is partly mediated by the nitrate group through
a sGC-cGMP pathway. This discovery highlights the potential of these drugs in treating colonic
inflammation and also represents a novel mechanism for correcting MMP dysregulation in inflammatory
diseases. New studies are guaranteed to test these new compounds in other inflammatory conditions
where MMP-9 upregulation plays an important role.
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Abstract: Chronic Kidney Disease (CKD) represents a risk factor for fatal and nonfatal cardiovascular
(CV) events, including peripheral vascular disease (PVD). This occurs because CKD encompasses
several factors that lead to poor prognoses, mainly due to a reduction of the estimated glomerular
filtration rate (eGFR), the presence of proteinuria, and the uremic inflammatory milieu. The matrix
metalloproteinases (MMPs) are a group of zinc-containing endopeptidases implicated in extracellular
matrix (ECM) remodeling, a systemic process in tissue homeostasis. MMPs play an important role
in cell differentiation, angiogenesis, inflammation, and vascular damage. Our aim was to review
the published evidence regarding the association between MMPs, PVD, and CKD to find possible
common pathophysiological mechanisms. MMPs favor ECM deposition through the glomeruli, and
start the shedding of cellular junctions and epithelial-mesenchymal transition in the renal tubules.
MMP-2 and -9 have also been associated with the presence of systemic vascular damage, since they
exert a pro-inflammatory and proatherosclerotic actions. An imbalance of MMPs was found in the
context of PVD, where MMPs are predictors of poor prognoses in patients who underwent lower
extremity revascularization. MMP circulating levels are increased in both conditions, i.e., that of
CKD and PVD. A possible pathogenic link between these conditions is represented by the enhanced
production of transforming growth factor-β that worsens vascular calcifications and atherosclerosis
and the development of proteinuria in patients with increased levels of MMPs. Proteinuria has been
recognized as a marker of systemic vascular damage, and this may explain in part the increase in
CV risk that is manifest in patients with CKD and PVD. In conclusion, MMPs can be considered a
useful tool by which to stratify CV risk in patients with CKD and PVD. Further studies are needed to
investigate the causal-relationships between MMPs, CKD, and PVD, and to optimize their prognostic
and predictive (in response to treatments) roles.
Keywords: metalloproteinases; MMPs; TIMPs; CKD; peripheral vascular disease; biomarkers;
proteinuria; eGFR; PAD.
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1. Introduction
Chronic Kidney Disease (CKD) is defined as the presence of abnormalities in kidney function
or structure for at least 3 months [1]. The Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines classify CKD according to the level of estimated glomerular filtration rate (eGFR), a marker
of kidney function, and the amount of urine protein (proteinuria or albuminuria), which represents
the principal marker of kidney damage and the primary cause of CKD [2]. The onset of CKD exerts
a deleterious impact on individual health. Indeed, it has been demonstrated that either an eGFR
reduction < 60 mL/min/1.73 m2 or a small increase in proteinuria are associated with a poor prognosis,
as shown by the increased rate of cardiovascular (CV) fatal and nonfatal events, all-cause mortality,
and the progression of kidney disease resulting in the need for renal replacement therapies (kidney
transplantation or dialysis) [3,4].
CV risk is severely increased in patients with CKD, and the impact of CV events in this population
is crucial if one considers that the rate of CV events (such as myocardial infarction, stroke, arrhythmias,
peripheral vascular disease, and chronic heart failure) over time is higher than the risk for kidney
disease progression [5]. This strong association has been attributed to the coexistence of traditional and
nontraditional CV risk factors in CKD patients, with the former being represented by hypertension,
smoking, hypercholesterolemia, and metabolic abnormalities, and the latter by the two main prognostic
measures of CKD, i.e., proteinuria and eGFR [6,7].
Among the wide spectrum of CV events, a relevant role is portrayed by peripheral vascular
disease (PVD). It has been demonstrated that the presence of mild-to-moderate CKD increases the risk
of peripheral artery disease, leg revascularization, leg amputation, and hospitalizations [8]. Either an
eGFR reduction below 60 mL/min/1.73 m2 or slight increases of albuminuria (>30 mg/g) have been
associated with a 1.5 to 4 times higher risk of peripheral artery disease (PAD). This evidence is strong,
being derived from patients without PAD at basal visit, and reproducible, being confirmed in the
general population, as well as in high-risk populations, regardless of the geographic area. Notably,
the rate of PVD among patients with End-Stage Kidney Disease (ESKD) is higher than the incidence
of acute myocardial infarction, stroke, and arrhythmias [9]. Hence, CKD patients warrant clinical
surveillance and prompt the need for strategies to prevent the onset of PVD.
The magnitude of the association is so important that research has recently focused on discovering
new biomarkers that are potentially useful in the clinical management of CKD patients at increased
risk for PVD. Matrix Metalloproteinases (MMPs) are zinc-containing endopeptidases that are involved
in regulating tissue development and homeostasis [10]. Although all MMPs are better acknowledged
for their role in remodeling the extracellular matrix (ECM), they actually interact with both ECM and
non-ECM substrates. Cell adhesion molecules and growth factors or their receptors represent these
latter group of substrates. The wide range of interactions in which MMPs play an active role also
explains why these endopeptidases participate in a number of functions such as cell differentiation,
migration, apoptosis, and angiogenesis. On the other hand, MMPs have also been attributed to
a profibrotic and pro-inflammatory role. MMP-2 and MMP-7 were increased in plasma and urine
samples of CKD patients, and may affect direct damage to the kidney with the onset of albuminuria [11].
Moreover, imbalances in the expression and the levels of MMPs or their inhibitors have been linked to
the structural changes that occur in the development of PAD, atherosclerotic plaque maturation, and
arterial remodeling [12].
The purpose of this review is to examine the role of MMPs in increasing the risk of peripheral
vascular disease by the specific aggravating condition of Chronic Kidney Disease.
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2. Materials and Methods
The PubMed and ISI Web of science databases were searched for articles by using the
following terms: ‘chronic kidney disease”, “chronic renal insufficiency”, “metalloproteinases”, “MMP”
“atherosclerosis” “peripheral vascular disease”. Titles and abstracts were screened by three authors
(Michele Provenzano, Michele Andreucci, and Raffaele Serra) to identify potentially relevant studies.
All potentially eligible studies were subsequently evaluated in detail by one reviewer and three authors
(Michele Provenzano, Michele Andreucci, Carlo Garofalo, and Raffaele Serra) through consideration of
the full text. Reference lists of retrieved articles were also searched for relevant publications. Clinical
trial, meta-analyses, narrative review, and systematic reviews published in the last 10 years were
included. Bibliographies of relevant articles and reviews were manually screened to identify additional
studies. Studies were excluded if they were not in the English language, if they did not fit the research
question, or if they had insufficient data.
3. Results
3.1. Study Selection
Initial database searches yielded 180 studies from PubMed and 445 from ISI Web of Science in the
last 10 years. After the evaluation of the bibliographies of the relevant articles, we evaluated 67 eligible
full text articles. The current evidence on MMP expression and kidney disease, the link between MMPs
and CV risk specifically in CKD patients, and the association between MMPs and peripheral vascular
disease are described below.
3.2. Metalloproteinases and the Kidney
MMPs are classified, according to their structure (or function) and the substrate selectivity, into
six groups: Collagenases (MMP-1, MMP-8 and MMP-13), which cleave native collagen and with
possible antifibrotic function; Gelatinases (MMP-2 and MMP-9), whose function is to cleave denatured
collagens, type IV collagens in basement membranes and some chemokines; Stromelysins (MMP-3,
MMP-10, MMP-11 and MMP-19), which degrade a number of substances such as fibronectin, laminin
but are unable to cleave native collagen; Matrilysins (MMP-7 and MMP-26) act by degrading ECM
components (laminin and entactin); Membrane-type MMPs (MMP-14, -15, -16, -17, -24, and -25), so
called because they are anchored to the exterior of the cell membrane; and other MMPs that are
tissue or cell-type specific [10,13]. The MMP activity is modulated by a series of four known enzymes
called tissue inhibitors of metalloproteinases (TIMPs). TIMPs participate either in the activation or
inhibition of MMP activity and, like MMPs, regulate several cellular functions such as cell proliferation,
apoptosis, and angiogenesis [14]. It has been demonstrated that MMPs exert a role in the development
of proteinuric kidney diseases in humans. Indeed, a number of studies depicted increased serum
and urine levels of MMP-2, -8, and -9 in diabetic patients, with MMP-9 in particular being positively
correlated with the degree of proteinuria in these patients [15–18]. It is remarkable that, in addition
to MMP-9, urinary levels of neutrophil gelatinase-associated lipocalin (NGAL) have been found to
increase in patients with diabetic nephropathy [19]. NGAL and MMP-9 are coexpressed, and their
interaction prevents the degradation of MMP-9. It has, thus, been postulated that the increase in
NGAL may prolong the action of MMP-9 as a trigger of kidney damage [20]. MMP-7, which is
normally expressed in the proximal and distal convoluted tubules, as well as in the collecting duct, is
found to be overexpressed in diabetic patients where it is also inversely correlated with the degree
of kidney function [21]. Other than in diabetic patients, MMP expression is altered in many other
glomerular diseases. Typical patterns of MMP-2 and MMP-9 are differentially expressed in patients
with focal segmental glomerulosclerosis, minimal change disease, membranous nephropathy, and
ANCA-associated vasculitis [22–26]. Regardless of the specific kidney disease involved, several
mechanisms of damage have been put forward to explain the pathophysiologic effects of MMPs
(Figure 1).
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Figure 1. Expression of MMPs and TIMPs, and pathophysiological mechanisms of vascular and kidney
damage [10,11,27–31]. EMT, epithelial-mesenchymal transition; VSMC, vascular smooth muscle cells;
TGF-β, transforming growth factor-β.
MMPs intervene in all phases of renal fibrosis, from infiltration of mononuclear cells to cells
proliferation and scarring. All these processes lead to a progressive decline of renal function in CKD
patients. Henger and Colleagues performed a hierarchical clustering analysis to assess the differential
gene expression in human kidney fibrosis. Interestingly, they observed that several MMP (MMP-3,
-13, -14) genes were upregulated in different degrees of fibrosis [32]. With respect to inflammation,
different MMPs play different, often opposing, actions. MMP-7 and MMP-9 expand inflammatory
processes, particularly by their chemotactic effect on human dendritic cells [33,34]. Conversely, MMP-13
and MMP-14 have been hypothesized to act as anti-inflammatory mediators [35]. MMP-3 may also
promote epithelial-to-mesenchymal transition, the conversion of tissue phenotype, from the epithelial
to fibroblastic, thereby accelerating fibrosis [36]. Abnormalities in the accumulation/degradation of
ECM due to imbalanced levels of MMPs and TIMPs have also been described in rat and humans [37–39].
Indeed, downregulation of MMP-1 and the overexpression of TIMP-1, MMP-2, MMP-7, and MMP-9
are associated with a profibrotic effect, as well as with a destructive effect on renal parenchyma [38,39].
Moreover, increased TIMP-1 plasma levels were predictors of incident CKD, regardless of other
systemic and inflammatory biomarkers (C-Reactive Protein or Brain Natriuretic Peptide) and many
clinical parameters (liver function, concomitant lipid-lowering, or antihypertensive medications) [40].
3.3. Vascular Effects of Metalloproteinases in CKD Patients
The structural remodeling of ECM, together with the profibrotic effect of MMPs, are detrimental
for other organs apart from the kidney. Elevated blood concentrations of TIMP-1 have been associated
with an increased risk of developing chronic heart failure (CHF) and, in patients already diagnosed
with CHF, they were predictors of poor prognoses [41,42]. Moreover, the increase in MMP-9 and
TIMP-1 conferred risk of all-cause mortality and incident CV disease in community studies [43,44].
Possible explanations for the relationship between MMPs and CV risk are varied. Whereas all MMPs
are likely risk factors for atherosclerosis and cardiac dysfunction, a more specific mechanism of damage
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has been postulated for MMP-9 and TIMP-1. Indeed, MMP-9 is involved in the intracellular cleavage
of myosin filaments, a mechanism that leads to ventricular hypertrophy [45]. TIMP-1 has shown a
direct relation with the left ventricular mass in the Framingham Heart Study participants [41]. The
CKD condition is associated with an increased prevalence of CV morbidity and mortality. The United
States Renal Data System (USRDS) showed that the frequency of each CVD, including myocardial
infarction, coronary artery disease, and peripheral vascular disease was higher among patients with
CKD compared with those without (Figure 2) [9].
 
Figure 2. Prevalence of cardiovascular diseases according to the presence (dark blue bars) or absence
(turquoise bars) of Chronic Kidney Disease (CKD) in the United States, in the year 2015. AF, atrial
fibrillation; AMI, acute myocardial infarction; CAD, coronary artery disease; CVA/TIA, cerebrovascular
accident/transient ischemic attack; HF, heart failure; PAD, peripheral arterial disease.
The CV burden in these patients is significant if one considers that the rate of CV events is similar
to that of reaching ESKD [46,47]. As a result of this epidemiological and public health evidence, great
effort has been placed in finding early atherosclerosis biomarkers that predict CV events in CKD
patients and serve as a possible target for new therapeutic agents [48]. MMPs were included in the
set of investigated substances. Indeed, MMP-2 was positively associated with carotid Intima-Media
Thickness (cIMT) and abdominal aortic calcification, suggesting that an association between this MMP
and subclinical atherosclerosis is plausible [49–51]. Moreover, MMP-2 was also found to be higher in
patients with a positive history of CV disease vs no history of CV disease [52,53]. MMP-9 was also
strongly associated with cIMT, the development of carotid plaques, and systemic atherosclerosis [49,50].
MMP deregulation is intensified in patients with advanced CKD stages that are also associated with a
reduction of their clearance. All these mechanisms enhance the inflammatory process that is chronically
activated in CKD patients, due to oxidative stress, the uremic milieu, and the metabolic acidosis [54].
The combination of uremic status and imbalance in pro-inflammatory substances (such as MMPs)
accelerates the atherosclerotic process, arterial stiffness, and vascular calcification, and impairs the
vascular repair process as well [55]. Circulating MMP-2, -9, and -10 have been found to increase in
CKD patients, and have been implicated in the vascular damage process. Moreover, MMP-2 and -9
are able to reduce the plaque stability in advanced CKD stages, thus rendering the plaque itself more
prone to rupture [56,57].
3.4. Metalloproteinases and Peripheral Vascular Disease
MMPs play a role in the pathogenesis and prognosis of arterial and venous disease. With respect
to the damage occurring in the arterial tissue, multiple studies have shown that MMPs are involved
in one or more steps of atherogenesis and aneurysm development [58]. Evidence that confirms this
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hypothesis comes from both basic and clinical studies. During the progression of atherosclerotic
plaques, a number of MMPs are produced, including TIMP-1, MMP-1, -2, -3, -9, and -14 [59]. An in vivo
study on Fischer male rats showed that TIMP-1 directly regulates the smooth muscle cell migration [27].
A similar function has been recognized in human studies on MMP-14 and TIMP-1, with being both
involved in the process of cellular migration to the plaque fibrous cap and plaque inflammation [28,29].
MMP-9 also contributes to the destruction of the fibrous cap itself in patients with increased CV
risk [30]. Interestingly, increased concentrations of MMP-2, -3, and -9 have been found within the
aneurysm human tissue, being mainly produced by the macrophages localized in the aneurysm
wall [31]. These different enzymes are differentially expressed according to the aneurysm dimensions
and severity [60,61]. MMP-2 is increased in small aneurysms (<5.5 cm), whereas MMP-9 is dominant
in large aneurysms (5.5–7 cm). Moreover, it has also been shown that different localizations of MMP
activity within the aneurysm wall modify the risk of rupture [60]. In clinical studies, abnormal
circulating levels of MMP-1, -2, -8, -9, and TIMP-1 were found in patients with Peripheral Arterial
Disease; their increase was attributed to the presence of ischemic tissue [12,62,63]. Circulating levels
of MMP-1 and -8 were also found as predictors of poor prognosis, in terms of major amputation or
death, in patients who underwent lower extremity bypass [64]. These multiple findings enhanced the
importance of MMPs as biomarkers of arterial disease severity that also provide important prognostic
information in clinical practice.
Regarding venous diseases, it has been observed that alterations in ECM remodeling are common
in the case of varicose veins and chronic venous insufficiency (CVI). With regards to varicose veins,
the expression of MMP-1, -2, -3, -7, and -9 is increased, particularly in the smooth muscular cell of
the vein wall, both in human and mice models [65,66]. Moreover, an analysis of human saphenous
vein showed that this expression is even higher in varicose veins with inflammation, as compared to
those without inflammation [65]. Mechanisms underlying the association between MMPs and varicose
vein physiopathology might involve the effect of MMPs on ECM degradation and the relaxation of
the venous wall [66]. An upregulation of MMP-1, -2, -9, and -13, together with a downregulation of
TIMP-1 and TIMP-2, have been described in patients with CVI [67,68]. The distribution of MMP varies
based upon the stage (from CVI to active wound) and cells, suggesting that MMP-1 and TIMP-1 are
needed in the re-epithelialization phase, while MMP-9 and -13 primarily participate in the remodeling
of the collagenous matrix [69]. A summary of the principal pieces of evidence provided from this
paper is depicted in Table 1.
Table 1. Summary of main paper results.
Key-Messages
MMPs and CKD
• The metalloproteinases (MMPs) are associated with kidney damage. Increased
levels of MMP-2 and MMP-9 mediate the deposition of extracellular matrix (ECM)
in the glomerular cells while inducing the loss of cellular junctions, and start
epithelial-mesenchymal transition (EMT) in the tubular cells. These processes
result in tubular atrophy and fibrosis [52,70].
• In the pathogenesis of renal damage, a crucial role is played by the
downregulation of MMP-1 and the overexpression of TIMP-1, MMP-2, MMP-7,
MMP-9, and neutrophil gelatinase-associated lipocalin (NGAL). These molecules
are involved in the inflammatory process and in all phases of renal fibrosis, which,
taken together, lead to a progressive decline in renal function. Furthermore,
MMP-3 could also promote EMT [32,37–39].
• The cardiovascular risk among patients with Chronic Kidney Disease (CKD) is
not trivial. These patients experience a higher rate of cardiovascular events over
time than kidney disease progression [5–7].
• In CKD patients, the combination of uremic milieu, oxidative stress, and
imbalance in pro-inflammatory substances, such as MMPs and metalloproteinase
tissue inhibitors (TIMPs), amplifies the atherosclerotic process, arterial stiffness
and vascular calcification. MMP-2 and MMP-9 have been implicated in carotid
Intima-Media Thickness (cIMT) and plaque instability. Moreover, increased levels
of TIMP-1 have been associated with a higher risk of CHF [49–52].
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• MMPs play a role in the pathogenesis of peripheral vascular disease. It has been
demonstrated that TIMP-1, MMP-1, -2, -3, -9, and -14 favor the progression of
atherosclerotic plaques. Increased levels of MMP-2, -3, and -9 are involved in the
weakening of the aneurysm wall. In relation to varicose veins, the expression of
MMP-1, -2, -3, -7, and -9 is increased. Therefore, the amount of these MMPs is
related to a major risk of amputation or death in patients who underwent lower
extremity bypass, making that parameter a good predictor of poor prognosis
[27–31,59].
• Circulating levels of MMP-2 and MMP-9 were found in patients with acute and
chronic lower limb ischemia. These MMPs induce the release of transforming
growth factor beta (TGF-β). TGF-β affects the balance between endothelial cells
and smooth muscle cells [71].
3.5. Synthetic Metalloproteinases Inhibitors in Experimental and Clinical Research
MMP activity is regulated at different levels, including either intracellular (mRNA expression
and post-translational modification of MMP structure) or extracellular (stimulation or inhibition
of their enzymatic activity from endogenous or exogenous substrates) process. The net activity of
MMPs is a crucial step, since its up- or down- regulation could affect MMP activity, and ultimately
lead to metabolic diseases, cancer, cardiovascular, and renal disorders [72]. For these reasons, new
pharmacological agents that interfere with MMP activity have been developed and utilized as potential
tools that could benefit a wide spectrum of patients. Synthetic MMPs inhibitors (MMPs-I) include
broad-spectrum and specific MMPs-I. The vast majority of these compounds contain Zn2+ in their
structure, and have structured as Zn2+ binding globulin (ZBG). Indeed, ZBGs inactivate MMPs by
displacing the Zn2+- bound water in the MMPs, and favor the anchorage of the drug to the MMPs
substrate binding-pocket [73]. ZBGs encompass hydroxamic acids Batimastat (BB-94), Marimastat
(BB-2516), and Ilomastat (GM6001), that displays a broad-spectrum inhibition of MMPs. More selective
ZBGs molecules have also been developed, and include hydrazides and sulfonylhydrazides that
specifically inhibit MMP-1, -2, and -9. Hydroxamic ZBGs are effective, but they have poor oral
bioavailability and, by inhibiting multiple MMPs, cause several musculoskeletal side effects [74].
Hence, heterocyclic bidentate chelators have been developed that have shown more biostability and
lower toxicity in cells assays. Tetracyclines are antibiotic molecules that, by chelating Zn2+ ion, are able
to inhibit MMPs. Doxycycline inhibits MMP-2 and-9 [75]. Chemically-modified tetracyclines reach
higher plasma levels for prolonged periods of time, require less frequent administration, are associated
with lower rate of side effects when administered orally, and are thus preferred over conventional
tetracyclines [76]. Apart from zinc-based compounds, several MMPs-I act by a noncompetitive,
nonzinc-binding, mechanism of inhibition. They show high selectivity that minimizes the side effects,
and thus, are considered very promising molecules [77]. MMPs-Is have already been used in pilot
studies in mice and in human models of kidney damage [11]. MMPs-I BB-1101 has shown to reduce
proteinuria in rats with anti-Thy1.1 nephritis, an experimental model of glomerular damage induced
by antibody against Thy 1 gene [78]. A similar effect on proteinuria was found with the MMPs-I
BB-94 in an experimental model of kidney allograft rejection in mice and the tetracycline antibiotic
doxycycline in human patients with diabetic nephropathy already under renin-angiotensin-aldosterone
inhibition [79,80]. Interestingly, doxycycline also reduced the aneurysm expansion in small randomized
clinical trials enrolling patients with abdominal aortic aneurysm [81,82].
4. Discussion
The evidence for how the circulating levels or the expression of MMPs increase cardiovascular
risk is well documented in both basic and clinical studies. However, to our knowledge, this represents
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the first review to encapsulate and describe the dual association between MMPs and CKD and MMPs
and PVD.
Two large meta-analyses have separately summarized the strength of the relationship between
MMP-2, TIMP-1, and subclinical atherosclerosis in CKD patients or between MMPs and vascular risk,
regardless of the level of kidney function [58,83]. They concluded that imbalances in MMPs/TIMPS were
implicated in the pathogenesis, clinical manifestations, and prognosis of arterial and venous diseases.
According to our results, we can also affirm that the CKD condition contributes to reinforcing
the risk-pathways oriented from MMPs toward PVD. Numerous pieces of evidence support this: (1)
Numerous MMP molecules are likely responsible for both CV (including PVD) and kidney damage and
related clinical manifestations. Hence, such biomarkers warrant further investigation. The Gelatinases
MMP-2 and MMP-9 are produced by both intrinsic glomerular and tubular cells [52,70]. It has been
shown that the increased activity of MMP-2 and MMP-9 across the kidney tubules may lead to structural
alterations in the tubular basement membrane, which starts epithelial-mesenchymal transition (EMT).
EMT consists of the process in which a component of adherent junctions, the E-cadherin, and cell
adhesion are mislaid, whereas epithelial cells acquire a mesenchymal phenotype by expressing and
producing α-smooth muscle actin (αSMA) and matrix protein. All these mechanisms subsequently
trigger tubular atrophy and fibrosis [71,84]. Moreover, Peiskerova and coworkers have demonstrated
that levels of MMP-2 were significantly higher in CKD patients Stage III–V as compared to those with
Stage I–II, and correlated with fibroblast growth factor 23 (FGF-23) and levels of serum phosphate, two
important surrogates of oxidative stress and CV risk in these patients [52,71]. Similarly, gelatinases
have also been implicated in the onset of structural changes associated with PAD. Circulating levels of
MMP-2 and MMP-9 have been found to increase in patients with acute and chronic lower limb ischemia
(i.e., intermittent claudication and critical ischemia), as well as in patients with hyperlipidemia when
compared with healthy subjects [12,85,86]. The connecting link between CKD, gelatinases, and PAD is
mainly represented by the increased atherosclerotic risk and arterial remodeling due to the imbalance
of ECM enzymes. Indeed, MMP-2 and MMP-9 are capable of releasing latent transforming growth
factor beta (TGF-β), which acts as a mediator in the cross-talk between endothelial cells and vascular
smooth muscle cells [71]. Imbalances in MMPs and alterations in endothelial cells are a direct causative
factor of abnormal extracellular matrices, vascular calcification with arterial stiffness, atherogenesis,
and high pulse pressure [71,87]. TIMP-1 has been shown to exert a similar role. In CKD patients,
TIMP-1 serum concentrations were significantly increased from Stage I–III to IV–V [88]. Moreover,
TIMP-1 has been found to be a predictor of the new onset of CKD and heart failure, regardless of age,
gender, and biomarkers of systemic inflammation (c-reactive protein and brain natriuretic peptide) [40].
TIMP-1 is also increased in patients with PAD, with ischemic muscle being a possible source for this
enzyme [12]. Interestingly, an association between TIMP-1 levels and TGF-β was described in young
patients with CKD, suggesting that this factor may be involved in the pathogenesis of inflammation
and CV damage even at an early stage of the disease [89].
A further crucial role in the link between metalloproteinases, CKD, and PVD is indicated by
NGAL. It has been shown that NGAL levels are increased in atherosclerosis and chronic inflammatory
processes, and in particular, are overexpressed in atherosclerotic plaques which are vulnerable to
rupture [90]. Moreover, NGAL circulating levels have been found to increase in patients with CKD,
being directly related to diabetic status and inversely to the eGFR levels [91]. From a prognostic
perspective, in both CKD and general populations, plasma NGAL was a significant predictor of CV
fatal and nonfatal events, including PVD [92,93]. These findings were globally reinforced by the
evidence that plasma and tissue NGAL expression contribute to the pathogenesis and severity of
central and peripheral aneurismal disease [94]. In this context, it has been proposed that NGAL reflects
the leukocyte-mediated inflammatory response, with higher values being associated with weakness
of the vascular wall and impaired vascular damage [95]. (2) CKD is characterized by a persistent
low-grade inflammation with the production of pro-inflammatory cytokines, and MMP activity has
been implicated in these pathways. The uremic milieu may also induce oxidative stress and recurrences
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in thrombotic events and infections, as well as impairment in arterial stiffening and calcification of both
the intima and media of the arterial wall [55]. In the pathogenesis of all these processes, a crucial step
is represented by ECM remodeling. MMPs are directly involved in ECM processes in almost all tissues.
(3) In patients with already diagnosed CKD, serum levels of MMPs have been found to be significantly
associated with the degree of proteinuria. This means that MMPs may be directly implicated in the
development of glomerular or tubular damage typical of a wide spectrum of kidney diseases. The
presence of proteinuria is a strong predictor of CV events (and PVD as well), and is recognized as
a marker of endothelial systemic damage. Moreover, its prognostic role is even stronger than that
attributed to the traditional CV risk factors in CKD patients (i.e., Framingham risk factors) [7,8,48].
Indeed, MMPs are detected and elevated in human kidneys with nephritic syndrome, which is a
high-risk condition with severe proteinuria [51,96]. (4) It should not be excluded that MMPs play a
predictive other than a prognostic role in patients with CKD or PVD. This means that the reduction of
MMPs following a selective treatment could be associated with a better prognosis in these patients.
Recently, several therapeutic agents that modulate the function of MMPs have been developed. The
tetracycline antibiotic doxycycline and the nonselective inhibitors of MMPs, Batimastat and Marimastat,
have been shown to cut vascular tissue remodeling by reducing MMP activity [97,98]. However, larger
clinical studies are needed to generalize and translate these effects to clinical application. Moreover,
the reduction in proteinuria that followed the use of doxycycline was associated with a reduction in
the glomerular expression of MMP [58]. Also, the Renin-Angiotensin-Aldosterone system inhibitors
(RAAS-I), that are currently considered the most effective renoprotective drugs against the risk of ESKD
and CV events in CKD patients, have been shown to decrease the MMPs levels [99–101]. However, all
these important pieces of evidence have led to the hypothesis that MMPs could be one of the causal
links between CKD and CV risk, including PVD. (5) In the era of precision medicine, the need to
ameliorate prognoses in patients with chronic diseases is currently increasing [102]. To this end, a
number of clinical trials evaluating the beneficial effect of new drugs on cardiovascular (including
peripheral vascular disease) and renal outcomes have been started [103]. Interventions varied between
studies, with the effect of blood pressure lowering drugs, albuminuria lowering agents, diuretics, and
endothelin receptor antagonist being tested. Results from these first studies increased the interest in
a relatively new drug class, Sodium–glucose cotransporter 2 (SGLT-2) inhibitors. SGLT2-Is reduce
the reabsorption of glucose from the proximal tubules of the kidney. The SGLT2-Is canagliflozin and
empagliflozin reduced the risk of developing fatal and nonfatal CV events in previous trials, with this
effect being associated with a reduction of albuminuria in the first 3 to 6 months of treatment [104,105].
However, an interesting recent analysis of human proximal tubular epithelial cells showed that
empagliflozin is also able to reverse the renal suppression of Reversion Inducing Cysteine Rich Protein
with Kazal Motifs (RECK), a membrane anchored endogenous MMP inhibitor whose expression is
induced by hyperglycemia in animal and human models of diabetic kidney disease [106]. Interestingly,
empagliflozin reduced the epithelial-to-mesenchymal transition, a mechanism that is strictly linked to
MMPs activity and that anticipates kidney fibrosis, by directly reducing migration of tubular cells and
expression of pro-inflammatory mediators (TRAF3IP2, NF-κB, p38MAPK, miR-21, and IL-1β, IL-6,
TNF-α, and MCP-1). This means that SGLT2-Is may exert a protective effect on renal tubules that is
independent from the albuminuria reduction. Thus, new large intervention studies evaluating the
effect of drugs that interfere with MMPs activity are expected in the future to evaluate their impact on
prognoses of albuminuric and nonalbuminuric CKD patients. This would be particularly important
considering that nonalbuminuric CKD patients are growing in prevalence as referred patients in
nephrology clinics [47,107]. In the context of intervention studies, MMPs may play a role as “predictive”
biomarkers, since their assessment could identify a population of patients which is more likely to
benefit from a specific drug. This point is crucial, since the development and optimization of new
treatments that reduce CV risk in CKD patients may help to overcome the variability in response to the
old standard treatments [108].
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In addition to clinical trials perspective, further efforts are needed in the context of observational
studies and risk stratification. Indeed, risk stratification of CKD patients may improve prevention
strategies, acting to slow down CKD progression and reduce the high residual risk in CKD patients.
In observational research, it may be useful to evaluate the potential role of MMPs as “prognostic”
biomarkers used to identify the likelihood of a patient to develop a clinical outcome, regardless of
treatment (i.e., under the standard of care). Such a measure may improve physicians’ abilities to identify
patients with poor prognoses [109]. One approach involves the discovery of novel biomarkers that may
add proper prognostic information on top of already known risk factors [46,107,110–113]. Investigators
from the Steno Diabetes Center, a prospective cohort that contributed to the comprehension of prognosis
of diabetic patients with or without CKD, showed that MMP-1 and MMP-2 are associated with an
increased risk of CV events and CV mortality, regardless of age, gender, eGFR, and albuminuria [114].
A similar effort in improving risk stratification is ongoing in the case of PAD management. It has
indeed been demonstrated that patients suffering from PAD are exposed to a higher risk of CV events
than those with coronary heart disease [115,116]. Hence, ameliorating prognoses of these patients
is mandatory and urgent. A previous recent analysis showed that variations in the serum levels of
MMPs before and after lower limb surgical revascularization in patients with critical limb ischemia are
significantly associated with the subsequent outcome (major amputations or death). From our research,
we can also assert that measuring the serum levels of MMPs could be even more useful in patients
with CKD, PVD, or both conditions, as they potentiate the risk of progression for these conditions.
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Abstract: Matrix metalloproteinases are enzymes that degrade the extracellular matrix. They have
different substrates but similar structural organization. Matrix metalloproteinases are involved in
many physiological and pathological processes and there is a need to develop inhibitors for these
enzymes in order to modulate the degradation of the extracellular matrix (ECM). There exist two
classes of inhibitors: endogenous and synthetics. The development of synthetic inhibitors remains a
great challenge due to the low selectivity and specificity, side effects in clinical trials, and instability.
An extensive review of currently reported synthetic inhibitors and description of their properties
is presented.
Keywords: matrix metalloproteinases; TIMP; synthetic inhibitors
1. Introduction
Matrix metalloproteinases (MMPs) are a protein family within the metzincin superfamily,
comprising zinc-dependent endopeptidases with similar structural characteristics but with different
substrate preferences. MMPs are produced and secreted from cells as inactive proenzymes depending,
herein, on a structural alteration for activation [1–6]. In human tissues, there are 23 different types
of MMPs expressed and they can be subdivided according to their substrate specificity, sequential
similarity, and domain organization [1,2,4,7–17] (Table 1).
The most common structural features shared by MMPs are [1,2,4,5,7,8,10–14,16,18] (Figure 1) a
pro-domain, a catalytic domain, a hemopexin-like domain, and a transmembrane domain for membrane
type MMPs (MT-MMPs) although some MMPS do not have all the structural features represented in the
figure. The pro-domain keeps MMP inactive by a cysteine switch, which interacts with the catalytic zinc
making it impossible to connect the substrate. The catalytic domain has two zinc ions, three calcium
ions, and three histidine residues, which are highly conserved [1–9,11–20]. In the terminal zone of the
catalytic domain there is a region that forms the outer wall of the S1’ pocket [1,14,17]. This pocket is the
most variable region in MMPs and it is a determining factor for substrate specificity [1,2,6,7,11,17,18].
However, there are six pockets (P1, P2, P3, P1’, P2’, and P3’) and the fragments of the substrates or
inhibitors are named depending on the interaction with these pockets (R1, R2, R3, R1’ or Ra, R2’,
and R3’). The linker is proline-rich, of variable length, allowing inter-domain flexibility and enzyme
stability [4,8,12,13]. The hemopexin-like domain is necessary for collagen triple helix degradation and
is important for substrate specificity [3,4,7,9,19].
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Table 1. Matrix metalloproteinases (MMPs) classes.
Class MMP
Collagenases
MMP-1, Collagenase-1, Interstitial or Fibroblast collagenases
MMP-8, Collagenase-2, or Neutrophil collagenases
MMP-13 or Collagenase 3
Gelatinases
MMP-2 or Gelatinase A






MMP-26, Matrilysin-2, or Endometase
Membrane-type















Figure 1. Schematic representation of the general structure of MMP.
The MMPs can process ECM proteins and glycoproteins, membrane receptors, cytokines, hormones,
chemokines, adhesion molecules, and growth factors [1,3,4,6,7,9–11,13,14,20–26]. However, the
presence and the activity of MMPs have been demonstrated to be intracellular [25,26]. For example,
some studies show intracellular localization of MMP-2 in cardiac myocytes and colocalization of
MMP-2 with troponin I in cardiac myofilaments [23]. The MMP-2 activity has also been detected
in nuclear extracts from human heart and rat liver [23]. The MMPs are involved in many biologic
processes, such as tissue repair and remodulation, cellular differentiation, embryogenesis, angiogenesis,
cell mobility, morphogenesis, wound healing, inflammatory response, apoptosis, ovulation, and
endometrial proliferation [1,2,4,6,8,10,11,13,16–18,20,27]. The deregulation of MMPs activity leads to the
progression of various pathologies depending on which enzyme is involved [1,6,10,13–17,20,27]: cancer
and metastasis, inflammatory processes, arthritis, ulcers, periodontal diseases, brain degenerative
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diseases, liver cirrhosis, fibrotic lung diseases, otosclerosis, atherosclerosis, multiple sclerosis, dilated
cardiomyopathy, aortic aneurysm, or varicose veins.
Although therapeutic strategies for specific inhibition of MMPs have been long researched,
they are difficult to develop because these enzymes are involved in a myriad of pathways [2,5].
However, this inhibition can be done at the biomolecular expression and active enzyme terms [2,5,18].
The MMPs inhibitors can be divided into endogenous inhibitors, which can be specific or non-specific,
and synthetic inhibitors [1,2,4,7,10,12–14,16,20,28,29] (Table 2).
Table 2. MMPs inhibitors classification.
Specific Inhibitor Tissue Inhibitor of Metalloproteinases (TIMP)
Endogenous inhibitor Non-specifics inhibitors
α2-macroglobulin
Tissue factor pathway inhibitor (TFPI)
Membrane-bound β-amyloid precursor protein
C-terminal proteinases enhancer protein
Reversion-inducing cystein-rich protein with





Catalytic domain (non-zinc binding) inhibitors
Allosteric and exosite inhibitors
Antibody-based inhibitors
2. Specific Endogenous Inhibitor-Tissue Inhibitors of Metalloproteinases (TIMPs)
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous proteins responsible for the
regulation of MMPs activity, but also of families such as the disintegrin metalloproteinases (ADAM
and with thrombospondin motifs ADAMTS) and therefore for maintaining the physiological balance
between ECM degradation and MMPs activity [1,2,8,9,18,30]. There are four TIMPs (TIMP-1, -2, -3,
and -4) (Table 3), with 22–29 KDa and 41%–52% sequential similarity [2,4,12,13,16,20,31].
Table 3. Tissue inhibitors of metalloproteinases (TIMPs) classification.
TIMP Expression Inhibition Inhibition Mode
1
Several tissues with transcription
inducible by cytokines and hormones
Strong interaction with MMP-1, -2, -3, and -9
Weak interaction with MT1-MMP, MT3-MMP,
MT5-MMP, and MMP-19
TIMP-1 forms a complex with
pro-MMP-9 by binding to the
hemopexin domain
2 Constitutive expression Strong interaction with MMP-2
TIMP-2 has four residues in the
N-terminal domain and an adjacent
CD-loop region, which allows
interaction between TIMP and the
active center of MMP-2
3
In response to mitogenic stimulation
and during cell cycle progression MMP-1, -2, -3, -9, and -13
The inhibition mode is different from
the other TIMPs for its unusual
localization, as it is largely sequestered
into the extracellular matrix or at the
cell surface via heparan sulphate
proteoglycans
4
Especially abundant in the heart, but is
also expressed in injured tissue MMP-2 and -14 -
TIMPs consist of a N- and C-terminal domain with 125 and 65 amino acids, respectively,
each containing six conserved cysteine residues, which form three conserved disulphide
bonds [2,4,7–9,12,31,32] (Figure 2a). The N-terminal domain is an independent unit, which can be
inhibited by MMPs, in a 1:1 ratio [2,4,8–10,12,13,16,20]. This domain has two groups of four residues:
Cys-Thr-Cys-Val and Glu-Ser-Val-Cys (Figure 2b), which are connected by disulphide bounds which
are important for TIMP activity [7,12]. This is the main domain responsible for MMP inhibition through
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its binding to the catalytic site in a substrate-like manner [31]. The several domains allow the TIMP
and pro-gelatinases interactions [4].
Figure 2. (a) TIMP-1-catalytic domain of the MMP-3 complex. (b) TIMP-1-catalytic domain of the
MMP-3 complex, where two conserved groups, Cys-Thr-Cys-Val and Glu-Ser-Val-Cys, are represented
in yellow.
3. Non-Specific Endogenous Inhibitors
Non-specific endogenous inhibitors have been reported to inhibit MMPs (Table 4), however, the
inhibition mechanism details have only been partially discovered [7,12].
Table 4. Non-specific endogenous inhibitors [4,7,12,13,33,34].
Non-Specific Inhibitor Inhibition
α2-macroglobulin MMP-2 and -9
Tissue factor pathway inhibitor MMP-1 and -2
Membrane-bound β-amyloid precursor protein MMP-2
C-terminal proteinase enhancer protein MMP-2
Reversion-inducing-cysteine-rich protein with Kasal motifs (RECK) MMP-2, -9, and -14
GPI-anchored glycoprotein -
Human α2-macroglobulin is a glycoprotein with four identical subunits that act by entrapping
MMP and the complex is cleared by endocytosis [2]. The α2-macroglobulin has been found in blood
and tissue fluid [2,31]. The tissue factor pathway inhibitor (TFPI) is a serine proteinase inhibitor,
which targets MMP-1 and -2, but this inhibition mode is still unknown [7,12]. The C-terminal proteinase
enhancer protein and tissue factor pathway inhibitor have sequences with certain similarities to the
N-terminal domain of TIMPs [31].
4. Synthetic Inhibitors
MMPs are molecular targets for the development of therapeutic and diagnostic agents [14].
The development of synthetic MMP inhibitors was initially based on the peptide sequence, recognized by
proteases, with different chemical functionalities, capable of interacting potently with zinc ion [11–13,19].
The requirements for an effective inhibitor are [2,11,13,17,19,35]:
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- A functional group able to chelate the zinc ion (II)-zinc binding group (ZBG). The first generation
inhibitors used hydroxamate (CONHO−) but the second generation use carboxylate (COO−),
thiolates (S−), phosphonyls (PO2−), for example (Figure 3);
- At least one functional group that promotes hydrogen bonding with the protein backbone;
- One or more side chains undergoing Van der Waals interactions with enzyme subsites.
Figure 3. Examples of zinc binding groups (ZBGs). (a) Hydroxamate-based inhibitor; (b) thiolate-based
inhibitor; (c) carboxylate-based inhibitor; (d) phosphorous-based inhibitor. The R group is the scaffold
of inhibitor.
ZBGs have negative charges that prevent their penetration in the cell, restricting their activity to
the extracellular space which reduces their cell toxicity [2]. Changes in the ZBG structure or in the
point of attachment of the ZBG to the backbone of the MMP inhibitor can change its potency and
selectivity [2]. When comparing what selectivity or potency of different ZBGs leaving the structure
constant, Castelhano et al. arrived at the following list [36]: hydroxamic acid >> formylhydroxylamine
> sulfhydryl > aminocarboxylates > carboxylate.
The selectivity of inhibitor is a primordial goal of MMPs’ inhibitors (MMPis) design to increase
efficacy and prevent side effects [2]. This selectivity is based on two molecular characteristics [11]:
a chelating capacity for catalytic zinc and the presence of hydrophobic bridges of the active center for
the S1’ pocket. Numerous strategies have been suggested for creating selective MMP inhibitors [27]
(Figure 4): endogenous-like inhibitors, exosite targeting inhibitors, a combination of exosite binding
and metal chelating inhibitors, and function-blocking antibodies.
Figure 4. Types of MMPs’ inhibitors: (a) endogenous-like inhibitors that chelate the catalytic zinc (II)
ion; (b) exosite targeting inhibitors that alter the conformation of the enzyme; (c) a combination of
exosite binding and metal chelating inhibitors; (d) antibodies inhibitors.
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The synthetic inhibitors have had a great challenge in their development since first it is necessary
to identify the enzymes that are involved in disease progression. Moreover, this goal has an
additional difficulty as there are more than 50 human metalloproteinases (23 MMPs, 13 ADAM,
and 19 ADAMTS) [2].
4.1. Hydroxamate-Based Inhibitors
The first generation of MMPis (1995–1999 [16]) were designed based on the knowledge of
the triple helix collagen amino acid sequence (cleavage site) and the information derived from
specific substrates [6,15,19,31,35,37]. These compounds contain a hydroxamic acid group as
ZBG [5,6,15,18,27,28,31,37]. Hydroxamic acids (HA) were first described in 1986 [38,39]. They are
easy to synthesize, are monoanionic compounds, bidentate chelating agents, and due the excellent
zinc-chelating capability they are the more popular ZBG for MMPs [2,6,17,18,27–29]. The hydroxamic
group established interactions with zinc ions, through two oxygens and two hydrogen bonds
(NH and OH groups of HA with Ala and Glu, respectively), forming a distorted triangular
bipyramid [2,5,18,19,28,29] (Figure 5a). Reich et al., in 1988 [40], used a hydroxamic acid compound,
SC-44463 (Figure 5b), to block collagenase and prevent metastasis in a mouse model, which initiated
the era of MMP inhibition therapeutics [40].
Figure 5. (a) Interaction between hydroxamate group and catalytic zinc (II) ion. The oxygen of
the hydroxamate forms a strong hydrogen bond with the carboxylate oxygen of the catalytic Glu,
while the NH of hydroxamate establishes another hydrogen bond with the carbonyl oxygen of Ala;
(b SC-44463 inhibitor.
The structure–activity relationship (SAR) studies for a series of hydroxamic acids with a quaternary
carbonyl group at R1 suggested that [13] (Figure 6):
(i) The stoichiometric orientation of the substituent at R1 position is crucial for the activity;
(ii) The phenylpropyl group was established as the best substituent at position R1;
(iii) Hydrophobic substituents at R2’ position and N-metiamides at R3’ position were considered as
the most appropriate.
Figure 6. General structure of hydroxamic acid. OH group: catalytic zinc binding group; Ra:
α substituent; R1: P1’ substituent group and this group is determinant to selectivity and activity; R2:
P2’ substituent and this substituent can be cyclized with Ra and R3; R3: P3’ substituent.
Modification in Ra position (α substituent): a beneficial effect is conferred by lipophilic substituents
capable of hydrogen bonding [19]. Analogues of Marimastat have been reported, where the α position
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is disubstituted by a hydroxyl group and a methyl group [19] (Figure 7a). The X-ray structures of the
MMP-3-inhibitor complex showed that there were hydrogen bonds between the hydroxyl group and
Ala165 [19]. By binding the positions Ra and R2 in a single chain, forming a cyclic inhibitor (Figure 7b),
there was a substantial increase in water solubility [19,29,41,42]. This strategy led to the discovery of
two inhibitors with similar potency to non-cyclized analogues, SE205 and SC903 [41] (Figure 7c,d).
Figure 7. (a) Analogue of Marimastat with the α position disubstituted; (b) analogue of Marimastat
with Ra and R2 position connected; (c) SE205; (d) SC903.
The introduction of conformational restrictions through the addition of a three-membered ring
between positions α and R1 (Figure 8a) has been reported by Martin et al. [43], and it resulted in
reduced inhibition of MMP-9 [43]. However, the introduction of a six-membered ring between these
same positions resulted in the inactivity of the compound [19] (Figure 8b).
Figure 8. Inhibitors with conformational restrictions between Ra and R1 positions. (a) Inhibitor with
three-membered ring; (b) inhibitor with six-membered ring.
Exploring the depth of S1’ pocket, bulky groups in Rα position confer selective inhibition for
MMP-2, -8, and -9 [29]. An example is the presence of a biphenyl group, which showed higher
inhibitory activity against MMP-9 [29].
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Modification in R1 position: the incorporation of long groups in the R1 position can promote the
selectivity of MMPis, since pocket S1’ can undergo conformational changes to accommodate certain
substituents [19].
Broadhurst et al. showed that an alkyl chain (C9) at the R1 position reduces the inhibition
of MMP-1, but maintains the inhibitory activity against MMP-2, -3, and -9 [19] (Figure 9a). For
matlystatin derivates in the C9 chain, R-94138 (Figure 9b) promotes the inhibition against MMP-9 [44].
The succinyl hydroxamates analogues in the C9 chain promote selectivity for MMP-2, however, a C10
chain (Figure 9c) results in MMP-1 inhibition, while a further increase of the chain to C16 (Figure 9d)
leads to a loss of activity against MMP-1 [19].
Figure 9. Inhibitors with modification of R1 position. (a) Inhibitor with alkyl chain. This inhibitor
has activity against MMP-2, -3, and -9, but the inhibition of MMP-1 is low; (b) R-94138, Matlystatin
derivate. The inhibition of MMP-9 is 10 times higher than analogues with C8 or C10 chains; (c) succinyl
hydroxamate analogue with C10 chain, which inhibits MMP-1; (d) succinyl hydroxamate analogue
with C16 chain, which inhibits MMP-1.
Replacement of the R1-R2 bond of succinyl hydroxamates acid inhibitors by a sulfonamide bond
(Figure 10a) results in substantial loss of inhibitory activity because the hydrogen bond (C=ONH;
Figure 10b) with leucine is stronger than the new sulfonyl oxygen bond, due to the pyramidal nature
of the sulfonamide [19].
Figure 10. (a) Succinyl hydroxamate acid with a sulphonamide bond. This compound presents
low inhibitory activity because of the pyramidal nature of the sulphonamide group. (b) Succinyl
hydroxamate acid with carbonyl bond.
Modifications in R2 position: modifications in the R2 position led to a modest effect in inhibitory
activity, in vitro, and affects the pharmacokinetic properties [29]. Marimastat and Ro31-9790 (Figure 11)
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have a good oral activity because the bulky tert-butyl group assists the adjacent amide bond during
absorption from an aqueous environment to the lipid environment of the cell membrane [45].
The beneficial combination of the tert-butyl group with the α-hydroxyl group increases the water
solubility [19,29]. Babine and Bender suggest that the tert-butyl as R2 group leads to less Van der Waals
interactions, comparing with other groups [46].
Figure 11. (a) Marimastat. The Ra position is substituted with a hydroxyl group (OH). (b) Ro31-9790.
The Ra position has no substituents.
Ikeda et al. described compounds with phenyl R2 substituents (Figure 12) (KB-R7785), which
are active orally, due to the beneficial effect of the R2 phenyl group on absorption, where the amide
shielding and lipophilicity may assist in transepithelial resorption [47]. This inhibitor shows activity
against MMP-1 in rats and its effectiveness in arthritis has been demonstrated [47].
Figure 12. KB-R7785 inhibitor.
Modifications in R3 position: the S3’ pocket is an open area and several groups can be introduced
at the R3 position [19]. The introduction of the benzhydryl group leads to compounds with selectivity
to the MMPs-3 and -7 [19].
4.1.1. Succinyl Hydroxamic Acid-Based Inhibitors
Succinyl hydroxamate derivates can be subdivided to peptide derivatives or non-peptide
compounds [48]. The N-acetylcysteine has been reported to affect the tumoral invasion process
and metastasis by MMP-2 and -9 inhibition [49]. The L-cysteine-2-phenylethylamide is an effective
inhibitor, in which the phenyl group fills the S1’ pocket of MMP-8 [50]. Foley et al. prepared several
dipeptides derivatives containing cysteine (RCO-Cys-AA-NH2) and concluded [51]:
- The variation of the acyl group and the second amino acid (AA) leads to the activity against
different MMPs.
- The R group interacts with the S1’ pocket.
Batimastat (Table 5) was the first MMPi to enter in clinical trials for cancer as it inhibits MMP-1,
-2, -7, and -9, but, due to its poor oral bioavailability, it was superseded by Marimastat [28,29,31]
(Table 5), which has an alpha-hydroxyl group increasing the aqueous solubility [29]. Marimastat
inhibits the activity of MMP-1, -2, -3, -7, -9, -12, and -13 [31]. However, Marimastat failed in clinical
trials due to the absence of a therapeutic effect and the patients treated developed musculoskeletal
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toxicity (MST) [6,31]. Batimastat, marimastat, and ilomastat are examples of succinyl hydroxamates,
which have very analogous structure to that of collagen and inhibit MMPs by bidentate chelation of
the Zn2+ [2,6,29].
Table 5. Batimastat and Marimastat.
Name Molecule α Substituent Effect
Batimastat Thienylthiomethylene Not available orally
Marimastat
Hydroxyl group (directed to the protein
surface, allowing the formation of
hydrogen bonds with solvent)
Available orally
Several studies by Jonhson et al. [52] demonstrated that derivatives of succinyl hydroxamic acid
(Figure 13a) are more potent for MMP-1 than the corresponding malonyl (Figure 13b) or glutaryl
(Figure 13c) derivates.
Figure 13. (a) Derivates of succinyl hydroxamic acid; (b) malonyl acid; (c) glutaryl acid.
Marcq et al. [53] developed succinyl hydroxamates derivates selective for MMP-2, by modifications
on Ilomastat structure (Figure 14a) to increase the overall hydrophobicity and, consequently,
the selectivity [53]. This study resulted in a compound (Figure 14b) with an isobutylidene group of
E geometry, which showed a 100-fold greater selectivity for MMP-2 over MMP-3, that is a 70-fold
increase compared to Ilomastat [53].
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Figure 14. (a) Ilomastat; (b) Ilomastat derivate with isobutylidene group.
Table 6 shows the IC50 and Ki values of some succinyl hydroxamic acid-based
inhibitors [6,15–19,29,35,37,54,55].
4.1.2. Sulfonamide Hydroxamic Acid-Based Inhibitors
In 1995, Novartis described the CGS-27023A (Figure 15a), a non-peptidic MMP-3 inhibitor, which
has good oral availability but did not succeed in clinical trials [56]. The isopropyl group slows down
the metabolization of the adjacent hydroxamic acid group and the 3-pyridyl substituent may aid
partitioning into the hydrated negatively charged environment of the cartilage [56]. By analysis of the
cocrystal structure of this inhibitor and MMP-12, it was possible to conclude that the binding mode
between the hydroxamate moiety and the catalytic zinc ion was the same as the binding mode of
hydroxamate-based inhibitors [6]. The interaction of CGS-27023A with MMP-3 was possible due to the
p-methoxy phenyl substituent occupation of the S1’ pocket and the pyridylmethyl and isobutyl groups
occupation of the S2’ and S1 pockets, respectively [29,56]. The modification of α to form the thioester
derivate led to an increase of the inhibition of the deep pocket of the MMPs [29,56] (Figure 15b).
Figure 15. (a) CGS-27023A; (b) thioester derivate of CGS-27023A.
The NNGH (Figure 16a) (N-Isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid) was
the starting point to many potent MMPis and is accommodated in the entry of the S1’ pocket, but does
not penetrate it [6]. Barta et al. described a series of arylhydroxamate sulphonamides, active against
MMP-2 and -13 (Figure 16b) [57]. In this compound, the sulfonyl group formed a single hydrogen
bond with Leu160 and the piperidine-O-phenyl moiety extends into the S1’ pocket by Van der Waals
interactions [57]. Noe et al. described a series of 3,3-dimethyl-5-hydroxy pipecolic hydroxamic
acid, which possess potent inhibitory activity for MMP-13 [58]. In the first series of compounds,
the 3-position of the piperidine ring was explored by the introduction of a polar functionality and
it resulted in a compound with excellent activity on MMP-13 (Figure 16c), improved bioavailability,
and lower metabolic clearance [58].
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Figure 16. (a) NNGH; (b) arylhydroxamate sulphonamide compound; (c)
3-hydroxy-3-methylpipecolic hydroxamates.
The incorporation of a cyclic quaternary center α led to a strong inhibitory effect against MMP-1,
-2, -3, -8, -9, -12, and -13 [29]. The RS-113,456 (Figure 17a) is an inhibitor with better oral bioavailability
and metabolic stability compared to the hydroxamate derivates [35]. These two features were improved
by shifting the cyclic group to the α-position of the hydroxamic acid (Figure 17b) [29].
Figure 17. (a) RS-113,456; (b) RS-130,830.
Table 7 shows the IC50 and Ki values of some sulfonamide hydroxamic acid-based
inhibitors [6,15–19,29,35,37,54,55].
4.1.3. Phosphamides Hydroxamic Acid-Based Inhibitors
The hydroxamic acids based on phosphamides are effective as MMPis due to the electronic
environment of the phosphor atom [11]. The replacement of sulphonamide group by phosphinamide
group leads to a potent inhibitor of MMP-3 (Figure 18), the collagenases and gelatinases [29].
The interactions between this inhibitor and the MMP-3 are realized by the phosphinamide phenyl
group, that accommodates into the S1’ pocket and by the phosphinamide oxygen, which establishes the
hydrogen bonds with NH of Leu164 and Ala165 [29]. However, this group is susceptible to hydrolysis
at low pH, limiting the inhibitory activity [29].
Figure 18. Inhibitor with phosphinamide group.
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All hydroxamate-based inhibitors are very potent and they inhibit MMPs at low concentrations [18].
On the other hand, the hydroxamate acids have poor oral bioavailability, inhibit multiple MMPs,
and cause side effects [2,17,27,28,35]. Additionally, this functional group may be metabolized via
dehydroxylation or may be cleaved by endopeptidases and releasing hydroxylamine, can be hydrolyzed
to carboxylic acids or reduced to O-glucuronyl or O-sulfate, leading to decreased effective inhibitor
concentration and reducing its potency in vivo [18,27,28,35].
Table 8 shows the IC50 and Ki values of some phosphamides hydroxamic acid-based
inhibitor [6,15–19,29,35,37,54,55].
Table 8. IC50 and Ki values of phosphamides hydroxamic acid-based inhibitors.
IC50 (X = H; Y = (CH2)2C6H5; Z =Me; R = Ph): MMP-1 = 252 nM;
MMP-3 = 700 nM
IC50 (X = H; Y = (CH2)2C6H5; Z = Ph; R = Ph): MMP-1 = 854 nM;
MMP-3 = 1.75 μM
IC50 (X =Me; Y = CH2C6H5; Z =Me; R = Ph): MMP-1 = 120 nM;
MMP-3 = 67.9 nM
IC50 (X =Me; Y = CH2C6H5; Z = Et; R = Ph): MMP-1 = 608 nM;
MMP-3 = 700 nM
IC50 (X =Me; Y = CH2C6H5; Z = Ph; R = Ph): MMP-1 = 6.79 μM;
MMP-3 = 10.3 μM
IC50 (X = CH2i-Pr; Y = CH2C6H5; Z =Me; R = Ph):
MMP-1 = 20.5 nM; MMP-3 = 24.4 nM
IC50 (X = CH2i-Pr; Y = CH2C6H5; Z =Me; R =Me):
MMP-1 = 518 nM; MMP-3 = 1.04 μM
IC50 (X = CH2i-Pr; Y = H; Z = CH3): R isómer, MMP-1 = 2.51 μM;
MMP-3 = 2.55 μM
S isomer: MMP-1 > 100 μM; MMP-3 = 130.5 μM
IC50 (X = CH2i-Pr; Y = CH2C6H5; Z = CH3): R isomer,
MMP-1 = 20.5 nM; MMP-3 = 24.4 nM
S isomer, MMP-1 = 7.12 μM; MMP-3 = 9.17 μM
IC50 (X = CH3; Y = CH2C6H5; Z = C2H5): R isomer,
MMP-1 = 608 nM; MMP-3 = 700 nM
S isomer, MMP-1 = 33.3 μM; MMP-3 = 49.3 μM
IC50 (X = H; Y = (CH2)2C6H5): MMP-1 = 525 nM; MMP-3 = 700 nM
IC50 (X = CH3; Y = CH2C6H5): MMP-1 = 120 nM; MMP-3 = 67.9 nM
IC50 (X = CH3; Y = n-C6H13): MMP-1 = 1.29 μM; MMP-3 = 1.6 μM
IC50 (X = CH2i-Pr; Y = H): MMP-1 = 2.51 μM; MMP-3 = 2.55 μM
IC50 (X = CH2i-Pr; Y = CH2C6H5): MMP-1 = 20.5 nM;
MMP-2 = 13.3 nM; MMP-3 = 24.4 nM; MMP-7 = 886 nM;
MMP-8 = 5.3 nM; MMP-9 = 20.6 nM; MMP-13 = 7.4 nM
4.2. Non-Hydroxamate-Based Inhibitors
The side effects caused by hydroxamate-based inhibitors, due to the lack of selectivity
and in vivo lability, have been fostering the development of new compounds with alternative
ZBGs [5,6,11,16,17,27–29]. The second generation of MMPis (1999–2003 [16]) was designed with
a wide variety of peptidomimetic and non-peptidomimetic structures with higher selectivity
and exploiting the deep S1’ pocket present in some MMPs [6,15,16,18,59–61]. These compounds
include carboxylic acids, sulfonylhydrazides, thiols, aminomethyl benzimidazole, phosphorous-based,
nitrogen-based and heterocycles bidentate chelators, and can be monodentade, bidentade, and
tridentade chelates [2,6,18,28,29].
The non-hydroxamate-based inhibitors open up a wide spectrum of affinities for the zinc ion from
the catalytic site and new opportunities for targeting and inhibiting the active center [18,28]. They have
weak Zn2+ chelating ability and the rates of severe side effects, such as the musculoskeletal syndrome
(MSS) decreased dramatically compared with the hydroxamate inhibitors [28].
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4.2.1. Thiolates-Based Inhibitors
The ability of the monodentate binding of thiols to zinc ion in proenzymes has served as inspiration
for the design of several MMPis [5,29]. The potency of thiol inhibitors is intermediate between that
of hydroxamate- and carboxylate- based inhibitors [29]. The first example of inhibitor thiol-based
for MMP-1 is a bipeptidic analogue, where the incorporation of a thiol group as α substituent leads
to improvement of activity (Figure 19a) [19]. Derivates with “linker” substituent between P1-P1’
positions show a total loss of activity (Figure 19b) [19,62]. On the contrary incorporation of a methyl
carboxylate group leads to a significant increase in activity (Figure 19c) [19]. The increased activity of
these compounds may be a consequence of beneficial interactions between S1, the carbonyl ester, and
the thiol group, participating in the bidentate coordination of the zinc [19].
Figure 19. (a) Thiol-based inhibitor with the thiol group as α-substituent. The stoichiometric is S when
the thiol group is present. In its absence, the compound with R stoichiometric is more active than the
S analogue; (b) thiol-based inhibitor with “linker” substituent; (c) thiol-based inhibitor with methyl
carboxylate group.
Montana et al. have identified a series of inhibitors with mercaptoacyl, obtaining moderate
inhibitors (Figure 20a) against a wide variety of enzymes with a deep pocket shown to be orally active
in mouse models with arthritis [63]. The thiol and acyl carbonyl groups could cooperate in binding to
the zinc of the active site [63]. Warshasky et al. have produced a variety of compounds in the Montana
series, in which the amide nitrogen P2’ is linked to the group P1’ (Figure 20b) [19].
Figure 20. (a) Inhibitor with mercaptoacyl, where the thiol and acyl carbonyl groups could cooperate
in binding to the zinc ion. (b) Variant of Montana compounds. n = 0, the compound does not have
activity against MMPs-2, 3, and -12. n = 1, the compound has low activity against MMP-3.
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The β-mercaptoacilamide represented in Figure 21 is active against the MMP-9 in vitro and
exhibits oral activity in rats [19]. The 4-alcoxy substituent of cyclohexane group improved the activity
against all MMPs [19]. Replacement of the 4-ethoxy substituent with 4-propyloxy leads to a significant
reduction in MMP-1 activity and improves selectivity for MMP-3 [19]. The equivalent cyclopentyl
compounds are inactive [19]. The mercaptoamide is unstable in solution hence, to overcome this issue,
Campbell and Levin have prepared a series of mercaptoalcohols and mercaptoketones inhibitors [64].
The mercaptoalcohols have exhibited modest activity against MMP-1, -3, and -9, while the equivalent
mercaptoketones could be optimized to active broad-spectrum inhibitors [64].
Figure 21. β-mercaptoacilamide inhibitor.
In 2005, Hurst et al. [65] reported a series of mercaptosulphides inhibitors that targeted MMP-1 [65].
The structure–activity relationship indicates that the five-membered ring increases the stability of the
inhibitor compared to the linear structure, which can be quickly oxidized and lose its potency [65].
Table 9 shows the IC50 and Ki values of some thiolates-based inhibitors [6,15–19,29,35,37,54,55].
4.2.2. Carboxylates-Based Inhibitors
The carboxylic inhibitors are synthetic precursors of the more popular hydroxamates yet they
are weaker zinc (II) ligands than hydroxamates [17,27] and monodentate chelate [27]. Carboxylic
acid is present in several MMPis that contain large lipophilic groups, such as biphenyls, since they
fit in the S1’ pocket [5,6]. These ZBGs are particularly appreciated for their high stability in vivo
and their great positive effects on solubility, bioavailability, and selective properties [5,17]. The
hydroxamate-based inhibitors are more potent in physiological conditions than carboxylate inhibitors,
due to differences in acidity constants [29]. The carboxylate inhibitors bind more tightly to MMPs at
low pH, while hydroxamate-based ones have a wider range of pH from 5 to 8 [29]. Fray et al. [66]
compared the inhibition profiles of hydroxamates and carboxylic inhibitors (Figure 21a) and observed
that the substitution of a carboxylate by a hydroxamate causes a 10-fold increase in potency of the
inhibitor towards MMP-3 but decreases the selectivity against MMP-1, -2, -9, and -14 [66]. This effect
is attributed to the fact that the strong zinc (II) affinity to the hydroxamic acid group is the main
determinant of the binding energy, while in carboxylates this energy relies to a bigger extent on specific
interactions with the specific pockets [66].
Hagmann et al. [67] described a series with N-carboxyalkyl group substituents, which presented
inhibition for MMP-1, -2, and -3 [67] (Figure 21b). However, the substitution of the phenethyl group,
in P1’ position, for a linear alkyl chain removes the inhibitory activity for MMP-1 but it does not affect
the activity for MMP-2 and -3 [67]. A similar effect was achieved by the 4-substitution of the phenyl
ring of the phenethyl group with a small linear alkyl group [67] (Figure 22b). A similar range of P3′
esters has been identified with “phthalamidobutyl” (Figure 22b), increasing activity against MMP-3
and further increasing selectivity [67].
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Figure 22. (a) Fray et al. inhibitors. R = NH(OH), hydroxamate-based inhibitor. R = OH,
carboxylate-based inhibitor. (b) Hagmann inhibitors. If X = H and Y =Me the compound presents
inhibition to MMP-1, -2, and -3. When X = C4H9 and Y = Me, the inhibitor has a similar effect to
the previous one. The inhibitor with X = H and Y = Phthbutyl (phthalamidibutyl) shows activity
against MMP-3.
The interaction of the P1′ biphenyl substituent with pocket S1′ is an important factor contributing
to the binding of the inhibitor [19]. The X-ray structure of the acyclic compound with MMP-3 revealed
an important interaction between the phenyl terminal of the biphenyl group and the side chain of
histidine (His224) [19]. The carboxylic acids derived from “D-valine” have a selective inhibition for
MMP-2 and -3 [19]. The 4-substitution of the biphenyl ring helped to increase potency compared to the
unsubstituted analogue and also helped to improve the pharmacokinetic properties [19].
With the aim of development inhibitors with high selectivity for a single MMP, Wyeth published, in
2005, a series of biphenyl compounds with carboxylates sulphonamides (Figure 23a). These compounds
were tested for the treatment of osteoarthritis and indeed presented selectivity against MMP-13 [18].
Wyeth research developed a series of carboxylic acids-based inhibitors, which were potent and selective
against MMP-13, with the carboxylate function connected to a benzofuran via a biphenyl sulphonamide
spacer (Figure 23b) [16]. The presence of a bulky substituent in the benzofuran 4-position resulted in a
compound 100-fold more selective for MMP-13 over MMP-2 [16].
Figure 23. (a) Inhibitor of Wyeth with carboxylate sulphonamide; (b) inhibitor of Wyeth with the
carboxylate function connected to a bezofuran via biphenyl sulphonamide spacer.
Tanomastat (Bayer) inhibits MMP-2, -3, -9, and -13 but not MMP-1 [6,29]. This inhibitor participated
in clinical trials, proving tolerable and no serious MSS, but the efficacy was negative in small-cell lung
cancer because the median overall survival of patients treated did not increase [6,29].
Table 10 shows the IC50 and Ki values of some carboxylates-based
inhibitors [6,15–19,29,35,37,54,55].
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4.2.3. Phosphorus-Based Inhibitors
The capacity of the phosphoric group to reproduce the gem-diol intermediate during peptide
hydrolysis was explored with different structures to obtain potent MMPis [5]. The phosphorus-based
of the peptide-analogous inhibitors can be phosphonates/phosphonic acids, phosphoramidates,
phosphonamidates, and phosphinates/phosphinic peptides [27]. The phosphinic acid (PO(OH)-CH2)
mimics the transition state obtained in substrate degradation, where each oxygen atom can coordinate
both the catalytic zinc and the catalytic Glu [6,19,27]. The phosphinic acids are monodentate chelates [27].
In contrast to hydroxamate compounds, the phosphinic compounds interact with both the primed
and unprimed side of the catalytic site [17,27,35] due to the placement of the ZBG in the middle of the
scaffold and not at its N- or C-terminal, as in the cases of hydroxamate and carboxylate inhibitors [17].
Another advantage of phosphinic acids is the improved metabolic stability compared with hydroxamate
acids [27].
The effectiveness of phosphoric acid inhibitors has been studied and it has been found that the
three pockets unprimed are connected to obtain the maximum performance [19]. The S1-S2 pockets
can be exploited using aromatic groups [19,68], that is why Reiter et al. prepared compounds with
4-benzyl (Figure 24) as a substituent to fill S2 pocket. They found that in the absence of this substituent
or its replacement by small aliphatic or cyclohexyl methyl groups led to a loss of activity [19,68].
Figure 24. Compound prepared by Reiter et al., with a 4-benzyl substituent. The 4-benzyl group
fills the S2 pocket and if the benzyl group was omitted or replaced by a small aliphatic or cyclohexyl
methyl group, the activity is lost. The isobuthyl group fills the S1’ pocket in a manner similar to other
substrate-like inhibitors.
Matziari et al. [69] synthesized a series of phosphinic pseudopeptides bearing long P1’ side chains,
compounds that contain groups at the ortho-position of the phenyl ring and are selective for MMP-11 by
the interaction of these groups with residues located at the entrance of the S1’ cavity [69]. These results
suggest that the development of compounds able to probe the entrance of the S1’ cavity might represent
an alternative strategy to gain selectivity [69].
Other phosphorus-based ZBGs are the carbamoyl phosphates, in which the two oxygens form
a five membered ring with the zinc ion [18]. The negative charge of these inhibitors prevents their
penetration into the cell and restrain them for extracellular space, contributing to low cytotoxicity [18].
Pochetti et al. [70] described a compound with high affinity to MMP-8 (Ki = 0.6 nM) but inhibits also
MMP-2 (Ki = 5 nM) and MMP-3 (Ki = 40 nM) (Figure 25). The R enantiomer is more potent (1000 time
more) than the S enantiomer (Ki = 0.7 μM) [70].
Figure 25. Pochetti’s inhibitor.
The classical approach to synthesizing phosphinic compounds limits the full exploitation of this
class of compounds for development of highly selective inhibitors of MMPS [35].
Table 11 shows the IC50 and Ki values of some phosphorus-based inhibitors [6,15–19,29,35,37,54,55].
150











































































































































































































































































































































































































































































































































































































































































































































































































Biomolecules 2020, 10, 717
4.2.4. Nitrogen-Based Inhibitors
The nitrogen-based inhibitors have a binding preference to late transition metals and improved
selectivity to zinc-dependent enzymes like MMPs [2]. The nitrogen-based inhibitors are studied by
the Food and Drug Administration (FDA) and its metabolic availability and bioavailability are well
described [2,18]. This ZBG type binds to Zn2+ using the nitrogen atom and the carbonyl oxygen
adjacent to nitrogen, which favors the formation of an enol because it is established by two hydrogen
bonds [18].
The pyrimidine-2,4,6-trione inhibitors were published in 2001 by Hoffman-LaRoche.
These compounds show relative specificity to gelatinases and potential usefulness as anticancer
drugs [2]. The derivatization of position 5 of this compound promotes access to S1’ and S2’ pockets [18].
In development of osteoarthritis drugs, the pyrimidine-2,4,6-trione inhibitors have been optimized to
inhibit MMP-13 [2].
4.2.5. Heterocyclic Bidentate-Based Inhibitors
Heterocyclic bidentate ZBGs have better biostability and higher catalytic zinc ion binding
capacity than hydroxamic acids, due to ligand rigidity [2]. Compared heterocycles bidentate and
acetohydroxamic acid, the first are more potent to inhibit MMP-1, -2, and -3 and show low toxicity in
cell viability assays [2].
Pyrones are biocompatible and they present good aqueous solubility [16]. The arylic portion was
added to fit the MMP-3 hydrophobic S1’ pocket, resulting in the compounds more potent than the
corresponding hydroxamate-based inhibitors [16].
Table 12 shows the IC50 and Ki values of some heterocyclic bidentate-based
inhibitors [6,15–19,29,35,37,54,55].
4.2.6. Tetracyclines-Based Inhibitors
Tetracyclines are antibiotics that can chelate zinc and calcium ions and inhibit MMP
activity [2,16,29]. Chemically modified tetracyclines (CMT) are preferred over conventional
tetracyclines because they reach higher plasma levels for prolonged periods, consequently require less
frequent administration, cause less gastrointestinal side effects, and have promising anti-proliferative
and anti-metastatic activity [2,16,29]. The CMT binds to pro- or active MMPs, disrupt the native
conformation of the protein, and leave the enzymes inactive [29]. In the search for new anticancer agents,
the first series of CMT was obtained by removal of the dimethylamino group from the carbon-4 position,
resulting in a compound without antimicrobial activity but with anticollagenolytic activity, in vitro
and in vivo [16]. Preclinical studies demonstrated that CMT can inhibit gelatinases, stromelysins,
collagenases, and MT-MMPs, by downregulating the expression of gelatinases, reducing the production
of pro-enzymes and inhibiting the activation of pro-gelatinases and pro-collagenases [16,29].
Doxycycline (Figure 26a) is a semi-synthetic tetracycline that inhibits MMP-2, -9, -7, and -8 and is
the only compound approved as an MMP inhibitor for the treatment of periodontitis [2,6]. The COL-3
(Figure 26b) showed specificity for MMP-2, -9, and -14, by decrease trypsinogen-2 and inducible nitric
oxide (iNO) production, which are regulators of MMP activity [16]. Although COL-3 is currently being
evaluated in clinical phase II trials, it showed poor solubility and stability [16].
4.2.7. Mechanism-Based Inhibitors
The mechanism-based inhibitors coordinate with catalytic zinc ion, in a monodentate mode,
allowing the nucleophilic attack by a conserved glutamic residue on the active site and forming a
covalent bond [2,17]. This attack causes a conformational change in the catalytic site environment [17]
preventing dissociation of the inhibitor and decreasing the rate of catalytic turnover and the amount of
inhibitor needed to saturate the enzyme [2].
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Figure 26. (a) Doxycycline; (b) COL-3.
Table 13 shows the IC50 values of some tetracyclines-based inhibitors [6,15–19,29,35,37,54,55,71].
Table 13. IC50 values of tetracyclines-based inhibitors.
Doxycycline
IC50: MMP-1 > 400 μM; MMP-7 = 28 μM;
MMP-3 = 30 μM; MMP-13 = 2 μM
CMT-1
IC50: MMP-8 = 30 μM; MMP-13 = 1 μM
Matastat (COL-3; CMT-3)
IC50: MMP-1 = 34 μg·mL−1; MMP-8 = 48 μg·mL−1;
MMP-13 = 0.3 μg·mL−1
Minocycline
IC50: MMP-9 = 272 μM
In 2000, Mobashery et al. [72] were the first to report this novel type of MMPi that blocks
gelatinases with a unique mechanistic mode [72]. The thiirane inhibitor showed a mechanism-based,
slow-binding inhibition for MMP-2 and MMP-9 [72]. Bernardo et al. [73] also reported a slow-binding
thiirane-containing inhibitor, (Figure 27), selective for MMP-2 and -9, where the sulfur group coordinates
with the catalytic zinc ion, activates the thiirane group to interact with the active site glutamate,
by nucleophilic attack causing a loss of activity [73]. These inhibitors are the first example of a
suicide-inhibitor of MMPs [73].
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Figure 27. Inhibitor developed by Bernardo el al. The sulfur group coordinates with the catalytic
zinc ion and the activation of the thiirane group happened with interactions between the active site
glutamate, by nucleophilic attack.
Thiirane-based ND-322 is a small molecule selective to MMP-2/MT1-MMP [2]. This inhibitor
has been shown to reduce melanoma cell growth, migration, and invasion, and to delay metastatic
dissemination [2].
SB-3CT is a selective inhibitor of MMP-2 and -9 [2]. The inhibition mechanism is similar to a
“suicide inhibitor” in which a functional group is activated, leading to covalent modification of the
active site [2]. SB-3CT also shows slow-binding kinetics with MMP-2, -3, and -9, contributing to slow
dissociation of the MMP-inhibitor complex, but it is a reversible inhibitor which differentiates it from
the truly irreversible suicide inhibitors [2]. O SB-3CT has potential benefits in brain damage caused by
cerebral ischemia and has anti-cancer effects in T-cells lymphoma and prostate cancer models [2].
4.3. Catalytic Domain (Non-Zinc Binding) Inhibitors
The catalytic domain of MMPs contains other regions that can be exploited [17]. The first
3D-structure of the complex MMP-1 (catalytic domain)-synthetic inhibitor was reported in 1994 by
Glaxo researchers [35]. Thereafter, other complexes have been studied and it was found that the
S1’ pockets have different depths among MMPS and this difference has been utilized in developing
selective MMPis [28,35].
Stockman and Finel optimized two distinct series of MMP-3 inhibitors: PNU-141803 (amide,
Figure 28a) and PNU-142372 (urea, Figure 28b) [19]. The connection between MMP-3 and PNU-142372
shows that the aromatic ring from the inhibitor extends to the S3 pocket (hydrophobic) and the
thiadiazole sulfur group interacts with the catalytic zinc [19]. Moreover, the two nitrogen atoms
form hydrogen bonds with Ala164 and Glu202 residues [19]. The alkylation of nitrogen atom or its
replacement for carbon leads to the removal activity [19]. The replacement of a tyrosine for a serine
within the S3 pocket (present in MMP-1) leads to the removal of inhibitory activity and explains the
absence of activity against collagenases [19].
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Figure 28. (a) PNU-141803; (b) PNU-142372.
Sanofi-Aventis developed a compound (Figure 29) for MMP-13 (IC50 = 6.6 μM), with very high
selectivity [6]. This compound binds deeply to the S1’ pocket and to a side pocket that has not been
identified for other MMPs [6]. The pyridyl moiety is towards to the entrance of the S1’ pocket, without
interacting with the catalytic Zn(II) ion and the oxygen atoms neither from the amide (peptidic) bonds
of the main chain (between Thr245 and Thr247) nor from hydroxyl group from the Thr247 side chain in
the S1’ pocket [6].
Figure 29. Sanofi-Aventis compound.
Many natural compounds have been shown to possess selective inhibition [28]. Wang et al.
identified 19 potential MMPis from 4000 natural compounds isolated from medicinal plants [28].
The caffeates and flavonoids were found to be selective inhibitors against MMP-2 and -9, by occupying
the S1’ and S3 pockets [28].
The marine natural products are another pharmacological resource and include derivates from
algae, sponges, and cartilages [28]. Some examples are Neovastat, Dieckol, and Ageladine A and they
manifest anti-angiogenic, anti-proliferative, and anti-tumor effects [28].
Although the natural MMPis are more biocompatible and less toxic, they have disadvantages
such as the effective dosages are in micromolar scale, which is thousands of times higher than synthetic
inhibitors and are difficult to patent, making the pharmacological companies and investors reluctant to
sponsor large-scale clinical trials [28].
4.4. Allosteric and Exosite Inhibitors
The catalytic zinc ion is common in all MMPs, therefore, if interactions of the substrates with
this ion are minimized this would improve the inhibitor selectivity [2]. The hemopexin-like domain
can move relatively to the catalytic domain and allosterically manipulate enzymatic activity by
conformation deformation [28]. The allosteric drugs have a non-competitive inhibition mode [16,28],
they bind and lock the MMP active site, forcing it to take less favorable conformation for substrate
binding [2,16], avoiding off-target inhibition [28] and preventing the occurrence of side effects [28].
Exosite inhibitors are another alternative for selective MMPis since these inhibitors bind to alternative
sites of MMPs [16,28].
Remacle et al. reported NSC405020, a small molecule that binds selectively to the hemopexin-like
domain of MMP-14 [28]. This molecule inhibits the MMP-14 homodimerization and the interaction
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between the hemopexin-like domain and catalytic domain, preventing the type I collagen
degradation [28].
Dufour et al. developed a peptide targeting the MMP-9 hemopexin-like domain, which blocks
MMP-9 dimer formation and cell migration [28]. Scannevin et al. identified a highly selective
compound (JNJ0966), which binds to the MMP-9 pro-peptide domain, inhibiting its activation, but not
affecting the activity of MMP-1, -2, and -14 [28].
Xu et al. synthesized a peptide which inhibits the hydrolysis of type I and IV collagen by MMP-2,
through binding to its collagen binding domain [28].
4.5. Antibody-Based Inhibitors
Antibodies are selective and have high affinity to MMP [27]. Clinical trials utilizing antibodies have
provided evidence that selective MMP inhibitors do not induce MSS [27]. The therapeutic potential of
anti-MMP antibodies has yet to be realized [27]. The antibodies may also undergo proteolysis, may be
removed from circulation rapidly, and are costly [27].
Antibodies are large Y-sharped proteins which bind to an antigen via the fragment antigen-binding
(Fab variable region) [28]. Monoclonal antibodies are highly specific, and they have affinity to
MMPs [2,29]. The hemopexin domain can be a potential target for MMPs antibodies [2].
REGA-3G12 and REGA-2D9 are antibodies specific to MMP-9 [2,27,28] but not MMP-2 [28].
The inhibition mode of the REGA-3G12 involves the catalytic domain, the N-terminal region
Trp116-Lys214 [28], and not the catalytic zinc ion or the fibronectin region [2]. The AB0041 and
AB0046 are monoclonal anti-MMP-9 antibodies, which showed inhibition to tumor growth and
metastasis in a model of colorectal carcinoma [27].
Andecaliximab (GS-5745), the humanized version of AD0041 [27], is a highly selective antibody
and exerts allosteric control over tumor growth and metastasis in a colorectal carcinoma model (IC50
= 0.148 nM) [28]. This antibody is the only inhibitor that has undergone clinical trials [27,28] and it
inhibits the pro-MMP-9 activation and inhibits non-competitively the MMP-9 activity [27].
DX-2400 is an antibody isolated from phage and it targets MMP-14 and the MMP-14-pro-MMP-2
complex, decreasing MMP activity [28]. DX-2400 inhibits the metastasis in a breast cancer xenograft
mouse model [27]. However, the LAM-2/15 is the only selective inhibitor that inhibits MMP-14 catalytic
activity, but not the pro-MMP-2 activation or MMP-14 dimerization [28]. The 9E8 is another antibody
targeting MMP-14 which does not affect the catalytic activity of MMP-14 but inhibits the pro-MMP-2
activation [28].
Human scFv-Fc antibody E3 is bound to the catalytic domain of MMP-14 and inhibits type I
collagen binding [27]. Human antibody Fab libraries were synthetized and the peptide G sequence
(Phe-Ser-Ile-Ala-His-Glu) was incorporated resulting in Fab 1F8 antibody inhibitor, which inhibits the
catalytic domain of MMP-14 [27].
Antibodies can also inhibit a specific activation of an MMP [27]. For example, the mAb 9E8
inhibits the MMP-14 activation of proMMP-2 but not the catalytic activities of MMP-14 [27]. The
antibody LOOPAB also inhibits the MMP-14 activation of pro-MMP-2 but not collagenolysis activity of
MMP-14 [27]. There are antibodies that reduce the MMP expression [71].
5. Why Do MMP is Fail?
MMI inhibitor side effects are predominantly related to off-target metal chelation [74]. The majority
of MMPis used clinically are hydroxamic acid derivates with low selectivity [74] hence, they can
inhibit other proteinases [28]. The most frequent side effects observed in MMPis clinical trials is
the musculoskeletal syndrome (MSS) [17,28], which manifested as pain and immobility in the joints,
arthralgias, contractures in the hands, and an overall reduced quality of life [14,15,74], leading to MMPis
failing in the last phases of clinical trials [14]. Several studies indicate that the development of MSS is
related to dose and time, with slightly different kinetic for the different MMPis, and the development of
MSS is an indicator of successful MMPis [14,74]. The MMP inhibitors focused on chelating the catalytic
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zinc ion have poor selectivity and resulted in MSS and gastrointestinal disorders [27]. However, the
exact causes of MSS remains unknown [74], but can be related to a simultaneous inhibition of several
MMPs [6,17,27].
Analysis of the expression of a target protein shows its presence at high levels when a disease is
manifested or at low levels or absence in a healthy state [74]. However, these studies do not determine
if a particular protein is directly associated with the disease process or if it is involved in ancillary
event [74]. Studies of genetic manipulation in mouse as animal models determine the roles of MMPs in
various pathological processes [74]. However, there are caveats in the use of animal models [74]:
- The observed effects can be a consequence of the manipulated absence of MMP, being a
compensation mechanism;
- The mouse models are unable to replicate the complexity of any human disease. The mouse
models serve to recreate specific processes or sets of processes but not the physiological changes
that occur in humans.
6. Conclusions
Due to the side effects rising from the lack of selectivity and from the insufficient knowledge about
the role of each MMP in the different pathological processes, none of the designed synthetic MMP
inhibitors have yet passed the clinical trials and reached the market [6,27]. The poor performance of
MMP inhibitors in clinical trials has globally been attributed to [27]:
- Inhibition of other metalloenzymes;
- Lack of specificity within the MMP family;
- Poor pharmacokinetics;
- Dose-limiting side effects/toxicity;
- In vivo instability;
- Low oral availability/inability to assess inhibition efficacy.
In 1988, the first inhibitor was synthesized but after nearly 30 years, only one drug, Periostat®,
doxycycline hydrate, had obtained approval from the FDA for the treatment of periodontal
disease [6,16,17,27,28]. This inhibitor exhibited also therapeutic effects in treating aortic aneurysm,
multiple sclerosis, as well as Type II diabetes [28].
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Abstract: Matrix metalloproteinase-7 (MMP-7) is a secreted zinc-dependent endopeptidase that
is implicated in regulating kidney homeostasis and diseases. MMP-7 is produced as an inactive
zymogen, and proteolytic cleavage is required for its activation. MMP-7 is barely expressed in
normal adult kidney but upregulated in acute kidney injury (AKI) and chronic kidney disease (CKD).
The expression of MMP-7 is transcriptionally regulated by Wnt/β-catenin and other cues. As a secreted
protein, MMP-7 is present and increased in the urine of patients, and its levels serve as a noninvasive
biomarker for predicting AKI prognosis and monitoring CKD progression. Apart from degrading
components of the extracellular matrix, MMP-7 also cleaves a wide range of substrates, such as
E-cadherin, Fas ligand, and nephrin. As such, it plays an essential role in regulating many cellular
processes, such as cell proliferation, apoptosis, epithelial-mesenchymal transition, and podocyte
injury. The function of MMP-7 in kidney diseases is complex and context-dependent. It protects
against AKI by priming tubular cells for survival and regeneration but promotes kidney fibrosis and
CKD progression. MMP-7 also impairs podocyte integrity and induces proteinuria. In this review, we
summarized recent advances in our understanding of the regulation, role, and mechanisms of MMP-7
in the pathogenesis of kidney diseases. We also discussed the potential of MMP-7 as a biomarker and
therapeutic target in a clinical setting.
Keywords: matrix metalloproteinase-7; fibrosis; proteinuria; acute kidney injury; chronic kidney
disease; apoptosis
1. Introduction
Matrix metalloproteinase-7 (MMP-7), also known as matrilysin-1, is one of the smallest secreted
proteases of the MMP family, which consists of more than 20 structurally-related zinc-dependent
endopeptidases with broad substrate specificity [1,2]. Collectively, MMPs degrade virtually all kinds
of extracellular matrix (ECM) proteins and contribute to their turnover and remodeling. Furthermore,
MMPs can also cleave many non-ECM substrates, making them a critical player in a wide variety of
physiologic and pathologic processes, such as cell proliferation and apoptosis, endothelial cell function,
inflammation, and tumor metastasis and invasion [3,4].
Extensive studies have shown that many MMPs are implicated in regulating kidney development
and the pathogenesis of kidney diseases. Dysregulation of MMPs has been described in a wide variety
of kidney disorders, including acute kidney injury (AKI), chronic kidney disease (CKD), diabetic kidney
disease (DKD), glomerulonephritis, and inherited kidney diseases. Over the last two decades, due to
the availability of MMP knockout models and specific pharmacological inhibitors, the role of MMPs,
particularly MMP-2 and MMP-9, in regulating the development and progression of kidney diseases
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have been extensively investigated. The detailed discussion of these MMPs in kidney pathology as
well as in non-renal diseases is beyond the scope of the present paper, and the interested readers are
referred to several comprehensive reviews on this topic [1,2,5]. Instead, the focus of this review is on
MMP-7 in kidney diseases.
MMP-7 was first discovered in the rat uterus [6]. Structurally, MMP-7 comprises a pro-peptide
domain and a catalytic domain. While it was formerly believed to cleave only ECM proteins,
the evidence is emerging that MMP-7 also degrades a variety of non-ECM substrates, such as nephrin,
E-cadherin, Fas ligand (FasL), pro-MMP-2, and pro-MMP-9 [7–10]. As such, MMP-7 is able to regulate
a diverse array of biological processes, such as podocyte dysfunction, epithelial to mesenchymal
transition (EMT), cell proliferation, and apoptosis [11,12]. It should be stressed that many actions of
MMP-7 in the kidney are highly specific and unique. For instance, only MMP-7, but neither MMP-2
nor MMP-9, can cleave podocyte slit diaphragm protein nephrin and cause proteinuria [7]. In this
context, it is conceivable that MMP-7 may be more important than other MMPs to the pathogenesis of
kidney diseases.
In the past several years, significant progress has been made in our understanding of the biology of
MMP-7 in kidney diseases. Numerous novel substrates of MMP-7 have been identified, enabling us to
better comprehend the exact role of MMP-7 in the pathogenesis of kidney disorders. Mounting evidence
suggests that urinary MMP-7 (uMMP-7) can be utilized as a noninvasive biomarker for predicting
AKI prognosis and monitoring CKD progression in patients [13–15]. In this review, we discussed
the expression, regulation, novel substrates, and mechanisms of MMP-7 in various kidney diseases.
2. MMP-7 Structure, Activation, and Regulation
The human MMP-7 gene is located on chromosome 11 q22.3. The cDNA of MMP-7 encodes
a protein containing 267 amino acids. Structurally, MMP-7 only consists of a pro-peptide domain and
a catalytic domain (Figure 1A), which separates it from most other MMPs that contain an additional
hinge region and a hemopexin-like domain [1,2,16]. The crystal structure of MMP-7 containing the two
domains aforementioned is shown in Figure 1B.
Figure 1. Structure of proMMP-7. (A) Full-length proMMP7 only consists of two domains: a pro-peptide
domain (pro) and a catalytic domain (cat), which separates it from the prototype of MMPs. (B)
The pro-peptide domain consists of three α-chains and connecting loops. The catalytic domain contains
two zinc ions, two copper ions, and a ball-like structure consisting of three α-helices, five β-sheets, and
multiple loops [16]. The image was prepared from Protein Data bank entries 2MZE (proMMP-7) using
the PyMol (http://www.pymol.org). MMP, matrix metalloproteinase.
MMP-7 protein is produced and secreted as an inactive zymogen, which is maintained by
a conserved cysteine residue that interacts with the zinc in the active site, rendering the protease
inactive [16]. Disruption of this so-called cysteine switch is required for activation and can occur via
proteolytic cleavage by many proteases, including trypsin, plasmin, or even other MMPs [17]. To
generate a functional MMP-7 from the zymogen, the pro-peptide domain is proteolytically degraded in
170
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a stepwise manner [18]. The latent form of MMP-7 is a 28 kDa protein. After removing an approximately
9 kDa sequence from the pro-peptide domain, the resultant 19 kDa peptide represents the active and
functional endopeptidase. MMP-7 is also bound by two calcium ions, which plays an important role in
stabilizing the secondary structure of the protein.
The activity of MMP-7 is regulated by a family of naturally occurring endogenous inhibitors
known as tissue inhibitors of metalloproteinases (TIMPs). There are four known TIMPs; however, it
remains elusive which TIMP has the greatest specificity for MMP-7. There are also potent inhibitors of
MMP-7, such as MMP inhibitor II, that can reversibly block MMP-7 activity. However, the selectivity
of these inhibitors for MMP-7 is uncertain, as they often inhibit, to a lesser degree, other MMPs as
well. One of the challenges in the field is to develop potent and selective inhibitors that are specific for
a given MMP.
The expression of MMP-7 is transcriptionally regulated by different cues, particularly
the Wnt/β-catenin and transforming growth factor-β (TGF-β). The promoter of the human MMP-7
gene contains a TATA box, an activator protein 1 (AP-1) site, and T cell factor (TCF)-binding elements.
The AP-1 binding site is essential for mediating MMP-7 expression in response to growth factors,
oncogenes, and phorbol ester, while the TCF-binding elements are responsible for mediating MMP-7
induction by Wnt/β-catenin. As TGF-β is known to activate β-catenin signaling [19], it remains elusive
whether TGF-β controls MMP-7 expression directly or via β-catenin indirectly.
3. MMP-7 Expression in the Kidney
MMP-7 is commonly expressed in epithelial cells, including the liver, the ductal epithelium of
exocrine glands in the skin, salivary glands, and pancreas, and the glandular epithelium of the intestine
and reproductive organ and breast. Under normal physiologic conditions, adult kidney exhibits
little MMP-7 expression [12,18,20]. Consistent with this notion, mice with global knockout of MMP-7
are phenotypically normal, without any renal abnormality [12]. These data suggest that MMP-7 is
dispensable for kidney structure and function in basal physiologic conditions.
The expression of MMP-7 is, however, induced in a wide variety of kidney diseases, including AKI,
CKD, glomerular disease, inherited kidney disease, and renal cell carcinoma [11,21–24], suggesting
that MMP-7 induction is a common feature of the kidney after various injuries. The expression and
localization of MMP-7 protein in various kidney disorders are summarized in Table 1.
3.1. Animal Models
MMP-7 is markedly induced after AKI. In experimental animal models of AKI induced by
ischemia-reperfusion injury (IRI), cisplatin, or folic acid, both mRNA and protein levels of MMP-7 are
upregulated [11]. Following IRI, MMP-7 protein is mainly expressed and localized in the renal tubular
epithelium, particularly in the S3 segment of proximal tubules, the epicenter of kidney injury in this
model [11]. These results indicate a spatial correlation of MMP-7 induction with tubular injury and
repair and regeneration. At this stage, the exact cues for triggering MMP-7 induction in AKI in vivo
remain ambiguous, but it is most likely related to activation of Wnt/β-catenin signaling. In vitro studies
show that human kidney proximal tubular cells (HKC-8) increase MMP-7 expression upon stimulation
of Wnt/β-catenin, whereas inhibition of Wnt/β-catenin by small molecule inhibitor ICG-001 negates
MMP-7 induction [21].
Induction of MMP-7 is a common finding in a wide variety of CKD characterized by renal fibrosis.
MMP-7 expression is increased in renal tubular epithelia in the mouse model of unilateral ureteral
obstruction (UUO) [21]. Similar results are obtained in adriamycin nephropathy, a model of focal and
segmental glomerulosclerosis (FSGS). Immunohistochemical staining reveals that MMP-7 expression
and Wnt/β-catenin activation are closely correlated in both UUO and adriamycin nephropathy [21]. This
result is compatible with the findings in tumors that MMP-7 transcript overlaps with the accumulation
of β-catenin protein [25,26]. Therefore, it is conceivable that MMP-7 expression in CKD is causatively
linked to the activation of Wnt/β-catenin signaling.
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Table 1. Expression of matrix metalloproteinase-7 (MMP-7) in kidney diseases.
Disease Location Expression Ref.
Animal models
Ischemia–reperfusion -induced AKI 1 Renal tubular epithelia Increase [11]
Folic acid-induced AKI Renal tubular epithelia Increase [11,23]
Cisplatin-induced AKI Renal tubular epithelia Increase [11]
UUO 2




Renal tubular epithelia, interstitial
cells, podocytes Increase [12,21]
Lupus nephritis Renal tubular epithelia Increase [27]
Membranous nephritis Renal tubular epithelia Increase [12]
Autosomal dominant polycystic
kidney disease
Epithelial cells lining cysts,
atrophic tubules Increase [23]
Diabetic nephropathy Renal tubular epithelia, interstitialcells Increase [12,21]
Hydronephrosis Cells lining dilated and atrophictubules Increase [23]
Thrombotic microangiopathy Renal tubular epithelia Increase [12]
IgA nephropathy Renal tubular epithelia, infiltratedinflammatory cells Increase [12,21]
Acute renal allograft rejection Renal tubular epithelia No change [28]
Chronic allograft nephropathy Renal tubular epithelia Increase [29]
Amyloid light-chain amyloidosis Glomerulus, tubular interstitium,vasculatures Increase [30]
Light chain deposition disease Glomerulus, tubular interstitium,vasculatures No change [30]
Renal cell carcinoma Cancer cells and endothelial cells Increase [22]
1 Acute kidney injury. 2 Unilateral ureteral obstruction. 3 Focal segmental glomerulosclerosis.
3.2. Human Kidney Biopsies
Consistent with animal studies, the induction of MMP-7 expression is also evident in the kidney
from patients with various renal disorders. For instance, in the kidney biopsies of patients with an
autosomal dominant polycystic kidney disease, MMP-7 staining is observed in tubular epithelial lining
cysts and atrophic tubules [23]. In the specimens of patients with hydronephrosis, MMP-7 is detected
in dilated and atrophic renal tubules [31].
Kidney tissues from patients with IgA nephropathy (IgAN) show positive MMP-7 staining in
renal tubular epithelia, fluids in the tubular lumen, and glomerular podocytes [12,21]. The RNA
sequencing data from IgAN patients also show a significant increase in the mRNA expression of MMP-7
in the kidneys [32]. MMP-7 protein is increased in both tubular epithelial cells and the tubulointerstitial
compartment of human diabetic kidneys [12,33]. Similarly, renal biopsy specimen analysis reveals
MMP-7 induction in lupus nephritis and chronic allograft nephropathy [27,29]. Induction of MMP-7
expression has also been observed in the kidneys of patients with FSGS [12,21].
3.3. Mechanism of MMP-7 Regulation In Vivo
As to the cues responsible for MMP-7 induction in vivo, many studies have pointed to
Wnt/β-catenin signaling, which is activated in virtually every kind of nephropathy [21,34,35]. When
Wnt ligands bind to their receptors,β-catenin is stabilized and subsequently translocates into the nucleus
for binding to the TCF/lymphoid enhancer-binding factor to regulate the transcription of its target genes,
including MMP-7 [34,36,37]. Bioinformatics analysis reveals the presence of putative TCF-binding
sites in the promoter region of the MMP-7 gene [21]. Chromatin immunoprecipitation confirms
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that β-catenin activation promotes the binding of TCF to the MMP-7 gene promoter, resulting in
the expression of MMP-7 in kidney tubular epithelial cells [21].
There is also a correlation between MMP-7 and TGF-β in vivo, suggesting that TGF-β may
play a role in mediating MMP-7 expression. Both TGF-β1 and MMP-7 are upregulated in
streptozotocin-induced diabetic nephropathy rats. Sirtuin 1 (Sirt1) deacetylates Smad4 and inhibits
the expression of MMP-7, indicating that the over-activation of TGF-β is related to the excessive
acetylation of Smad4, which, in turn, causes MMP-7 induction [38,39]. Along these lines, resveratrol
increases the expression of Sirt1, which inhibits MMP-7 and ultimately alleviates renal injury and
fibrosis. Furthermore, TGF-βmay indirectly augment MMP-7 by activating canonical Wnt signaling [19].
TGF-β also inhibits Dickkopf-1, an antagonist of Wnt, and potentiates the activity of β-catenin, thereby
activating Wnt/β-catenin signaling [40,41]. Of interest, a study shows that MMP-7 can further induce
TGF-β production via an MMP-7/Syndecan-1/TGF-β autocrine loop [42,43].
4. MMP-7 As a Biomarker for Kidney Diseases
Early identification and diagnosis are of importance in slowing the progression of kidney disease
and preventing its complications [44]. Serum creatinine and blood urea nitrogen (BUN), two widely
used markers for the diagnosis of kidney failure, increase only in the advanced stage of nephropathy.
Consequently, kidney diseases are usually diagnosed at a later stage, and the implementation of
therapeutic interventions is usually delayed. Therefore, there is an urgent need to develop novel
biomarkers for early detection and prognostic assessment of kidney disorders [45]. MMP-7 is
upregulated in various kidney diseases, and its protein is predominantly distributed in the apical
region of tubular epithelial cells and is detected in the fluids present in the tubular lumen [12,21],
suggesting that this protein could be secreted to the urine. Therefore, the level of uMMP-7 can be used
as a potential non-invasive biomarker of kidney disease.
4.1. uMMP-7 Predicts the Risk of AKI
AKI is a relatively common disorder among hospitalized patients, occurring in more than 20% of all
hospitalizations in large academic hospitals [46]. AKI causes approximately 2 million deaths each year
worldwide. Current diagnostic criteria for AKI require changes in serum creatinine and urine output,
which are not sensitive and represent delayed markers. Estimated glomerular filtration rate (eGFR)
must decline by approximately 50% before any changes in serum creatinine can be detected [47,48].
Therefore, a sensitive and robust biomarker to predict the risk of AKI and its associated outcomes in
patients is urgently needed. Over the past decades, there are tremendous efforts in the nephrology
community to discover and validate potential biomarkers for AKI. Several biomarkers, such as kidney
injury molecule-1 (Kim-1), neutrophil gelatinase-associated lipocalin (NGAL), and TIMP-2/insulin-like
growth factor-binding protein-7 (IGFBP7), have been identified. Although some of them are applied to
the clinic, they have various limitations.
There are two prospective cohort studies showing uMMP-7 as a valuable predictor of severe AKI
after cardiac surgery [13,49]. In a prospective, multicenter, two-stage cohort study with 721 patients
undergoing cardiac surgery, compared with the lowest quartile, a postoperative uMMP-7 level of
22.6 μg/g creatinine in children represents a >36-fold risk of severe AKI, whereas a postoperative
uMMP-7 level of >15.2 μg/g creatinine in adults indicates a 17-fold risk of severe AKI [13]. In terms
of predicting prognosis, higher uMMP-7 levels shortly after cardiac surgery are associated with an
increased risk of acute dialysis or in-hospital deaths among children and adults, as well as longer
duration of intensive care unit and hospital stays [13]. uMMP-7 outperforms other biomarkers,
including urinary interleukin-18, NGAL, urinary angiotensinogen, albumin-to-creatinine ratio, and
TIMP2/IGFBP7 [50–53], and the area under the receiver operating characteristic curve (AUC) of
uMMP-7 is the largest for predicting severe AKI [13]. Of particular interest, uMMP-7 level peaks at
4 h after surgery, whereas the rise in serum creatinine occurs after 24 h in patients [13]. This is of
clinical significance because it allows much earlier identification of the patients who have a high risk of
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developing AKI than serum creatinine. Therefore, uMMP-7 could be a valuable and robust biomarker
for predicting the AKI after cardiac surgery. More studies are needed to replicate the results in larger
and more diverse populations and in different settings of AKI.
4.2. uMMP-7 As a Biomarker of CKD Progression
Kidney fibrosis is a common outcome of virtually all CKDs [54,55], which is characterized by
excessive accumulation and deposition of ECM, leading to tissue scarring. Measuring the extent of
renal fibrosis is essential for determining the prognosis of renal outcomes, monitoring CKD progression,
and evaluating the therapeutic efficacy of new treatments [55]. Currently, renal fibrosis is assessed only
via percutaneous renal biopsy [55,56]. It is necessary to find non-invasive surrogate biomarkers for
evaluating the development and progression of kidney fibrosis. Because activation of Wnt/β-catenin is
a common feature of fibrotic CKD [57–60], one would speculate that the activity of renal Wnt/β-catenin
signaling parallels the severity of renal fibrosis. Because the uMMP-7 level reflects the activity of renal
Wnt/β-catenin [21], it is then reasonable to measure uMMP-7 to estimate the extent of kidney fibrosis.
In patients with CKD, uMMP-7 levels are found to positively correlate with renal fibrosis scores
and have an inverse association with the renal function [12]. Therefore, uMMP-7 levels may serve as
a noninvasive biomarker for kidney fibrosis and a predictor for CKD outcomes, as well as monitor
the dynamic of fibrosis progression. Consistent with the findings in the kidney, MMP-7 also affects liver
and lung fibrosis after a chronic injury. MMP-7 is upregulated in biliary atresia-associated liver fibrosis,
and its expression is considered the best strategy to distinguish between cirrhosis and pre-cirrhosis
stages [61,62]. Elevated MMP-7 levels are also detected in the peripheral blood of patients with human
idiopathic pulmonary fibrosis (IPF) and may be used as a biomarker for predicting disease progression
and death [63–66]. Serum MMP-7 levels are also increased in IPF patients with severe obstructive
sleep apnea [67]. It should be pointed out that uMMP-7 is much more robust than serum MMP-7 in
predicting kidney injury, as it is mainly produced from the injured tubular epithelium and expressed
apically in CKD. In this context, uMMP-7 is particularly suitable for assessing the severity of fibrosis in
the kidney, compared to other organs.
The feasibility and validity of uMMP-7 as a biomarker to predict CKD progression are recently
supported by a prospective cohort study for uMMP-7 to serve as a predictor for IgAN progression [15].
The course of IgAN is highly variable and heterogeneous. The clinical manifestations range from
benign asymptomatic microscopic hematuria to severe hypertension and progressive CKD, and renal
pathological appearances range from normal to different degrees of mesangial cell proliferation [68].
At present, the final diagnosis of IgAN mainly relies on renal biopsy [68]. On the basis of a histological
assessment, variables including mesangial hypercellularity (M), endocapillary hypercellularity (E),
segmental glomerulosclerosis (S) and tubular atrophy and interstitial fibrosis (T) give rise to MEST score
and provide valuable information to prognostication of IgAN [69]. The lack of sensitive and specific
surrogate indicators for long-term outcomes makes it challenging to improve treatment options [70].
A recent prospective observational cohort study shows that the level of uMMP-7 may serve as an
independent and powerful predictor for IgAN progression, even for those patients who are still in
the early stages of IgAN, as defined by an eGFR of ≥ 60 mL/min/1.73 m2 [15]. High levels (> 3.9 μg/g of
creatinine) of uMMP-7 increase the risk of IgAN progression by 2.7 times in an adjusted analysis [15].
Several earlier studies have suggested numerous possible biomarkers in serum or urine for predicting
IgAN progressions, such as galactose-deficient IgA1, auto-antibodies against Gd-IgA1, fibroblast
growth factor 23, angiotensinogen, epidermal growth factor, and Kim-1 [71–77]. Measurement of
uMMP-7 level outperforms each of these biomarkers in risk prediction and improves the risk predictive
power of a MEST score [15]. Some retrospective follow-up studies also show that an increase in
serum MMP-7 levels is associated with a high risk of poor renal outcome and renal fibrosis [74]. In
addition, uMMP-7 is also identified to serve as an independent predictor of tissue remodeling and
renal interstitial fibrosis in children with CKD [78]. Another study shows that among people with type
2 diabetes and proteinuric DKD, uMMP-7 concentration is strongly associated with disease progression
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and subsequent mortality [14]. Taken together, these findings indicate that uMMP-7 may hold promise
as a noninvasive biomarker for kidney fibrosis and CKD progression.
5. Roles of MMP-7 in Kidney Diseases
Thanks to the availability of MMP-7 knockout mice, we now have a better understanding of
the role of MMP-7 in the pathogenesis of kidney diseases. Although the specific action of MMP-7 in
different nephropathy models has not been fully clarified, numerous studies have discovered discrete
roles of MMP-7 in renal pathophysiology in different settings. Furthermore, the role of MMP-7 may
also evolve with different disease types or the time course of kidney disorders. For instance, MMP-7
may be reparative in the early stages of AKI, whereas it may be detrimental as the disease progresses.
Table 2 summarizes the roles of MMP-7 in various kidney diseases.
Table 2. Roles of MMP-7 in kidney diseases.
Disease Role of MMP-7 Ref.
AKI 1
Protecting against AKI by priming tubular cells for
proliferation and survival [11]
UUO 2




Increasing urinary albumin excretion by impairing
the glomerular filtration barrier [7]




MMPs, including MMP-7, contribute to the deregulation of
extracellular matrix remodeling and possibly EMT. [29]
Light chain deposition
disease
The decrease of MMPs, including MMP-7, leads to
the accumulation of tenascin and extracellular matrix [30]
Amyloid light-
chain amyloidosis
The increase of MMPs, including MMP-7, leads to
the reduction of extracellular matrix [30]
Renal cell carcinoma Affecting tumor progression by regulating invasion andangiogenesis [22]
1 Acute kidney injury. 2 Unilateral ureteral obstruction. 3 Chronic kidney disease.
5.1. MMP-7 Protects Against AKI
MMP-7 is induced specifically in renal tubular epithelium after AKI, a condition characterized
by the death of tubular cells and the infiltration of inflammatory cells to the kidney [80–82]. In AKI
patients after cardiac surgery, uMMP-7 levels increase rapidly and peak at 4 h, suggesting MMP-7
induction is an early event [13]. Using MMP-7-/- null mice, a recent study shows that MMP-7 has
a renal protective effect against AKI as it alleviates injury by reducing the number of dead tubular
cells, promoting the proliferation of tubular cells, and suppressing inflammation [11]. Compared
with wild-type controls, MMP-7-/- mice display higher mortality, elevated serum creatinine, and more
severe histologic lesions after IRI or cisplatin. These changes are accompanied by more prominent
tubular cell death and interstitial inflammation in MMP-7-/- kidneys. In a rescue experiment, injection
of exogenous MMP-7 protects against kidney injury in MMP-7-/- mice after IRI, confirming a renal
protective action of MMP-7. Of note, MMP-7 may only play a protective role in the early stages of AKI
because the long-term activation of MMP-7 leads to kidney fibrosis [12].
5.2. MMP-7 Promotes Kidney Fibrosis and CKD Progression
CKD is characterized by excessive ECM accumulation and interstitial fibroblast activation [54,83–
85]. Given its proteolytic potential to degrade ECM proteins, MMP-7 was originally thought to be
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anti-fibrotic. Surprisingly, it is found that MMP-7 plays a critical role in the development of fibrotic
CKD [12]. In mice, the genetic ablation of MMP-7 reduces the fibrotic lesions and ECM accumulation
induced by UUO. Knockout of MMP-7 also preserves E-cadherin protein and inhibits the de novo
expression of vimentin in renal tubules of obstructed kidneys, suggesting that MMP-7 may promote
EMT in vivo. Although the role of EMT in renal fibrosis remains controversial, partial EMT is an
indispensable part of renal fibrosis [57,86]. Along these lines, it appears that MMP-7 plays an important
role in the onset and progression of renal fibrosis by impairing the integrity of renal tubular epithelium
and causing partial EMT [12]. Loss of E-cadherin mediated by MMP-7 leads to β-catenin liberation
and nuclear translocation, which facilitates CKD progression [57,87]. Of note, MMP-7-mediated
β-catenin liberation further induces MMP-7 expression, creating a vicious cycle [12]. Furthermore,
TGF-β is known to induce MMP-7 expression, consistent with their role in promoting EMT and kidney
fibrosis [38,39]. More studies are needed to confirm the detrimental role of MMP-7 in other models
of CKD.
5.3. MMP-7 Induces Podocyte Dysfunction and Proteinuria
In glomerular diseases, MMP-7 is specifically induced in glomerular podocytes of the diseased
kidney, implying its potential role in regulating podocyte injury and proteinuria. Indeed, a recent
study shows that the infusion of MMP-7 protein or injection of MMP-7 expression vector induces
transient proteinuria in normal mice [7], suggesting that MMP-7 can trigger podocyte injury and impair
the glomerular filtration barrier. Furthermore, MMP-7-/- mice are protected against proteinuria and
glomerular injury induced by either angiotensin II or adriamycin [7]. Consistent with this finding,
incubation of isolated glomeruli with MMP-7 ex vivo increases glomerular permeability and causes
foot process effacement. These observations illustrate that MMP-7 impairs glomerular filtration and
causes proteinuria in vivo.
CKD progression is characterized by increasingly widespread lesions in different compartments
of the kidney parenchyma. There is ample evidence to suggest that the progression of the primary
glomerular disease can trigger tubular injury and interstitial fibrosis, but whether tubular injury affects
the function of the glomerulus remains ambiguous [88]. Recently, using conditional knockout mice
with tubule-specific ablation of β-catenin, we discovered that tubule-derived MMP-7 is a pathological
mediator of glomerular damage [7]. MMP-7 is secreted as a soluble protein from the tubules to
the glomeruli and mediates the impairment of slit diaphragm integrity, leading to podocyte dysfunction
and increased proteinuria [7]. This suggests that MMP-7 is the key mediator of tubular-to-glomerular
crosstalk that promotes proteinuria and CKD progression.
6. Mechanisms and Novel Targets of MMP-7 in Kidney Diseases
The diverse actions of MMP-7 in kidney diseases are presumably mediated by its ability to cleave
different substrates. As the primary role of activated MMP-7 is to break down ECM components,
MMP-7 is well known to degrade macromolecules, including casein, type I, II, IV, and V gelatins,
fibronectin, and proteoglycan [2,89]. Recent findings reveal, however, that MMP-7 is also capable of
degrading a multitude of non-ECM substrates, such as FasL, E-cadherin, nephrin, and proMMP-2
and -9 [8–10,12]. These novel actions of MMP-7 play a crucial role in mediating its diverse functions
in the pathogenesis of kidney disorders. Figure 2 illustrates the mechanisms of MMP-7 action in
kidney disease.
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Figure 2. The mechanisms of MMP-7 action in kidney disease. (A) In renal tubular epithelial
cells, MMP-7 promotes cell proliferation and reduces cell death by degrading E-cadherin and FasL,
respectively, and finally plays a role in protecting the kidney during acute kidney injury (AKI). (B)
However, MMP-7 also degrades E-cadherin and activates proMMP-2 and -9, leading to renal fibrosis.
(C) In podocytes, MMP-7-mediated degradation of nephrin impairs the integrity of the slit diaphragm,
which subsequently causes an increase in proteinuria and eventually leads to renal fibrosis.
6.1. FasL
There are two signaling pathways leading to apoptosis: the intrinsic pathway and extrinsic
pathway [90–92]. The FasL plays a central role in the death receptor-dependent extrinsic apoptosis
pathway [93]. Dependent upon different pathological conditions and different cells, MMP-7 shows
a bi-directional effect on the induction or degradation of FasL, which plays distinct roles in regulating
cell survival/death in different settings. MMP-7 degrades FasL to decrease the apoptosis of renal
tubular cells through FasL/Fas-associated death domain (FADD)/caspase-7 activation, which is one of
the mechanisms underlying MMP-7 protection of kidney tubular cells against death in the early stage
of AKI [11] (Figure 2). Consistently, MMP-7-induced cleavage of the membrane-bound FasL also plays
a role in the process of pulmonary fibrosis [94].
Studies also show that MMP-7 affects the fate of renal interstitial fibroblasts in the opposite way.
MMP-7 is shown to induce the expression of FasL in cultured fibroblasts, which promotes fibroblast
apoptosis and facilitates its resolution after kidney repair following AKI [95]. This observation is
supported by studies conducted on cancer cells, which also shows that MMP-7 induces the expression of
FasL and subsequently activates the extrinsic apoptotic pathway [10,96]. Furthermore, MMP-7 enhances
the staurosporine-mediated intrinsic apoptosis pathway [97,98], leading to fibroblast apoptosis [95]. In
this regard, MMP-7-induced fibroblast apoptosis requires the synergistic action of both the intrinsic
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and extrinsic pathways. At this stage, the mechanism by which MMP-7 induces FasL expression
remains to be determined. It is likely that MMP-7 cleaves and activates an unidentified intermediate
molecule, which, in turn, induces FasL expression.
6.2. E-Cadherin
E-cadherin, a classical member of the cadherin superfamily, is an epithelial marker that plays an
important role in maintaining the integrity of tubular epithelial cells and cell–cell adhesion [99]. It
is a calcium-dependent cell–cell adhesion receptor composed of five extracellular cadherin repeats,
a transmembrane region, and a highly conserved cytoplasmic tail. MMP-7 is capable of degrading
E-cadherin via ectodomain shedding. It has been shown that MMP-7 affects both CKD and AKI by
cleaving E-cadherin [8,100]. Loss of E-cadherin impairs the integrity of tubular epithelial cells, which is
recognized as the initial step of partial EMT, a process that is essential for tubular atrophy and kidney
fibrosis [101,102]. Because E-cadherin and β-catenin associate with each other in a cellular adhesion
complex [99,103], the cleavage of E-cadherin would result in the dissociation of the E-cadherin/β-catenin
complex, leading to β-catenin liberation (Figure 2). In essence, MMP-7 can induce kidney fibrosis by
activating β-catenin in the absence of Wnt ligands [12]. Notably, such β-catenin release caused by
MMP-7-mediated degradation of E-cadherin is also found in mouse prostate cancer cells [104].
The liberation of β-catenin caused by MMP-7-mediated degradation of E-cadherin provides
a rational explanation for why MMP-7 promotes renal fibrosis. The exact same pathway, however,
is beneficial and plays a protective role against AKI (Figure 2). E-cadherin maintains tight cell–cell
adhesion among tubular epithelia [105]. The ability of MMP-7 to degrade E-cadherin disrupts epithelial
cell contact inhibition [106] and leads to cell proliferation [107–109]. E-cadherin degradation also
leads to β-catenin liberation and downstream signaling. In vitro experiments have confirmed that
proliferation-related proteins, such as proliferating cell nuclear antigen (PCNA) and c-Fos, are increased
in isolated renal tubules cultured with mitogen-rich serum and MMP-7, compared with serum alone [11].
In short, by cleaving E-cadherin and releasing β-catenin, MMP-7 creates an environment conducive to
cell proliferation and protects renal tubules against AKI [11]. However, loss of cell contact inhibition
can also trigger EMT and lead to a profibrotic phenotype after the acute injury has resolved. Therefore,
MMP-7 induction could be beneficial in the early phase of kidney injury but not in the late stage of
chronic kidney disorders. The balance of beneficial versus detrimental effects may rely upon the time
point at which MMP-7 activation occurs.
6.3. Nephrin
Nephrin is a key component of the slit diaphragm, which connects adjacent podocyte foot
processes and plays a fundamental role in glomerular filtration [110]. We recently demonstrated that
nephrin is a specific and direct substrate of MMP-7 [7] (Figure 2). MMP-7 is shown to degrade nephrin
in cultured glomeruli, cultured cells, and cell-free systems, which is dependent on its proteolytic activity.
Such action of MMP-7 on nephrin degradation is rapid, starting as early as 5 min after incubation.
Furthermore, the action of MMP-7 on nephrin appears direct, cleaving purified recombinant nephrin
protein in a cell-free system. It should be stressed that the action of MMP-7 is specific, as other MMPs,
such as MMP-2 and MMP-9, are unable to degrade nephrin in the same conditions. These findings not
only identify nephrin as a novel substrate of MMP-7 but also offer a mechanistic insight into the role of
MMP-7 in the development of proteinuria and glomerular lesions [7]. Therefore, MMP-7-mediated
cleavage of nephrin impairs slit diaphragm integrity to promote podocyte injury and proteinuria.
6.4. Pro-MMP-2 and -9
MMP-7 also promotes renal fibrosis by proteolytically activating MMP-2 and MMP-9 from their
latent zymogen forms. In an in vitro experiment, it has been shown that MMP-7 activates pro-MMP-2
by propeptide removal [111]. Earlier studies in tumor cells also show that MMP-7 is a potential activator
of pro-MMP-2 [112], through competitively binding to the TIMP-2 from MMP-2/TIMP-2 complexes,
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leading to the release of functional MMP-2 [113,114]. Because MMP-2 can convert pro-MMP-9 into
MMP-9, it is conceivable that MMP-7 can activate MMP-9 by generating active MMP-2 in both direct
and indirect ways [113–115]. At present, some studies show that MMP-2 and MMP-9 play an important
role in the onset and progression of CKD via degrading type IV collagen, promoting partial EMT and
mediating a complex interaction with various cytokines [116,117]. Therefore, MMP-7 could promote
kidney fibrosis and CKD progression by activating MMP-2 and MMP-9.
7. Conclusion and Perspectives
Over the last several years, our understanding of MMP-7 in the pathogenesis of kidney disease
has dramatically improved. MMP-7 is upregulated in AKI, CKD, and glomerular diseases and is
predominantly localized in renal tubular epithelia. Recent findings on novel substrates of MMP-7,
such as nephrin, have shed new light on its role and mechanisms of action in a wide variety of kidney
diseases. By cleaving E-cadherin and FasL, MMP-7 protects the kidney from AKI by priming renal
tubular cells for survival and proliferation. The same MMP-7-mediated degradation of E-cadherin in
CKD setting, however, promotes tubular EMT and activates β-catenin in a Wnt-independent fashion,
leading to kidney fibrosis. MMP-7 can directly degrade nephrin, resulting in podocyte dysfunction and
proteinuria. Several clinical cohort studies suggest that uMMP-7 levels may be used as a noninvasive
biomarker for predicting AKI prognosis and monitoring CKD progression in patients.
Although the present studies have provided invaluable insights into the biological functions
of MMP-7 in kidney diseases, how to translate this knowledge into patient care is a daunting task.
The revelation of MMP-7 upregulation provides hopes for the application of uMMP-7 as a noninvasive
biomarker, and future clinical studies for validation in large and diverse populations of patients are
warranted. Developing a therapy to target MMP-7 will rely upon highly selective inhibitors for MMP-7,
which are not yet available. Future studies may focus on developing efficient strategies to inhibit
MMP-7 expression in vivo for modulating the course of kidney disease. We hope that continuing this
line of investigation will improve our understanding of the role of MMP-7 and its mechanism of action
in the pathogenesis of various kidney disorders, and eventually translate into improved patient care.
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